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Abstract 
 
Influenza A haemagglutinin is a surface glycoprotein of Influenza virus, 
responsible for the initial attachment of the virus to the target cell and, at a later 
stage, for viral membrane fusion. At the acidic pH of the endosome, the HA 
molecule undergoes an irreversible structural rearrangement. In consequence, the 
hydrophobic terminal segments of HA2 are moved to the same end of the refolded 
molecule, promoting membrane fusion. 
16 haemagglutinin subtypes (H1-H16) identified to date can be divided into two 
groups based on characteristic structural features. The low pH-induced structures 
of proteolytically prepared and E.coli-expressed fragments of influenza A H3 HA2 
(group 2 HA) were previously determined by X-ray crystallography. 
This study presents structures of proteolytically prepared and recombinantly- 
expressed fragments of H1 HA2 in a postfusion conformation. Refolded H1 HA2, 
belonging to group 1 HA, adopts a hairpin-like conformation, similar to that of a 
rearranged H3 HA2. Structures were compared to the known structures of low pH-
activated HA2, to gain a better understanding of the structural differences between 
the two groups of HA. 
The data show the structures of the refolded HA2 to be conserved between the HA 
groups with minor differences.  
These structural data are supplemented with functional studies involving the 
cross-reactive FI6 antibody. FI6 antibody binds near the conserved fusion 
subdomain of the HA molecule and thus interferes with the low pH-triggered 
conformational change of HA. Additional methods employed in this study, such as 
limited proteolysis, electron microscopy, biolayer interferometry and MDCK1 cell 
infection, give insight into the mechanism of FI6 antibody-mediated neutralization, 
and highlight the differences in infectivity of H1N1 and H3N2 viruses neutralized 
by the FI6 antibody. 
 
 5 
Table of contents 
 
Declaration ............................................................................................................................... 2	
Abstract ...................................................................................................................................... 4	
Table of contents .................................................................................................................... 5	
List of figures ........................................................................................................................... 8	
List of tables ........................................................................................................................... 10	
List of abbreviations .......................................................................................................... 11	
1. Introduction ...................................................................................................................... 14	
1.1 Influenza Viruses ...................................................................................................... 14	
1.1.1 Initial isolation ...................................................................................................... 14	
1.1.2 Classification and nomenclature of Influenza Viruses ................................ 15	
1.1.3 Influenza pandemics and epidemics ................................................................. 16	
1.2 Virus morphology and structure ....................................................................... 18	
1.3 Virus replication cycle ........................................................................................... 22	
1.4 Influenza virus HA and its functions ............................................................... 24	
1.4.1 Receptor-binding ................................................................................................... 26	
1.4.2 Membrane fusion .................................................................................................. 28	
1.4.3 Antigenic evolution ............................................................................................... 30	
1.5 Conformational changes in HA leading to membrane fusion ............... 32	
1.6 Structural information on the low pH-induced structural refolding 
of HA obtained to date .................................................................................................. 35	
1.6.1 Crystal structure of H3 HA0 precursor ........................................................... 35	
1.6.2 Crystal structure of H3 BHA ............................................................................. 35	
1.6.3 Crystal structure of postfusion viral H3 TBHA2 ........................................... 38	
1.6.4 Crystal structure of E.coli-expressed H3 HA2 ............................................... 40	
1.6.5 Crystal structure of E.coli-expressed Influenza B HA2 ............................... 44	
1.7 Group-specific structural features of HA ...................................................... 46	
1.8 Anti-HA antibodies .................................................................................................. 51	
1.8.1 Antibodies blocking receptor-binding ............................................................... 51	
1.8.2 Antibodies interfering with the conformational change of HA .................. 52	
1.9 Current treatments .................................................................................................. 54	
1.10 Objectives for thesis .............................................................................................. 55	
2 Materials and Methods .................................................................................................. 56	
2.1 Materials ....................................................................................................................... 56	
2.1.1 Virus strains .......................................................................................................... 56	
2.1.2 Antibodies ............................................................................................................... 56	
2.1.3 Reagents .................................................................................................................. 56	
2.1.4 Cell lines ................................................................................................................. 56	
2.2 Protein expression ................................................................................................... 57	
2.2.1 Viral H1 HA2 in a postfusion conformation ................................................... 57	
2.2.1.1 Virus infection and growth in embryonated eggs ................................................ 57	
2.2.1.2 Virus purification ........................................................................................................ 58	
2.2.1.3 Release of HA from purified virus with bromelain ............................................. 59	
2.2.1.4 Detergent extraction .................................................................................................. 60	
2.2.2 Recombinant H1 HA2 in a low pH conformation .......................................... 61	
2.3 Protein preparation ................................................................................................ 63	
2.3.1 Quantification of viruses using SDS-PAGE .................................................... 63	
2.3.2 Determination of protein concentration .......................................................... 65	
2.3.3 SDS-PAGE .............................................................................................................. 65	
 6 
2.3.4 Ion-exchange chromatography ........................................................................... 65	
2.3.5 Size-exclusion chromatography ......................................................................... 66	
2.3.6 Low pH treatment ................................................................................................ 67	
2.3.7 Limited proteolysis ............................................................................................... 68	
2.3.8 Immobilized metal affinity chromatography (IMAC) ................................... 70	
2.3.9 Protein crystallisation and crystal freezing .................................................... 72	
2.4 Analytical techniques ............................................................................................. 75	
2.4.1 Haemagglutination assay ................................................................................... 75	
2.4.2 Dynamic Light Scattering (DLS) ....................................................................... 75	
2.4.3 Circular dichroism (CD) spectroscopy .............................................................. 77	
2.4.4 N-terminal sequencing ........................................................................................ 78	
2.4.5 Electron microscopy (EM) ................................................................................... 78	
2.4.6 Biolayer interferometry ....................................................................................... 80	
2.4.7 MDCK1 cell infection ........................................................................................... 81	
2.4.7.1 Estimation of the amount of infectious virus in the prepared samples using 
the plaque assay ....................................................................................................................... 81	
2.4.7.2 Infection of MDCK1 cells in the presence of FI6 and Hc31 antibodies .......... 85	
3 Crystal structure of viral H1 TBHA2 ....................................................................... 86	
3.1 Virus growth and purification ............................................................................ 86	
3.2 Isolation of H1 HA .................................................................................................... 86	
3.3 Induction of H1 BHA conformational change by incubation at low 
pH ........................................................................................................................................... 89	
3.4 Removal of HA1 domains by limited proteolysis ........................................ 95	
3.5 Removal of the fusion peptide by limited proteolysis .............................. 97	
3.6 Crystallisation ......................................................................................................... 101	
3.7 Data collection and processing ........................................................................ 105	
3.8 Crystal structure of B59 H1 TBHA2 ............................................................... 113	
4 Crystal structure of recombinant H1 HA2 .......................................................... 115	
4.1 Protein expression and purification .............................................................. 115	
4.2 Conformational assessment of recombinantly-expressed H1 HA2 ... 118	
4.3 Comparison of recombinantly-expressed postfusion H1 HA2 and H3 
HA2 using CD .................................................................................................................. 122	
4.3.1 Secondary structure ........................................................................................... 122	
4.3.2 Thermal stability and pH dependence of unfolding transitions .............. 122	
4.4 Crystallisation ......................................................................................................... 123	
4.5 Data collection and processing ........................................................................ 124	
4.6 Crystal structure of Bac B59 H1 HA2 ............................................................. 131	
5 Postfusion H1 HA2 and its comparison to other HA2 structures .............. 133	
5.1 Viral and recombinantly-expressed H1 HA2 .............................................. 133	
5.2 Postfusion viral H1 and H3 TBHA2 ................................................................ 137	
5.3 Recombinantly-expressed H1 and H3 HA2 .................................................. 152	
5.4 Recombinantly-expressed H1 HA2 and Influenza B HA2 ..................... 156	
6 Characterisation of FI6 antibody binding to the two groups HA ............. 159	
6.1 Binding of the FI6 antibody to virus-bound HA ....................................... 159	
6.1.1 Assessment of the ability of the FI6 antibody to prevent the 
conformational change of virus-bound HA by limited proteolysis ..................... 160	
6.1.2 Binding of the FI6 antibody to virus-bound HA by electron microscopy 162	
6.2 Binding of the FI6 antibody to THA by electron microscopy ............. 164	
6.3 Binding of viruses to human and avian receptor analogs in the 
presence of FI6 by biolayer interferometry ....................................................... 166	
6.4 Determination of infectivity of H1N1 and H3N2 viruses neutralized 
by the FI6 antibody ...................................................................................................... 167	
7 Discussion .......................................................................................................................... 169	
 7 
7.1 Purpose of study ..................................................................................................... 169	
7.2 Crystal structure of B59 H1 TBHA2 ............................................................... 170	
7.3 Analysis of H1 TBHA2 fragment ...................................................................... 172	
7.4 Crystal structure of Bac B59 H1 HA2 ............................................................. 173	
7.5 Viral and recombinantly-expressed H1 HA2 .............................................. 174	
7.6 Comparison of postfusion H3 and H1 HA2 .................................................. 176	
7.7 Final conclusions in relation to the low pH- induced refolding of H3 
and H1 HA2 ...................................................................................................................... 183	
7.8 Comparison of postfusion H1 HA2 and Influenza B HA2 ...................... 185	
7.9 Implications for viral membrane fusion ...................................................... 185	
7.10 Functional studies using the FI6 antibody ............................................... 187	
7.11 Future work ............................................................................................................ 188	
Bibliography ........................................................................................................................ 189	
 
 8 
List of figures 
Figure 1.1 An influenza A virion. ............................................................................... 20 
Figure 1.2 Electron micrograph of X31 (H3N2) virus. .............................................. 21 
Figure 1.3 Schematic diagram of influenza virus cycle. ........................................... 23 
Figure 1.4 Human and Avian HA receptor-binding sites. ........................................ 27 
Figure 1.5 Hypothetical mechanism of HA-mediated viral membrane fusion. ....... 29 
Figure 1.6 Antigenic sites A-E on the surface of HA1 domains of H3 HA. .............. 31 
Figure 1.7 The low pH-induced conformational change of HA. ................................ 34 
Figure 1.8 Crystal structures of the precursor HA0 and cleaved BHA ................... 37 
Figure 1.9 Crystal structures of prefusion and postfusion H3 HA .......................... 39 
Figure 1.10 A trimer of E.coli-expressed H3 HA2. .................................................... 42 
Figure 1.11 Schematic of H3 HA molecule and the crystallized fragments ............ 43 
Figure 1.12 Structural alignment of X31 H3 EHA2 and influenza B HA2 ............. 45 
Figure 1.13 Sequence alignment of group 1 and group 2 HA in the region of HA2 48 
Figure 1.14 Group-specific structures of loop B ........................................................ 49 
Figure 1.15 Rotation of HA1 domains relative to the HA2 stem of HA ................... 50 
Figure 1.16 The FI6 antibody bound to a trimer of prefusion H3 HA ..................... 53 
Figure 2.1 Bac B59 H1 HA2 expression construct .................................................... 62 
Figure 2.2 Quantification of viruses using SDS-PAGE. ........................................... 64 
Figure 2.3 Protein solubility phase diagram for a given temperature .................... 73 
Figure 2.4 DLS profile for purified B59 H1 TTHA2 ................................................. 76 
Figure 3.1 Purification of H1 BHA by sucrose density gradient centrifugation. .... 87 
Figure 3.2 Release of viral H1 HA with BOG ............................................................ 88 
Figure 3.3 Induction of the conformational change of influenza virus HA ............. 90 
Figure 3.4 Assessment of a conformational state of low pH-treated H1 BHA by 
limited proteolysis ............................................................................................... 92 
Figure 3.5 Identification of trypsin digestion products of low pH-treated H1 BHA 
by N-terminal sequencing ................................................................................... 94 
Figure 3.6 Purification of H1 THA2 aggregates. ....................................................... 96 
Figure 3.7 Removal of the fusion peptide from H1 rosettes with trypsin ................ 98 
Figure 3.8 Removal of the fusion peptide from H1 rosettes with thermolysin ........ 98 
Figure 3.9 Removal of the hydrophobic fusion peptide using Proti-Ace proteases 100 
Figure 3.10 Removal of the hydrophobic fusion peptide using other enzymes. .... 100 
Figure 3.11 Crystals of PR8 H1 TBHA2 .................................................................. 102 
Figure 3.12 Crystals of B59 H1 TTHA2 and B59 H1 TBHA2 ................................ 104 
Figure 3.13 Anisotropy analysis of dataset B .......................................................... 106 
Figure 3.14 Analysis of I/sigma and Mean (I/sd) versus resolution for dataset B  106 
Figure 3.15 Anisotropy analysis of dataset A .......................................................... 107 
Figure 3.16 Analysis of I/sigma and Mean (I/sd) versus resolution for dataset A 107 
Figure 3.17 Truncations of a search model for molecular replacement ................. 110 
Figure 3.18 Ramachandran plot for B59 H1 TBHA2 model. .................................. 112 
Figure 3.19 Crystal structure of B59 H1 TBHA2 ................................................... 114 
Figure 4.1 Purification of Bac B59 H1 HA2 ............................................................ 116 
Figure 4.2 Chromatogram from final size-exclusion chromatography of Bac B59  
       H1 HA2 ............................................................................................................... 117 
Figure 4.3 Assessment of the conformational state of Bac B59 H1 HA2 by limited 
proteolysis .......................................................................................................... 118 
Figure 4.4 Far UV CD spectrum of Bac B59 H1 HA2 ............................................. 119 
Figure 4.5 Thermal denaturation of Bac B59 H1 HA2 ........................................... 121 
Figure 4.6 Crystals of Bac B59 H1 HA2 .................................................................. 123 
Figure 4.7 Resolution estimate for data collected from a crystal of  
Bac B59 H1 HA2 ....................................................................................................... 125 
 9 
Figure 4.8 Anisotropy analysis of the 3.4 Å dataset obtained from a crystal of Bac 
B59 H1 HA2  ..................................................................................................... 125 
Figure 4.9 Distribution of Rmerge over 1834 frames collected at 0.15°/frame, 
0.1s/frame exposure and λ=0.97625 from a crystal of Bac B59 H1 HA2 ....... 126 
Figure 4.10 Data completeness versus the 1834 frames collected at 0.15°/frame, 
0.1s/frame exposure and λ=0.97625 from a crystal of Bac B59 H1 HA2 ....... 126 
Figure 4.11 Model of postfusion H1 HA2 used as a search model for molecular 
replacement ....................................................................................................... 128 
Figure 4.12 Ramachandran plot for the model of Bac B59 H1 HA2 ...................... 130 
Figure 4.13 Crystal structure of Bac B59 H1 HA2 ................................................. 132 
Figure 5.1 A model of postfusion influenza H1 HA2 ............................................... 134 
Figure 5.2 The low pH-induced refolding of H1 HA2. ............................................. 136 
Figure 5.3 Structural alignment of prefusion H3 and H1 HA2 .............................. 139 
Figure 5.4 Structural alignment of postfusion X31 H3 TBHA2 and B59 H1 TBHA2
 ............................................................................................................................ 140 
Figure 5.5 Comparison of turns in X31 H3 TBHA2 and B59 H1 TBHA2 ............. 142 
Figure 5.6 Loops at residues 130-145 of X31 H3 TBHA2 and B59 H1 TBHA2 ..... 144 
Figure 5.7 Coiled coil prediction profiles for H1 and H3 HA2 ................................ 146 
Figure 5.8 Comparison of the H1 and H3 sequences in the region of HA2 residues 
38-86 in terms of coiled coil forming potential ................................................ 148 
Figure 5.9 Helical wheel representations of H3 and H1 sequences the region of 
HA2 residues 38-64 ........................................................................................... 149 
Figure 5.10 X31 H3 TBHA2, X31 H3 EBHA2 and B59 H1 TBHA2 proteolytic 
digestion products ............................................................................................. 151 
Figure 5.11 Recombinantly-expressed X31 H3 EHA2 and Bac B59 H1 HA2 ....... 154 
Figure 5.12 A symmetry generated trimer of Bac B59 H1 HA2 aligned to a trimer 
of X31 H3 EHA2 ................................................................................................ 155 
Figure 5.13 Comparison of recombinantly-expressed influenza B HA2 and Bac B59 
H1 HA2 .............................................................................................................. 157 
Figure 5.14 Comparison of turns at residues 106-112 of recombinantly-expressed 
influenza B HA2 and Bac B59 H1 HA2 ........................................................... 158 
Figure 6.1 Assessment of the ability of the FI6 antibody to prevent a 
conformational change of virus-bound HA by limited proteolysis ................. 161 
Figure 6.2 Electron microscopy of the FI6 antibody binding to the X31 virus ...... 163 
Figure 6.3 Electron microscopy of X31 H3 THA-FI6 antibody complexes ............. 165 
Figure 6.4 Binding of B59 H1N1 and X31 H3N2 virus-antibody complexes to sialic 
acid receptor analogs by biolayer interferometry ............................................ 166 
Figure 6.5 Quantification of viral infection in the presence of the Hc31 antibody 168 
Figure 6.6 Quantification of viral infection in the presence of the FI6 antibody .. 168 
Figure 7.1 Preparation of B59 H1 TBHA2 for crystallographic studies ................ 171 
Figure 7.2 Composite model of H1 HA2 in a postfusion conformation .................. 175 
Figure 7.3 Coiled coil prediction profiles for group 1 HA ....................................... 178 
Figure 7.4 Coiled coil prediction profiles for group 2 HA ....................................... 179 
Figure 7.5 Interhelical loops in prefusion H3 and H1 HA2 structures .................. 181 
Figure 7.6 Solvent accessible areas in prefusion H3 and H1 HA ........................... 182 
Figure 7.7 Differences in packing of helices E against central helices C in 
postfusion H3 and H1 HA2. .............................................................................. 184 
 
 10 
List of tables 
Table 2.1 Summary of a DLS measurement using B59 H1 TTHA2. ....................... 76 
Table 2.2 Composition of media and reagents used in the plaque assay. ................ 83 
Table 2.3 Immunostaining for influenza NP. ............................................................ 83 
Table 3.1 Scores for possible Laue groups for the B59 H1 TBHA2 crystal ........... 108 
Table 3.2 Number of B59 H1 TBHA2 monomers in the asymmetric unit of the  
       P321 (150) unit cell and the corresponding % solvent content. ....................... 108 
Table 3.3 Data collection and refinement statistics for B59 H1 TBHA2 ............... 111 
Table 4.1 Secondary structure content predictions for Bac B59 H1 HA2 at pH 5.2 
by CD spectroscopy at λ=195-260 nm. ............................................................. 120 
Table 4.2 Secondary structure content predictions for Bac B59 H1 HA2 at pH 7.2 
by CD spectroscopy at λ=195-260 nm. ............................................................. 120 
Table 4.3 Melting temperatures for X31 H3 EBHA2, X31 H3 TBHA2 and Bac B59 
H1 HA2 by CD spectroscopy at λ= 222 nm ...................................................... 122 
Table 4.4 Scores for H-3 m Laue group for a crystal of Bac B59 H1 HA2 calculated 
using Pointless (CCP4). .................................................................................... 127 
Table 4.5 Number of Bac B59 H1 HA2 monomers in the asymmetric unit of the  
       R 3 2 (155) unit cell and the corresponding % solvent content. ...................... 127 
Table 4.6 Data collection and refinement statistics for Bac B59 H1 HA2 ............. 129 
Table 5.1 Refolding of H1 HA2 in response to low pH. ........................................... 135 
Table 5.2 Structural comparison of B59 H1 TBHA2 and Bac B59 H1 HA2 .......... 135 
Table 5.3 Refolding of H3 HA2 in response to low pH. ........................................... 141 
Table 5.4 Structural comparison of prefusion H3 HA2 (PDB: 1HGF) and H1 HA2 
(PDB: 1RUZ) ...................................................................................................... 141 
Table 5.5 Structural comparison of X31 H3 TBHA2 (PDB: 1HTM) and B59 H1 
TBHA2 ............................................................................................................... 141 
Table 5.6 Structural comparison of prefusion H3 and H1 HA2  (PDB: 1HGF and 
1RUZ), and postfusion X31 H3 EHA2 (PDB: 1QU1) and Bac B59 H1 HA2 .. 153 
Table 5.7 Structural comparison of recombinantly-expressed influenza B (PDB: 
4NKJ) and Bac B59 H1 HA2 ............................................................................ 156 
 11 
List of abbreviations 
BHA Bromelain-released HA  
BHA2 Low pH-activated BHA aggregates 
Bicine N, N-Bis (2-hydroxyethyl) glycine 
Bis-tris 2,2-Bis (hydroxymethyl)-2, 2′, 2″-nitrilotriethanol 
BME 2-Mercaptoethanol 
BOG N-octyl-β-D-glucoside 
BSA Bovine serum albumin 
CD Circular dichroism 
DLS Dynamic light scattering 
DMEM Dulbecco's modified eagle's medium 
E.coli Escherichia coli 
EBHA2 E.coli-expressed H3 HA2 (residues 38-175) 
EDTA Ethylenediaminetetraacetic acid 
EG Ethylene glycol 
EHA2 E.coli-expressed H3 HA2 (residues 23-185) 
EM Electron microscopy 
F subdomain Fusion subdomain of HA2 
FCS Fetal calf serum 
FP Fusion peptide (HA2 residues 1-23) 
HA Influenza virus haemagglutinin 
HA assay Haemagglutination assay 
HA titer Haemagglutinin titer 
HA0 Uncleaved precursor haemagglutinin 
HA1 Receptor-binding domain of HA molecule 
HA2 Fusion domain of HA molecule 
HAU HA units 
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HI assay Haemagglutination inhibition assay 
IGG Immunoglobulin G 
IMAC Immobilized metal affinity chromatography 
kDa Kilo Dalton 
LAIV Live attenuated influenza vaccine 
LDAO Lauryldimethylamine-oxide 
M1 Influenza virus matrix protein 
M2 Influenza virus M2 ion channel protein 
MDCK cells Madin-Darby canine kidney cells 
MEM Minimum essential medium 
MES 2-(N-morpholino) ethanesulfonic acid 
MME Monomethyl ether 
MMS Microseed matrix screening 
MOI Multiplicity of infection 
mRNA Messenger RNA 
Mw Molecular weight 
MWCO Molecular weight cut-off 
NA Influenza virus neuraminidase 
NIMR National Institute for Medical Research 
 12 
NMR Nuclear magnetic resonance 
NP Influenza virus nucleoprotein 
NR Non-reducing 
NS-1 Influenza virus non-structural protein 1 
NS-2 Influenza virus non-structural protein 2 
O/N Overnight 
PB1 Influenza virus polymerase basic protein 1 
PB1- F2 Influenza virus polymerase basic protein 1, frame 2 
PB2 Influenza virus polymerase basic protein 2 
PBS Phosphate buffered saline 
PDB Protein Data Bank 
PDI Polydispersity index 
PEG Polyethylene glycol 
PFU Plaque forming unit 
pI Isoelectric point 
R Reducing 
RBC Red blood cells 
Rmsd Root-mean-square deviation  
RNA Ribonucleic acid 
Rpm Revolutions per minute 
RT Room temperature 
SDS Sodium dodecyl sulphate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
Sf9 cells Clonal isolate of Spodoptera frugiperda Sf21 cells 
Sia Sialic acid 
ssRNA Single-stranded RNA 
SST Sodium silicotungstate 
TBHA2 Bromelain-released and thermolysin/ trypsin-solubilized 
HA2 
TCPK treated Treated with L-1-tosylamido-2-phenylethyl chloromethyl 
ketone 
THA Detergent-extracted HA molecule 
THA2 Low pH-activated THA aggregates 
Tm Melting temperature 
TM anchor Transmembrane anchor (HA2 residues 185-211) 
Tris Tris [hydroxy methyl] aminomethane 
TTHA2 Detergent-extracted and thermolysin/trypsin-solubilized 
HA2 
Vm Matthews coefficient 
vRNA Viral RNA 
vRNP Viral RNP complex 
WHO World Health Organization 
WIC World Influenza Centre 
XDS X-ray Detector Software 
  
  
  
  
 
 13 
Viruses: 
• X31 - A/Aichi/2/68 (H3N2)  
• B59 - A/Brisbane/59/07 (H1N1) 
• PR8 - A/Puerto Rico/8/34 (H1N1) 
• Tokyo - A/Tokyo/3/67 (H2N2) 
 
Throughout the text, protein samples were named depending on the source virus 
strain, and with respect to the expression and purification protocol used. 
 
Viral protein samples: 
• B59 H1 TBHA2 - postfusion viral HA2 released from A/Brisbane/59/07 
H1N1 influenza A virus by proteolytic digestion with bromelain, triggered to 
undergo a conformational change at low pH, and solubilized by digestion 
with trypsin & thermolysin. The obtained structure contains HA2 residues 
65-155. 
• B59 H1 TTHA2 - postfusion viral HA2 released from A/Brisbane/59/07 
H1N1 influenza A virus using detergent extraction, triggered to undergo a 
conformational change at low pH, and solubilized by digestion with trypsin. 
 
Samples obtained from X31, PR8 and Tokyo strains prepared using the two 
methods, were named accordingly. 
 
Recombinant protein samples: 
• Bac B59 H1 HA2 - a fragment of postfusion H1 HA2 (residues 38-175) from 
A/Brisbane/59/07 H1N1 influenza A virus, and expressed using 
Baculovirus/insect cell system for crystallographic studies. 
• X31 H3 EHA2 - a fragment of postfusion H3 HA2 (residues 23-185) from 
A/Aichi/2/68 H3N2 influenza A virus, expressed in E.coli (Chen, Skehel et al. 
1999) (PDB: 1QU1). 
• X31 H3 EBHA2 - a fragment of postfusion H3 HA2 (residues 38-175) from 
A/Aichi/2/68 H3N2 influenza A virus, expressed in E.coli (Chen, Skehel et al. 
1999) (PDB: 1QU1). 
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1. Introduction 
 
1.1 Influenza Viruses 
 
1.1.1 Initial isolation  
 
Influenza is an acute respiratory disease described by Hippocrates in 412 BC. Its 
name originated in Italy in the 15th century, from an epidemic, associated with the 
seasonal movement of the sun and the stars. Scientific research into influenza was 
undertaken following the 1918 pandemic, which killed ~50 million people 
worldwide, and the virus was isolated by Wilson Smith, Christopher H Andrewes 
and Patrick Laidlaw at the MRC National Institute for Medical Research (NIMR), 
London, in 1933. The virus was extracted from ferrets, infected with filtered 
nasopharyngeal washings of an infected researcher (Smith 1933). In the research 
article published in The Lancet on the 8th July 1933, the disease-causing agent was 
identified as a virus, due to its small size, the observed transmissibility between 
ferrets, and neutralization of its infectivity using sera of recovered patients. In 
1936 Burnet successfully grew influenza virus in embryonated hens’ eggs, which 
advanced the development of the first influenza vaccine at NIMR in 1936, and the 
establishment of the World Influenza Centre (WIC) at NIMR, to study the 
antigenic drift of influenza strains worldwide. Influenza B and C viruses were 
isolated in 1940 and 1949, respectively (Francis 1940) (Taylor 1949). 
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1.1.2 Classification and nomenclature of Influenza Viruses 
 
Influenza viruses are negative sense ssRNA viruses of the Orthomyxoviridae. 
Influenza A, B and C, are three out of six genera of this family of enveloped 
viruses. Influenza A and B viruses have eight RNA segments coding for viral 
proteins, while influenza C viruses have seven RNA segments in their genome. 
Influenza A viruses infect humans, other mammals and birds, and the natural 
reservoir are aquatic birds. Influenza B viruses infect humans (usually children) 
but have also been isolated from seals (Osterhaus, Rimmelzwaan et al. 2000). 
Viruses of this type are less diverse and the mutation rate has been shown to be 2-
3 times slower than that of influenza A viruses (Nobusawa and Sato 2006). This 
low diversity combined with a limited host range lower the risk of a pandemic 
outbreak. Influenza C viruses infect humans, pigs and dogs, although human 
infections are rare.  
Influenza A viruses have been divided into subtypes since 1980 (WHO 1980), and 
their classification is based on the antigenic properties of the two glycoproteins 
present on the virus surface. These antigens, haemagglutinin (HA) and 
neuraminidase (NA), undergo an independent antigenic evolution, and to date, 16 
HA (H1-H16) and 9 NA (N1-N9) antigenic subtypes have been identified (Schild, 
Newman et al. 1980) (Webster, Bean et al. 1992) (Fouchier, Munster et al. 2005) 
(Skehel and Wiley 2000) (Klenk, Garten et al. 2011) (Tong, Li et al. 2012) (Tong, 
Zhu et al. 2013). Classification of viruses into different subtypes relies on their 
reactivity in double immunodiffusion assays (Schild, Newman et al. 1980) 
(Hinshaw, Air et al. 1982) (Kawaoka, Yamnikova et al. 1990).  
Genetic reassortment between human, swine and avian virus strains can result in 
a formation of new HA subtypes, characterized by different antigenic properties. 
Subtypes H1, H2 and H3 have established in humans, subtypes H3 and H7 infect 
equines, with H1, H2, H3 and H9 specifically infecting swine. Viruses within the 
subtype are referred to as virus strains.  
The identification system currently in place includes virus type, the host of origin 
(except for human strains), followed by the place of first isolation, lineage number, 
and finally, the year of isolation. Additionally, HA and NA antigenic subtypes are 
specified e.g. A/Brisbane/59/2007 (H1N1). 
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1.1.3 Influenza pandemics and epidemics 
 
Influenza viruses evolve due to genetic mutation and reassortment (Hay, Gregory 
et al. 2001). Point mutations in RNA segments coding for surface glycoproteins, 
haemagglutinin (HA) (segment 4) and neuraminidase (NA) (segment 6), are 
frequent. This continuous genetic evolution through the processes of antigenic drift 
and shift, allows for new antigenic subtypes to emerge, and survive by escaping 
host immunity (Zambon 1999). 
Gradual accumulation of these point mutations is known as antigenic drift. Apart 
from the selective immune pressure, the factor responsible for this progressive 
change is the lack of proofreading ability of viral RNA polymerase (Domingo, Sabo 
et al. 1978). A genetically changed virus can cause an epidemic in a human 
population, and antigenic drift is observed in Influenza A and B viruses, giving rise 
to new virus strains within a subtype. 
Genetic reassortment between strains of human, swine and avian origin can result 
in a significant antigenic change (occurring every 10-40 years). Such antigenic shift 
has only been observed in influenza A viruses and is promoted by their segmented 
genome. Viruses from different hosts can exchange genes in pigs, due to the 
presence of both α- (2,6)- and α- (2,3)- linked sialic acids, allowing for their co-
infection with human and avian virus strains at the same time. Genetic 
reassortment can lead to a dramatic change in the antigenic properties of one, or 
both glycoproteins (HA and NA) on virus surface, and subsequently result in a 
pandemic (Itoh, Shinya et al. 2009). A good example of a major antigenic shift is 
the emergence of H3N2 strain in 1968 in Hong Kong. This virus replaced the H2N2 
strain circulating between 1957 and 1967, and caused a pandemic. 
The deadliest pandemic recorded to date occurred in 1918 (known as the ‘Spanish 
flu’), and haemagglutinin on the virus surface was of subtype H1 (Gamblin, Haire 
et al. 2004). The 1918 pandemic was characterized by unusually high mortality 
rate among young adults (Simonsen, Clarke et al. 1998). The HA gene was 
reassembled from RNA fragments present in formalin-fixed lung tissues, and 
crystal structure of the uncleaved precursor of the extinct 1918 pandemic virus HA 
was obtained at 3 Å resolution, revealing a narrow, avian-like receptor-binding site 
(Gamblin, Haire et al. 2004). In 1957, H2N2 virus killed up to ~1.5 million people, 
in a pandemic known as ‘Asian flu’, and the virus was formed by a genetic 
reassortment between human and avian viruses, with both glycoproteins (HA and 
NA) of avian origin (Scholtissek, Rohde et al. 1978) (Kawaoka, Krauss et al. 1989). 
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The third pandemic occurred in 1968, when H3N2 virus in Hong Kong replaced the 
H2N2 virus. In this case, only HA glycoprotein was replaced (Dowdle, Coleman et 
al. 1969). The H3N2 pandemic virus was shown to contain 6 RNA segments of the 
H2N2 virus, and two segments (coding for HA and PB1) from an avian virus 
(Scholtissek, Rohde et al. 1978) (Kawaoka, Krauss et al. 1989), thought to be 
related to an avian A/duck/Ukraine/63 virus (Ha, Stevens et al. 2003).  
Human 1918-derived H1N1 virus reappeared in Russia in 1977, and then again in 
Mexico in 2009, and the virus it thought to have originated in swine (Smith, 
Vijaykrishna et al. 2009). The 2009 H1N1 virus was a reassortant of a European 
avian-like virus, and a North American swine H1N2 triple-reassortant (Dunham, 
Dugan et al. 2009), and the resulting virus was characterised by a higher 
transmissibility than seasonal flu (Fraser, Donnelly et al. 2009).  
Human viruses preferentially bind to α- (2,6) sialic acid receptors, found on cells of 
the upper respiratory tract, and avian viruses bind to α- (2,3) sialic acid receptors 
in birds’ intestine, and human lower respiratory tract (Rogers and Paulson 1983) 
(Matrosovich, Zhou et al. 1999) (van Riel, Munster et al. 2006) (Gambaryan, 
Tuzikov et al. 1997). Avian and swine viruses containing haemagglutinin of 
subtypes H5, H6, H7, H9 and H10 can cross the species barrier by acquiring the 
ability to bind to the human receptor (Ito, Couceiro et al. 1998), and the acquired 
ability of these subtypes to transmit efficiently between humans would pose a 
serious pandemic threat (Ito 2000) (Shortridge, Gao et al. 2000). In addition to 
receptor-binding specificity, one factor limiting human influenza virus replication 
to the respiratory tract is the availability of proteases, which are needed for 
cleavage and activation of HA molecules on the surface of newly formed viral 
particles. HA of the highly pathogenic avian strain A/H5N1 however, is efficiently 
cleaved in the cell, by ubiquitous subtilisin-like proteases. These enzymes can be 
found in the Golgi apparatus of most cells, allowing replication of avian A/H5N1 
virus outside of the human respiratory tract (Guo, Li et al. 2008). Human infection 
with H5N1 was first reported in Hong Kong in 1997, and its antigenic evolution 
potentially leading to human-to-human transmissibility, may result in a future 
pandemic (Smith, Fan et al. 2006) (Xiong, Xiao et al. 2014). This would require a 
change in its binding preference, from avian to human receptor (Chen, Blixt et al. 
2012) (Herfst, Schrauwen et al. 2012) (Imai, Watanabe et al. 2012) (Xiong, Coombs 
et al. 2013) (Zhang, Shi et al. 2013) (Xiong, Xiao et al. 2014). In contrast, the H7N9 
virus was found to be able to transmit via aerosols without further adaptation 
(Belser, Gustin et al. 2013). In 2013, an avian H10N8 virus manifested in China 
(To, Tsang et al. 2014), and its characteristic feature was high affinity for human 
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receptors. The structural conformation of the bound receptor was shown to be 
similar to that of 1918 H1N1 pandemic virus, and to a human H7 virus (Vachieri, 
Xiong et al. 2014). 
 
1.2 Virus morphology and structure 
 
Spherical virus particles measure ~100 nm in diameter, and filamentous particles 
can measure up to 1 µm (Calder, Wasilewski et al. 2010) (Lamb RA 2001). Viral 
core, containing eight ssRNA segments (McGeoch, Fellner et al. 1976), is enclosed 
in a lipid envelope, and this layer is derived from host cell membrane and formed 
during budding (Kates, Allison et al. 1962). The segmented genome exists as a 
structure called viral RNP (vRNP) complex (Compans, Content et al. 1972). The 
helical RNA segments code for viral proteins (PB2, PB1, PA, HA, NP, NA, M1, M2, 
NS1, NS2 and PB1-F2), and are associated with the trimeric polymerase complex, 
composed of polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2) 
and polymerase acidic protein (PA) (Area, Martin-Benito et al. 2004). The core of 
the polymerase complex is formed by PB1, and each segment is associated with 
multiple NPs. The ribonucleoprotein core is surrounded by a shell made of matrix 
protein (M1), and located directly beneath the lipid envelope (Schulze 1970) 
(Ruigrok, Barge et al. 2000). Viral non-structural protein 1 (NS1) is responsible for 
inhibition of the host antiviral response, for example by suppressing maturation 
and translation of interferon mRNA (Kochs, Garcia-Sastre et al. 2007), and 
therefore promoting viral replication. Non-structural protein 2 (NS2), also known 
as nuclear export protein (NEP), mediates export of viral ssRNA from the nucleus 
(O'Neill, Talon et al. 1998). Polymerase basic protein 1 frame 2 (PB1-F2) is 
responsible for virus-induced cell death by affecting the mitochondrial function of 
infected cells (Gibbs, Malide et al. 2003), and has been implicated in virus 
pathogenicity (Zamarin, Ortigoza et al. 2006). 
Two types of glycoprotein spikes are anchored in the lipid envelope (Laver and 
Valentine 1969), and these are rod-shaped haemagglutinin (HA) trimers (~350-400 
copies per virion), and mushroom-shaped neuraminidase (NA) tetramers (~50 
copies per virion) (Murti and Webster 1986). While NA releases newly formed virus 
particles from infected cells by cleaving sialic acid residues from the surface of the 
cell and the newly formed viral particles, HA is involved in the initial binding of 
the virus to the target cell, and later for fusion of viral and host cell membranes, 
 19 
eventually leading to the release of the viral genome into the host cytoplasm and 
its replication (Skehel and Wiley 2000).  
M2 is another integral membrane protein (~14-68 copies per virion) (Zebedee and 
Lamb 1988). It is a homotetrameric, low pH-activated, proton-selective channel, 
whose transmembrane domain forms a pore (Sugrue and Hay 1991). The main 
function of M2 is the control of pH across the viral membrane. Opening of the 
channel, and the resulting protonation of virus interior, are associated with 
protonation of highly conserved His37 residues of the M2 protein (Pinto, Holsinger 
et al. 1992). This acidification eventually leads to dissociation of M1 and uncoating 
of vRNP complexes prior to membrane fusion. M2 is also involved in maintaining a 
metastable state of newly produced HA molecules, by pumping protons out of the 
acidic trans-Golgi-network, where the translation takes place, and the residue 
responsible for forming this protective ‘channel gate’ is highly conserved Trp41.  
A schematic representation of influenza A virion and an electron micrograph of an 
influenza A H3N2 virus are shown in Figures 1.1 and 1.2, respectively. 
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Figure 1.1 An influenza A virion. Haemagglutinin (HA), neuraminidase 
(NA) and the M2 ion- channel protein anchored in the viral envelope are 
indicated. M1 is a matrix protein. RNA segments coding for viral proteins 
are shown. Together with viral nucleoprotein (NP) and polymerase 
proteins (PA, PB1, and PB2) form a ribonucleoprotein complex. Figure 
adapted from (Horimoto and Kawaoka 2005). 
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Figure 1.2 Electron micrograph of X31 (H3N2) virus. Negative stain; 
magnification 30 000 X. Image obtained from Dr Lesley Calder. 
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1.3 Virus replication cycle 
 
Influenza virus is transmitted via aerosols. An initial step of viral infection is HA-
mediated attachment of the virus to cell surface glycan-containing terminal sialic 
acid (Gottschalk 1959), and host specificity is determined by the type of its linkage 
to galactose: α- (2, 3) (in birds) or α- (2, 6) (in humans) (Rogers and Paulson 1983). 
The attached viruses are then taken up into the cells of the respiratory tract by 
endocytosis (Rossman, Leser et al. 2012), while opening of the M2 proton channel 
at the pH of endosomes causes acidification of their interior (Sugrue and Hay 
1991), and eventually to dissociation of M1 and uncoating of vRNP. Additionally, 
the acidic pH causes HA on the virus surface to undergo an extensive structural 
rearrangement, which eventually leads to fusion of viral and endosomal 
membranes (Skehel, Bayley et al. 1982). The released vRNP are moved to the 
nucleus, where negative sense viral RNA are initially transcribed to messenger 
RNA (mRNA), and then to complementary RNA (cRNA), by proteins forming the 
polymerase complex (PA, PB1 and PB2) (Hay, Lomniczi et al. 1977). While vRNP 
are formed in the nucleus, proteins associated with viral envelope (HA, NA and 
M2) are directed to the endoplasmic reticulum (ER) (Compans 1973) (Hay 1974), 
and inserted into the ER membrane (McCauley, Bye et al. 1979) (Bos, Davis et al. 
1984), where they are folded, oligomerized and glycosylated. All viral components 
are then transported to the budding site on the plasma membrane, where the 
segmented genome and viral envelope are assembled. The newly formed viruses 
are then released by the activity of viral NA, which is essential for a successful 
replication (Palese, Tobita et al. 1974). A schematic diagram of influenza virus 
replication cycle is shown in Figure 1.3. 
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Figure 1.3 Schematic diagram of influenza virus cycle. Viral particles are 
internalized via receptor-mediated endocytosis. The uncoated vRNP are 
released into the cytoplasm of infected cell in the process of HA-mediated 
viral membrane fusion. The released genome is transcribed in the 
nucleus. Viral proteins are produced in the cytoplasm, and transported to 
the cell membrane, where virus budding takes place. 
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1.4 Influenza virus HA and its functions 
 
Influenza A virus haemagglutinin (HA) is encoded by RNA segment 4, and named 
according to its ability to agglutinate erythrocytes (Hirst 1941). This antigenic 
integral envelope glycoprotein amounts to ~30% of the total virus protein (Lamb 
and Choppin 1983), and the number of HA copies on each viral particle is ~400 
(Imai, Mizuno et al. 2006). The molecule is involved in initial binding of influenza 
virus to the target cell (Hirst 1942), and for viral membrane fusion, necessary for 
entry of the viral genome into the cell (Skehel and Wiley 2000) (Gamblin, Haire et 
al. 2004). Each monomer of this ~220 kDa homotrimeric molecule (Wiley, Skehel et 
al. 1977) consists of two domains, HA1 (~56 kDa) and HA2 (~26 kDa), which are 
disulphide-linked (Skehel and Schild 1971) (Laver 1971). HA1 domains form 
globular heads of the molecule (Wilson, Skehel et al. 1981), and can be further 
subdivided into receptor-binding (R) (HA1 residues 115-261) and vestigial esterase 
(E) (HA1 residues 50-114) subdomains (Skehel and Wiley 2000). Vestigial (inactive) 
subdomain of influenza A HA is a fragment of a single glycoprotein HEF present in 
influenza C (Rosenthal, Zhang et al. 1998). Fusion subdomain is composed mainly 
of HA2 plus HA1 residues 1-49 (F’) and 269-309 (F). HA molecule is synthetized as 
a single precursor polypeptide (HA0) on the rough endoplasmic reticulum (RER) 
(Compans 1973), to which it is navigated via an N-terminal signalling sequence 
(McCauley, Bye et al. 1979). Following removal of a 17 amino acid long signal 
peptide, HA is co-translationally glycosylated and cleaved by trypsin-like proteases 
present in the respiratory tract (Lazarowitz, Compans et al. 1971) (Klenk, 
Scholtissek et al. 1972) (Lazarowitz and Choppin 1975). Glycosylation is important 
for the correct folding and oligomerization of HA trimer (Gallagher, Henneberry et 
al. 1992) (Chen, Helenius et al. 1995), which is essential for its transition from the 
rough endoplasmic reticulum to the Golgi network (Gething, McCammon et al. 
1986) (Copeland, Zimmer et al. 1988), where further glycosylation takes place. In 
the process of antigenic evolution, HA can acquire new glycosylation sites, majority 
of which are located in globular head domains (HA1) (Skehel and Wiley 2000). 
These carbohydrates mask the antigenic sites from recognition by antibodies 
(Skehel, Stevens et al. 1984), and can affect binding of HA to the sialic acid 
receptors, by overlapping with the receptor-binding site (Aytay and Schulze 1991) 
(Mir-Shekari, Ashford et al. 1997).  
Activation of HA by proteolytic cleavage takes place on the surface of the cell, or 
after virus budding (Compans, Klenk et al. 1970, Schulze 1970), and is performed 
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by trypsin-like proteases (Klenk, Rott et al. 1975) (Lazarowitz and Choppin 1975) 
or ubiquitous subtilisin-like proteases like furin, which recognize a sequence of 
polybasic residues (Arg-X-Arg/Lys-Arg) (Garten, Bosch et al. 1981) (Garten, 
Hallenberger et al. 1994) (Stieneke-Grober, Vey et al. 1992) found at the cleavage 
site of highly pathogenic H5 and H7 viruses (Webster and Rott 1987) (Perdue, 
Garcia et al. 1997) (Guo, Li et al. 2008). Proteolytic cleavage primes HA for fusion 
in the next cycle of infection, and produces a new N-terminus of HA2, known as the 
fusion peptide (FP), which is highly conserved among influenza strains and rich in 
hydrophobic residues (Phe, Leu, Ile and Val) (Skehel and Waterfield 1975) (Skehel 
and Wiley 2000). The fusion peptide (HA2 residues 1-23) contains large 
hydrophobic residues interspersed with glycine, and is essential for a successful 
membrane fusion (Gething, White et al. 1978) (Chen, Lee et al. 1998). Deletion of 
Gly1 (Garten, Bosch et al. 1981) (Cross, Wharton et al. 2001), or its substitution 
with Val or Glu (Qiao, Armstrong et al. 1999) have been previously shown to block 
membrane fusion. Cleavage of HA into HA1 and HA2 subunits is essential for virus 
infectivity (Klenk, Rott et al. 1975), and for human H1, H2 and H3 subtype viruses 
the cleavage point is a single Arg residue at position 329 of HA2 (Skehel and Wiley 
2000). The conserved glycine, adjacent to Arg329, becomes the new N-terminus of 
HA2 (Skehel, Waterfield et al. 1980) (Steinhauer 1999), and residue 328 of HA0 
becomes the new C-terminus of HA1. The C-terminal region of HA2 contains a 27-
amino acid transmembrane domain (TM) and a 10-amino acid cytoplasmic tail.   
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1.4.1 Receptor-binding 
 
One of the main functions of influenza virus HA is binding of the virus to sialic acid 
receptors on the target cell (Gottschalk 1959). Sialic acids belong to a class of nine-
carbon acidic amino monosaccharides, found at the termini of N-linked 
carbohydrate side chains of cellular glycoproteins and glycolipids of all species 
(Castells, Ballesta et al. 1990). Differences in the receptor specificity of HA 
molecules from human and animal viruses were discovered in experiments with 
cells expressing a particular type of sialic acid and red blood cells (Rogers and 
Paulson 1983). The avian receptor found on the intestinal epithelium of avian 
species contains sialic acid in α-(2,3)- linkage to galactose (Ito, Suzuki et al. 2000), 
while sialic acids of the human upper  respiratory tract receptor are linked to 
galactose via α-(2,6)- linkage (Rogers and Paulson 1983) (Baum and Paulson 1990) 
(Couceiro, Paulson et al. 1993) (Connor, Kawaoka et al. 1994) (Skehel and Wiley 
2000) (Matrosovich, Matrosovich et al. 2004). Equine viruses recognize α-(2,3)- 
linkage, while swine viruses bind to sialic acid in both, α-(2,3)- and α-(2,6)- linkages 
to galactose (Rogers and D'Souza 1989), both found in porcine tracheae (Ito, 
Couceiro et al. 1998).  
Receptor-binding site is located at the tip of each HA monomer (Rogers, Paulson et 
al. 1983), in a cavity surrounded by 190 helix (residues 189-199), 220 loop (residues 
224-228) and 130 loop (residues 133-138) of HA1 head domains (Weis, Brown et al. 
1988) (Sauter, Bednarski et al. 1989) (Skehel and Wiley 2000), and conformations 
of these loops vary between subtypes (Gamblin, Haire et al. 2004). The bottom of 
this shallow cavity is formed by conserved aromatic residues, which include Tyr98, 
Ser136, Trp153, His183 and Tyr195. Binding of sialic acid occurs via formation of 
hydrophobic interactions and hydrogen bonds between 130- and 220- loops, and the 
conserved amino acids found at the base of the receptor-binding site (Gamblin and 
Skehel 2010). The superposed human and avian H2 receptor-binding sites are 
shown in Figure 1.4. Several variable residues surrounding receptor-binding site 
have been implicated in the receptor-binding specificity. For H2 and H3 subtypes, 
Gln226Leu and Gly228Ser mutations cause the site to open, and the resulting 
rearrangement of residues within the receptor-binding site can cause a switch in 
specificity from avian to human receptors (Rogers, Paulson et al. 1983) (Connor, 
Kawaoka et al. 1994) (Matrosovich, Tuzikov et al. 2000) (Ha, Stevens et al. 2003). 
In case of H1 HA from the 1918 pandemic virus, this change is correlated with 
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Glu190Asp and Gly225Asp mutations (Matrosovich, Tuzikov et al. 2000) (Gamblin, 
Haire et al. 2004) (Stevens, Blixt et al. 2006).  
 
 
 
 
 
 
 
Figure 1.4 Human and Avian HA receptor-binding sites. Human H2 
A/Singapore/1/57 (PDB: 2WRC) and Avian H2 A/Duck/Ontario/77 (PDB: 
2WR5) receptor binding sites are shown in yellow and purple, 
respectively. Conserved residues such as Tyr98, Ser136, Trp153 and 
His183, together with other residues involved in receptor binding 
specificity are shown as sticks. Rmsd= 0.310 Å. 
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1.4.2 Membrane fusion 
 
The stem region of HA composed of HA2 is highly conserved across the known HA 
subtypes. This viral membrane-proximal region of the molecule is responsible for 
performing fusion of viral and endosomal membranes, in order to release the viral 
ssRNA genome into the host cell cytoplasm for replication (Skehel and Wiley 2000). 
In order to complete this stage of viral infection, HA0 precursor must first undergo 
a proteolytic cleavage into HA1 and HA2, as described in Section 1.4. Receptor-
bound viruses enter the cell using endosomes, and receptor binding is described in 
Section 1.4.1. The acidic pH of late endosomes (pH 5-6) induces an irreversible 
structural rearrangement of cleaved HA (Skehel, Bayley et al. 1982) (Skehel, 
Daniels et al. 1986) (Wharton 1987), and the pH value at which the conformational 
change of HA takes place varies, depending on virus strain (Wharton, Skehel et al. 
1986).  
It has been proposed, that the extension of the α-helical coiled coil of HA at low pH 
serves to transport the N-terminal fusion peptide (HA2 residues 1-23), from the 
hydrophobic cavity where it is located after cleavage of the HA0 precursor, towards 
the endosomal membrane (Skehel, Bayley et al. 1982) (Doms, Helenius et al. 1985), 
and this process is thought to be related to protonation of highly conserved His and 
Arg residues at low pH (Russell, Gamblin et al. 2004). Conformational changes at 
the viral membrane-proximal end of the molecule result in relocation of the C-
terminal transmembrane anchor of HA2 to the top of the rearranged molecule 
(Bullough, Hughson et al. 1994), and its proximity to the hydrophobic fusion 
peptide is thought to be crucial in the process of viral membrane fusion (Skehel, 
Bayley et al. 1982). Although to date not completely understood, viral membrane 
fusion is thought to proceed through the formation of an extended intermediate, 
which then collapses, leading to hemifusion (lipid mixing) and the formation of a 
fusion pore (content mixing), through which the viral genome enters the cytosol of 
infected cell (Harrison 2008) (Cross, Langley et al. 2009). Fusogenic properties of 
influenza viruses have been studied utilizing their ability to haemolyse 
erythrocytes at low pH (Maeda and Ohnishi 1980) (Huang, Rott et al. 1981), and by 
measuring decrease in FRET between two liposome membrane-bound fluorescent 
probes upon fusion (Stegmann, Hoekstra et al. 1985) (Wharton, Skehel et al. 1986). 
The hypothetical mechanism of viral membrane fusion is shown in Figure 1.5. 
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Figure 1.5 Hypothetical mechanism of HA-mediated viral membrane 
fusion.  
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1.4.3 Antigenic evolution 
 
In addition to the initial attachment and subsequent entry of the viral genome into 
the cell through the process of viral membrane fusion (Skehel and Wiley 2000) 
(Harrison 2008), HA serves as an antigen for antibody neutralization (Laver and 
Kilbourne 1966). Antigenically novel virus strains are produced in the processes of 
antigenic drift and shift (Skehel, Daniels et al. 1983), described in Section 1.1.3. 
These viruses can evade natural immunity gained from previous infections, and 
thus have a potential to cause epidemics. Mutations in HA arising in the process of 
an antigenic drift do not affect the overall structure of the molecule. The variable 
regions of HA include the receptor-binding sites, antigenic sites recognized by 
antibodies located within HA1 domains (Wiley, Wilson et al. 1981) (Wiley and 
Skehel 1987) (Skehel and Wiley 2000), and glycosylation sites found on the 
protein’s surface. Due to the proximity of the antigenic sites to the receptor-binding 
sites however, these point mutations may affect both antibody- and receptor-
binding functions of the molecule (Gambaryan, Marinina et al. 1998). New 
glycosylation sites (Asn-X-Ser/Thr, where X is any amino acid except Pro), acquired 
in the process of antigenic drift, can inhibit recognition of HA by antibodies 
(Skehel, Stevens et al. 1984), and thus allow for infection and spread of the virus 
(Schulze 1997), with large N-glycans sterically interfering with virus-receptor 
binding.  
The principal method for identification of viruses, antigenic analysis of different 
strains, and for quantification of antibodies (both infection- or immunization-
induced) is haemagglutination-inhibition (HI) assay, proposed in 1949 by the 
Committee on Standard Serological Procedures in Influenza Studies. The test is 
preceded by a removal of naturally occurring heat resistant inhibitors of 
haemagglutination from cultures of vibrio cholera using NA (Burnet and Stone 
1947). Employing monoclonal antibodies against HA facilitated studies of antigenic 
mutants, which neutralize majority of viruses grown at limited dilutions, and 
allowed for selection of antibody resistant mutants (Yewdell, Webster et al. 1979). 
This method, combined with peptide mapping, initially resulted in identification of 
four antigenic sites on influenza A H1 HA, and three on influenza A H3 HA (Wiley, 
Wilson et al. 1981) (Breschkin, Ahern et al. 1981). These results, together with 
sequence analysis of naturally occurring antigenic variants, X-ray crystallographic 
studies of antibody-selected mutants (such as G146D, G135R and Q189K) and HA-
Fab complexes, supported by electron microscopy of HA in complex with 
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monoclonal antibodies, eventually allowed to map five antigenic sites on H3 HA, 
(Wilson and Cox 1990) (Wiley and Skehel 1987) (Wiley, Wilson et al. 1981) 
(Bizebard, Gigant et al. 1995) (Fleury, Barrere et al. 1999) (Skehel and Wiley 
2000).  These antigenic regions named A-E are located within HA1 domains, and 
surround the highly conserved receptor binding site (Wiley, Wilson et al. 1981) 
(Weis, Brown et al. 1988) (Figure 1.6). 
As shown in experiments involving passaging human viruses in embryonated 
chicken eggs, followed by selection of mutant variants with changed receptor-
binding specificity, the selective pressure for amino acid substitutions in HA1 
affects the antigenic regions of HA and the efficiency of binding to the host cell, and 
is driven by the presence of antibodies that bind near the binding site. Given the 
short life span of birds, avian influenza viruses display a high conservation of 
antigenic sites on HA. In pigs, a short life span and therefore a low immune 
pressure, result in slow antigenic evolution of influenza virus HA. In humans, 
selection of new antigenic variants is likely to occur during reinfection of partially 
immune individuals, or as a result of a prolonged infection in immunocompromised 
children. Correct identification of antigenic changes in HA of currently circulating 
viruses is necessary for recommending the composition of the annual influenza 
vaccine. 
 
Figure 1.6 Antigenic sites A-E on the surface of HA1 domains of H3 HA. 
Receptor-binding site is indicated. The N- and C-termini of HA1 and HA2 
are labelled N1, C1 and N2, C2, respectively. Figure adapted from 
(Popova, Smith et al. 2012). 
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1.5 Conformational changes in HA leading to 
membrane fusion 
 
At the acidic pH of endosomes (pH 5-6), influenza virus haemagglutinin undergoes 
an irreversible structural rearrangement (Skehel, Bayley et al. 1982). Triggered by 
low pH, the molecule changes its conformation, releasing the hydrophobic N-
terminal fusion peptide of HA2 (residues 1-23) (Skehel, Daniels et al. 1986), which 
is moved to the top of postfusion HA2, presumably towards the endosomal 
membrane (Bullough, Hughson et al. 1994). As previously demonstrated using 
circular dichroism (CD), electron microscopy and sedimentation in sucrose density 
gradients, at the pH of membrane fusion, bromelain-released HA (BHA) forms 
rosettes of ~8 molecules, as a result of a fusion peptide-mediated aggregation 
(Skehel, Bayley et al. 1982) (Ruigrok, Wrigley et al. 1986). Low pH-treated BHA 
was also shown to bind lipid vesicles and non-ionic detergents, whose addition 
prevented the aggregation of the low pH-treated BHA (pH 5.0) (Skehel, Bayley et 
al. 1982). Previous CD analysis of the low pH-treated BHA (near-UV region), 
recorded changes in the CD spectrum, and increased signal intensity in the region 
of 270-280 nm, corresponding to the conformational change of the low pH-activated 
molecule (Skehel, Bayley et al. 1982).  
It is known that the HA1 domains move away from the trimeric stem of HA, 
allowing the central α-helices to elongate (Skehel, Bayley et al. 1982), and this 
dissociation is thought to be an initial step in the low pH-induced refolding of 
influenza haemagglutinin (Godley, Pfeifer et al. 1992). It has been previously 
shown that cross-linking of HA1 domains prevents the conformational change of 
HA (Godley, Pfeifer et al. 1992) (Barbey-Martin, Gigant et al. 2002). While HA0 
does not respond to acidic pH (Chen, Lee et al. 1998), it has been proposed, that 
displacement of HA1 domains in BHA is caused by protonation of its solvent-
exposed regions, which acquire a positive net charge at acidic pH, and dissociation 
is thought to be driven by a repulsive force (Huang, Opitz et al. 2002). The 
observed elongation of haemagglutinin at low pH (Skehel, Bayley et al. 1982) 
(Bullough, Hughson et al. 1994) (Chen, Skehel et al. 1999) exposes the previously 
inaccessible trypsin cleavage sites at residues 27 and 224 of BHA1 (H3 subtype) 
(Skehel, Bayley et al. 1982). The HA1 domains can therefore be secondarily 
digested using proteases post-purification (Skehel, Bayley et al. 1982) (Doms, 
Helenius et al. 1985). The low pH-induced refolding of HA exposes the interchain 
disulphide bond linking HA1 and HA2, and HA1 domains can then be removed 
using dithiothreitol (DTT) (Graves, Schulman et al. 1983).  
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This rearrangement of HA1 domains, and the formation of a central cavity, allow 
for the surrounding solvent to access HA2, its protonation, and subsequent 
formation of the extended coiled coil (Huang, Opitz et al. 2002). The extended 
structure is formed by a recruitment of loop B (HA2 residues 55-75) in the 
prefusion structure (Wilson, Skehel et al. 1981) to the central postfusion coiled coil.  
This loop (B) adopts an α-helical conformation in the postfusion structure of H3 
HA2, and serves to connect the long helix C (HA2 residues 76-105) and the short 
helix A (HA2 residues 38-55), observed in the crystal structures of postfusion H3 
HA2 (Bullough, Hughson et al. 1994) (Chen, Skehel et al. 1999).  
At the other end of HA molecule, a part of the prefusion central stem (HA2 
residues 106-112) undergoes a helix-to-turn transition, inverting the rest of the 
polypeptide chain (C-terminal to HA2 residue 112) by 180° (Bullough, Hughson et 
al. 1994) (Chen, Skehel et al. 1999). This rearrangement results in a relocation of 
the C-terminal TM anchor (HA2 residues 185-211), which is moved near the N-
terminal fusion peptide (HA2 residues 1-23), and the proximity of the two 
subdomains of HA2 at the same end of the postfusion molecule is thought to 
promote viral membrane fusion (Bullough, Hughson et al. 1994).  
Digestion of bromelain-released and low pH-treated BHA with trypsin, in order to 
remove disordered HA1 domains (Skehel, Bayley et al. 1982), followed by a 
digestion with thermolysin to remove the released hydrophobic fusion peptide 
(HA2 residues 1-23) (Ruigrok, Aitken et al. 1988), result in a fragment of viral HA2 
ectodomain in a postfusion conformation, generally referred to as TBHA2 
(Thermolysin/Bromelain-released HA2). The enzymatically prepared fragment is 
suitable for crystallographic studies (Bullough, Hughson et al. 1994), and 
structural refolding of H3 HA2 at pH ~5.0 is shown in Figure 1.7. 
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Figure 1.7 The low pH-induced conformational change of HA. Monomeric 
cartoon representation of bromelain cleaved HA on the left (PDB: 1HGF) 
(Wilson, Skehel et al. 1981) and thermolysin solubilized, postfusion H3 
TBHA2 on the right (PDB: 1HTM) (Bullough, Hughson et al. 1994). The 
HA1 domain of bromelain-released HA is shown in blue. HA2 molecules 
are coloured by segments, which undergo refolding at low pH. 4 α-helical 
segments: A, C, E and G, and 2 β-strands 1 and F are conserved in both 
structures. Loop B between helices A and C adopts a helical conformation 
in the refolded molecule. Segment D (BHA residues 106-112) refolds into a 
loop between helices C and E in TBHA2. Figure adapted from (Bullough, 
Hughson et al. 1994). 
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1.6 Structural information on the low pH-induced 
structural refolding of HA obtained to date 
 
1.6.1 Crystal structure of H3 HA0 precursor 
 
The crystal structure of an uncleaved, single-chain HA0 precursor from human 
A/Aichi/2/68 H3N2 virus (PDB: 1HA0) was determined in 1998 (Chen, Lee et al. 
1998), and an uncleaved trimer is shown in Figure 1.8. The haemagglutinin of this 
virus is identical to that of the strain that caused the ‘Hong Kong’ pandemic in 
1968. Arg329Gln substitution was introduced to prevent cleavage into HA1 and 
HA2. Only 19 residues near the cleavage site (HA1 residues 323-328, Gln329 and 
HA2 residues 1-12) have a different structural conformation when compared to the 
crystal structure of cleaved H3 HA (BHA) (PDB:1HGF), described in Section 1.6.2. 
These residues are organized into a loop on the glycoprotein’s surface, exposing 
HA1 residues 327- HA2 residue 5 to proteases (Chen, Lee et al. 1998).  
 
1.6.2 Crystal structure of H3 BHA 
 
The structure of a metastable, cleaved, bromelain-released HA (BHA) of A/Hong 
Kong/1968 H3N2 virus was previously determined to 3 Å resolution using X-ray 
crystallography (Wilson, Skehel et al. 1981). This was the first crystal structure of 
a membrane fusion protein, and was published by Wilson, Skehel and Wiley in 
Nature in 1981. Bromelain solubilized the trimeric fragment of HA ectodomain, by 
cleaving the hydrophobic transmembrane anchor (TM) at the C-terminus of HA2 
(residues 185-211), and the cleavage point was residue 175 of HA2 (Compans, 
Klenk et al. 1970) (Brand and Skehel 1972) (Skehel and Waterfield 1975) 
(Dopheide and Ward 1981). The prepared fragment was antigenically (Brand and 
Skehel 1972) (Wrigley, Laver et al. 1977) and structurally (Flanagan and Skehel 
1977) (Wiley, Skehel et al. 1977) intact and useful for crystallographic studies 
(Wiley and Skehel 1977) (Wilson, Skehel et al. 1981). In BHA, 328 residues of HA1 
are disulphide-linked to 175 residues of HA2, and the disulphide bond is located 
between Cys14 of HA1 and Cys137 of HA2. The 135 Å long trimeric structure, 
revealed a globular region composed of HA1, placed on top of a ~76 Å long, triple-
stranded, α-helical coiled coil, composed mainly of HA2. Residues 116-261 of each 
HA1 monomer are organized into 8-stranded antiparallel β-sheet, known as “Swiss 
roll”, which contains two antigenic sites in the form of loops (Figure 1.6). The 
 36 
globular HA1 domains are attached to the stem of the molecule by two disulphide 
loops (residues 52-277 and 281-305). Each HA2 subunit contains two antiparallel 
helices: a short α-helix A (29 Å long) connected to a long α- helix C (76 Å long) via a 
loop B. The newly formed positively charged N-terminal fusion peptide (HA2 
residues 1-23) is placed into a negatively charged cavity, which is considered a 
fusion-priming event (Skehel and Wiley 2000). At the viral membrane-proximal 
end, the molecule is arranged into a 5-stranded, antiparallel β-sheet, composed of 
the N-terminus of HA1 and the C-terminus of HA2. The central super helix 
contains three HA2 helices twisted around each other by ~100°. The top of the 
trimeric structure is tightly packed and stabilized by nonpolar residues including 
Ile77, Leu80, Val84, Leu91, Leu98, Leu99 and Leu102. These residues form Van 
der Waals interactions around the 3-fold axis of the molecule. Polar and charged 
residues stabilize the viral membrane-proximal part of the coiled coil, and these 
are His106, Asp109, Asp112, Ser113, Asn116, Glu120 and Arg123. Intra-chain and 
inter-subunit salt bridges were shown to further stabilize this trimeric α-helical 
structure (Wilson, Skehel et al. 1981). The length of the observed molecule (~135 Å) 
and the buried position of the fusion peptide, closer to the viral envelope (~35 Å) 
than to the tip of the molecule (~100 Å) indicated, that in order to perform viral 
membrane fusion, the molecule must undergo a significant structural 
rearrangement. Thirteen years later, the crystal structure of a fragment of H3 HA2 
ectodomain, isolated from the 1968 Hong Kong pandemic virus, was determined 
using X-ray crystallography (Bullough, Hughson et al. 1994), and its crystal 
structure is described in Chapter 1.6.3. A BHA trimer is shown in Figure 1.8. 
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Figure 1.8 Crystal structures of the precursor HA0 and cleaved BHA. HA0 
structure (PDB: 1HA0) (Chen, Lee et al. 1998) is shown on the left. Cleaved 
BHA structure (PDB: 1HGF) (Wilson, Skehel et al. 1981) is shown on the 
right. Upon cleavage by host cell proteases, HA is divided into receptor-
binding (HA1) and fusion (HA2) subdomains, shown in blue and red, 
respectively. The first residue of the newly formed FP (yellow) becomes 
the new N-terminus of HA2. 
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1.6.3 Crystal structure of postfusion viral H3 TBHA2  
 
A soluble fragment of H3 HA2 in a postfusion conformation was prepared by 
releasing HA from the viral envelope with bromelain (Brand and Skehel 1972) 
(Skehel and Waterfield 1975), low pH activation by incubation at pH 5.0, and 
subsequent digestions with trypsin and thermolysin to remove the hydrophobic 
subdomains of HA2. The structure of this proteolytic fragment of viral H3 HA2, 
referred to as H3 TBHA2, was determined using X-ray crystallography in 1994 
(Bullough, Hughson et al. 1994). The previously observed irreversibility of the low 
pH-triggered structural rearrangement of HA, and its increased thermal stability 
suggested, that this refolded molecule is more thermodynamically stable than the 
molecule in its prefusion conformation (Ruigrok, Martin et al. 1986) (Chen, 
Wharton et al. 1995). As observed in the obtained crystal structure of H3 TBHA2, 
the enzymatically-prepared molecule contains the first 27 residues of HA1, and 
residues 40-162 of HA2 (Bullough, Hughson et al. 1994). Comparison of H3 TBHA2 
to the structure of prefusion H3 BHA revealed, that the central α-helix extends at 
low pH. This elongation is achieved by a recruitment of residues 40-75 of H3 HA2 
to the top of the long postfusion α-helix, and formation of an extended coiled coil is 
possible due to the presence of heptad repeats of hydrophobic residues in this 
region of the molecule (HA2 residues 38-125). Closer to the viral membrane, HA2 
residues 106-112, which are helical in prefusion HA2, refold to form a reverse turn, 
which repositions the rest of the molecule by 180°. Residues 113-129 fold into a 
short α-helix E, which runs in an opposite direction to the central stem and forms a 
six-helix-bundle. The polypeptide chain is then arranged into a loop, a fragment of 
which forms a β-hairpin (HA2 residues 131-140). Together with a disulphide-linked 
fragment of HA1, these residues are organized into an antiparallel β-sheet. The β-
hairpin motif extends further to form another short helix G (residues 146-154), 
packed against the central stem, and the rest of the polypeptide chain exists as an 
extended β-strand. Residues beyond HA2 residue 153 (one monomer) and residue 
162 (two monomers) in viral H3 TBHA2 (Bullough, Hughson et al. 1994) seem to be 
disordered. The ~100 Å long postfusion core, comprises HA2 residues 40-105, which 
display the knobs-into-holes packing (Crick 1953). Compared to the crystal 
structure of H3 BHA, only 30 residues (HA2 residues 76-105), belonging to helix C, 
remain unchanged. This dramatic structural rearrangement as compared to BHA, 
serves to relocate the two hydrophobic subdomains of HA2 (the fusion peptide and 
the transmembrane anchor) towards the endosomal membrane (Bullough, 
Hughson et al. 1994). The two structures are compared in Figure 1.9. 
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Figure 1.9 Crystal structures of prefusion and postfusion H3 HA. Trimeric 
cartoon representation of bromelain cleaved BHA is shown on the left 
(PDB: 1HGF) (Wilson, Skehel et al. 1981) and thermolysin solubilized, low 
pH-treated H3 TBHA2 is shown on the right (PDB: 1HTM) (Bullough, 
Hughson et al. 1994). HA1 domains are shown in blue, and HA2 domains 
are shown in red. The N- and C-termini are indicated. 
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1.6.4 Crystal structure of E.coli-expressed H3 HA2  
 
Recombinantly-expressed fragments of H3 HA2 containing HA2 residues 38-175 
(EBHA2) and HA2 residues 23-185 (EHA2), lacking the HA1 domains, the fusion 
peptide, and the transmembrane anchor, spontaneously folded into the same 
extended conformation as postfusion viral H3 TBHA2 (Bullough, Hughson et al. 
1994) described in Section 1.6.3, when expressed in E.coli (Chen, Wharton et al. 
1995). In order to prevent a potential aggregation of recombinantly-expressed 
molecules, HA2 Cys137, which forms a disulphide bond with Cys14 of HA1, was 
mutated to Serine. Cysteines 144 and 148, which form a disulphide bond within 
each HA2 monomer, were preserved. The expressed fragments were trimers of ~48 
kDa, with high α-helical content and high melting temperatures, recorded 
previously for TBHA2 (Ruigrok, Martin et al. 1986). Their rod-like structure, 
ability to bind the low pH-specific antibodies, and the obtained proteolytic digestion 
products agreed with those previously observed for viral postfusion H3 TBHA2 
(Ruigrok, Aitken et al. 1988) (Wharton, Calder et al. 1995).  
The crystal structure of recombinantly-expressed H3 EHA2 (Chen, Skehel et al. 
1999) suggests, that prefusion HA2 is metastable, and that low pH may be needed 
in order to induce the dissociation of HA1 subdomains in vivo (Chen, Wharton et 
al. 1995). Fragments of postfusion H3 HA2 (residues 1-185), containing the 
hydrophobic fusion peptide (HA2 residues 1-23), were previously expressed in 
E.coli. The expressed fragment was attached to a highly charged octapeptide FLAG 
(DYKDDDDK), which restored the solubility of the molecule (Chen, Skehel et al. 
1998). This fusion peptide-containing fragment (known as F185) was shown to 
have a high α-helical content and high melting temperature, as previously observed 
for H3 EBHA2 and TBHA2 (Ruigrok, Martin et al. 1986). While removal of FLAG 
resulted in aggregation of the protein molecules into rosettes, removal of the 
hydrophobic fusion peptide (HA2 residues 1-23) using thermolysin, restored protein 
solubility (Chen, Skehel et al. 1998) (Skehel and Wiley 2000). 
The crystal structure of H3 EHA2 revealed the previously unobserved N- and C-
terminal segments of the postfusion molecule, and the N-terminal residues were 
organized into an N-cap domain (HA2 residues 34-37). These residues were shown 
to stabilize and terminate the α-helical coiled coil, by the formation of hydrogen 
bonds with three unpaired residues at the N-terminus of each α-helix (HA2 
residues 38-40), and the last helical residue is Leu38 (Chen, Skehel et al. 1999). 
The capping residues (HA2 residues 34-37) interact with the extended C-termini of 
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the postfusion molecule (HA2 residues 174-178), stabilizing both membrane-
interacting regions (Chen, Skehel et al. 1999). High conservation of Ala35, Ala36 
and Asp37 suggests, that a similar N-cap exists in viral postfusion HA2 (Skehel 
and Wiley 2000). Given that beyond the observed N-cap the HA2 molecule is likely 
disordered, it is thought, that HA2 ectodomain and the fusion peptide may exist as 
two separately folded domains, linked by a flexible linker (HA2 residues 25-33) 
(Chen, Skehel et al. 1999). The stabilizing N-cap observed in the crystal structure 
of E.coli-expressed H3 HA2 (EHA2) (Chen, Skehel et al. 1999) is shown in Figure 
1.10. A schematic representation of H3 HA, and fragments of viral and 
recombinantly-expressed H3 HA2 crystallized to date are shown in Figure 1.11. 
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Figure 1.10 A trimer of H3 EHA2. Recombinantly-expressed trimer is 
shown in A. Viral membrane-distal end of the molecule viewed 
perpendicular to the molecular three-fold symmetry axis is shown in B. N-
cap residues 34-37 are shown in blue, residues 38-40 in green, residues 
174-178 in yellow. N-cap domain of EHA2 viewed down the molecular 
three-fold symmetry axis is shown in C. Colours as in B. (PDB: 1QU1) 
(Chen, Skehel et al. 1999). 
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Figure 1.11 Schematic of H3 HA molecule and fragments crystallized to 
date. HA1 and HA2 domains are shown in blue and green, respectively. 
Top model: Cleaved HA, with the TM domain (HA2 residues 186-211) 
shown in dark green, the FP (HA2 residues 1-23) shown in magenta, and 
the disulphide bond linking HA1 residue 14 and HA2 residue 137 shown in 
black. Shown below are: BHA (Wilson, Skehel et al. 1981), TBHA2 
(Bullough, Hughson et al. 1994), EHA2 (HA2 residues 23-185) (Chen, Skehel 
et al. 1999) and EBHA2 (HA2 residues 38-175) (Chen, Wharton et al. 1995). 
Figure adapted from (Chen, Skehel et al. 1999). 
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1.6.5 Crystal structure of E.coli-expressed Influenza B 
HA2  
 
Influenza B viruses cause seasonal influenza outbreaks, and share low levels of 
sequence identity with influenza A (~39%). Influenza B viruses are divided into 
two co-circulating lineages: Yamagata and Victoria (Rota, Wallis et al. 1990). 
Recently, a crystal structure of E.coli-expressed, influenza B/Yamagata/73 (HA2 
residues 31-181) in a postfusion conformation has been reported, revealing a 
hairpin-like structure as that of influenza A HA2 (Ni, Chen et al. 2014). As shown 
in Figure 1.12, the postfusion stem can be divided into three α-helical segments: 
helix A (residues 38-55), helix B (residues 56-75), and helix C (residues 76-105). 
Overall, the observed structure (Ni, Chen et al. 2014) is similar to that of 
postfusion influenza A H3 HA2 (Bullough, Hughson et al. 1994) (Chen, Skehel et 
al. 1999), and main structural differences can be seen in the regions of loops and in 
segment B (HA2 residues 56-75), belonging to the central, postfusion core of the 
extended molecule (Ni, Chen et al. 2014). The postfusion structure of the N-
termini, containing residues of the N-cap domain (residues 34-37), and that of 
segment A of the long α-helix, were shown to be conserved between postfusion HA2 
from influenza A and influenza B. The C-termini (HA2 residues 154-181) of the 
rearranged influenza B HA2 were shown to form contacts with the capping 
residues of the N-cap domain (Ni, Chen et al. 2014). Aligned monomers of E.coli-
expressed influenza A H3 HA2 and influenza B HA2 in a postfusion conformation 
are shown in Figure 1.12. 
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Figure 1.12 Structural alignment of X31 H3 EHA2 and influenza B HA2. A 
monomer of E.coli-expressed H3 EHA2 is shown in red (Chen, Skehel et al. 
1999) (PDB: 1QU1) and monomer of influenza B HA2 in a postfusion 
conformation is shown in pink (Ni, Chen et al. 2014) (PDB: 4NKJ). The N- 
and C-terminal residues are indicated. Segments A-G undergo refolding at 
low pH, and the postfusion stem comprises helix A (residues 38-55), helix 
B (residues 56-75) and helix C (residues 76-105). 
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1.7 Group-specific structural features of HA  
 
The 16 HA antigenic subtypes fall into two phylogenetic groups (Air 1981) (Russell, 
Gamblin et al. 2004), and sequence identity between them is 30-70% (Nobusawa, 
Aoyama et al. 1991) (Kawaoka, Yamnikova et al. 1990) (Rohm, Zhou et al. 1996). 
The primary sequence is a basis for classification of HA subtypes into group 1 (H1, 
H2, H5, H6, H8, H9, H11, H12, H13 and H16) and group 2 (H3, H4, H7, H10, H14 
and H15) HA. Crystal structures of H1, H2, H3, H5, H7, H9, and H16 HA have to 
date been reported. Sequence alignment of representative subtypes from group 1 
and group 2 HA in the region of HA2 (residues 1-221) is shown in Figure 1.13. 
The two HA groups are further subdivided into four clades based on the 
phylogenetic characterization and sequence homology of HA gene. Group 1 HA is 
subdivided into two clades represented by H1 (H1, H2, H5, H6, H11, H13, H16) 
and H9 (H8, H9, H12) subtypes, respectively. Group 2 HA is subdivided into two 
clades represented by subtypes H3 (H3, H4, H14) and H7 (H7, H10, H15) 
(Nobusawa, Aoyama et al. 1991).  
The characteristic structure and orientation of an interhelical loop B, present in 
each prefusion HA2 monomer, is one of the group-specific structural features of HA 
(Russell, Gamblin et al. 2004). Loop B (HA2 residues 56/59-74) connects the 
prefusion helices A (HA2 residues 38-55/58) and C (HA2 residues 75-105). Clades 
represented by H3 and H7 subtypes (group 2 HA) are characterised by a sharp 
nature of the turn at HA2 residue 75. The structure of this turn has been 
correlated with the presence of glycine at residue 75 of HA2 (the N-terminus of the 
conserved helix C), or with the presence of a carbohydrate side chain at residue 82 
of HA2, in clades H3 and H7, respectively (group 2 HA) (Keil, Geyer et al. 1985). 
Clades H1 and H9 (group 1 HA) can be distinguished by a presence of tall turns at 
HA2 residue 75. Group-specific structures of prefusion loops B are shown in Figure 
1.14. The characteristic nature of these fragments of prefusion HA2 (residues 
56/59-75) is thought to affect the orientation of HA1 domains relative to the stem of 
the molecule (composed mainly of HA2), which is different in the two HA groups 
(Russell, Gamblin et al. 2004). Differences in rotation of the receptor binding 
domains about the three-fold symmetry axis of the molecule are the largest across 
groups, and difference between H1 and H7 is 31°. Within the group these 
differences are reduced to 6° (H3 to H7), and are the smallest within the subtype. 
For example the orientation of HA1 subdomains versus HA2 subdomains of H1 
HA, isolated from three different virus strains: the 1918 pandemic virus (Reid, 
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Fanning et al. 1999), classical swine H1 A/swine/30 virus (Shope 1931), and from 
the prototype human H1 A/Puerto Rico/8/34 virus (Francis 1934), was previously 
shown to be very similar (rotation by 1°) (Russell, Gamblin et al. 2004). Rotation of 
HA1 domains relative to HA2 stem for representatives of the two HA groups is 
shown in Figure 1.15. Another group- and clade-specific structural feature of HA2 
is the type of ionisable residues found in the cavity that accommodates the 
hydrophobic fusion peptide (at the N-terminus of HA2). Protonation of these 
residues after exposure of the virus to the low pH of the endosomes (pH~5.0), is 
thought to be a trigger for the conformational change of HA, required for 
haemagglutinin to perform viral membrane fusion by the formation of an extended 
intermediate (Chen, Skehel et al. 1999) (Ni, Chen et al. 2014). While some residues 
within this cavity (Asp109, Asp112 and Lys51) are conserved across all HA 
subtypes, other amino acids are group-specific. The conserved His17 of HA1, and 
His106 of HA2 are found in the primary sequences of group 2 HA (clades H3 and 
H7).  Subtypes belonging to group 1 HA (clades H1 and H9) contain a conserved 
His111. Some amino acids belonging to this pocket are clade-specific, like HA2 
Arg106 and Lys106, in clades H1 and H9, respectively (Ha, Stevens et al. 2002) 
(Russell, Gamblin et al. 2004).  
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Figure 1.13 Sequence alignment of group 1 and group 2 HA in the region 
of HA2. Group 1 HA is represented by H1 (B59), H2 and H5. Group 2 HA is 
represented by H3, H7 and H10. Sequence alignment was carried out 
using PRALINE multiple sequence alignment (Simossis and Heringa 2003) 
(Simossis and Heringa 2005). Residues are coloured by conservation.  
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Figure 1.14 Group-specific structures of loop B. Monomeric cartoon 
representation of prefusion H3 HA2 (PDB: 1HGF) and H1 HA2 (PDB: 
1RUZ). Helical segments A, C, D, E and G, which undergo refolding at low 
pH, are highlighted. Loop B, the fusion peptide, and other key residues 
are indicated. 
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Figure 1.15 Rotation of HA1 domains relative to HA2 stem of HA. 
Molecules are shown as monomers. Group 1 HA is represented by subtype 
H1, and group 2 HA is represented by subtype H3. Figure from (Russell, 
Gamblin et al. 2004). 
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1.8 Anti-HA antibodies 
 
1.8.1 Antibodies blocking receptor-binding 
 
Majority of human anti-HA antibodies generated upon vaccination or infection, are 
directed against HA1 domains, which undergo a frequent antigenic change, and 
accumulated mutations resulting from RNA polymerase errors and selective 
immune pressure, lead to annual epidemics. As described in Section 1.4.3, five 
antigenic sites involved in antibody recognition have been characterized on the 
surface of globular head domains of H1 (Caton, Brownlee et al. 1982) and H3 HA 
(Wiley, Wilson et al. 1981). The serum antibody response is therefore subtype-
specific, and cross-reactive antibodies are uncommon. The HA1-specific antibodies 
may block virus infectivity by interfering with the receptor-binding function of the 
molecule (Knossow and Skehel 2006). The antibody-binding epitopes located “below 
the tip” of HA were initially identified using electron microscopy (Wrigley, Brown 
et al. 1983). By binding to the viral membrane-distal end of HA, these antibodies 
block the attachment of the viral particle to the target cell (Outlaw and Dimmock 
1991). The footprints of these antibodies range from 1200 A2 -1500 A2, and can 
therefore sterically block receptor binding, by covering the receptor-binding site, 
the surface area of which is ~800 A2 (Skehel 2009). Structural studies on H3 HA in 
complex with Fab fragments from two neutralizing monoclonal antibodies, named 
HC19 and HC45, revealed HC19 directly blocking receptor-binding function of HA 
by interacting with the conserved residues of the receptor-binding site, and HC45 
was found to neutralize infectivity indirectly, by binding 17 Å below the receptor-
binding site (Bizebard, Gigant et al. 1995) (Fleury, Wharton et al. 1998) (Fleury, 
Barrere et al. 1999). Despite a much weaker affinity for HA, the HC19 antibody, 
which binds near the receptor-binding site, has been shown to neutralize infectivity 
more efficiently than HC45 (Fleury, Barrere et al. 1999). Human monoclonal 
antibody known as CH65 was also found to neutralize a broad spectrum of H1 
viruses, by overlapping with the receptor-binding site (Whittle, Zhang et al. 2011). 
Cross-reactive antibodies directed at the conserved receptor-binding site and its 
surroundings have recently been identified, and these are C05 (neutralizes 
subtypes H1, H2 and H3) (Ekiert, Kashyap et al. 2012), and S139/1 (neutralizes 
various subtypes including H1 and H3) (Lee, Yoshida et al. 2012). 
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1.8.2 Antibodies interfering with the conformational 
change of HA 
 
Antibodies, which do not block virus entry, can neutralize influenza viruses at a 
later stage of viral infection, for example by interfering with the low pH-triggered 
conformational change of HA, and thus viral membrane fusion (Corti, Voss et al. 
2011). These antibodies block infection by binding to the conserved, viral 
membrane-proximal end of HA, near its fusion subdomain. It has been shown, that 
broadly-neutralizing antibodies are generally less effective than a strain-specific 
antibody in vitro (Haaheim and Schild 1980). These antibodies, however, can 
provide a significant protection in vivo (Mozdzanowska, Furchner et al. 1997) 
(Mozdzanowska, Feng et al. 2006). Such cross-reactive antibodies have been 
prepared, complexed with HA, and structures of the complexes were solved using 
X-ray crystallography. These monoclonal antibodies are known as CR6261 (Ekiert, 
Bhabha et al. 2009) and F10 (Sui, Hwang et al. 2009), and neutralize multiple 
influenza A subtypes of group 1 HA, by heavy chain-mediated binding to a 
conserved epitope composed of helix A of HA2 and few residues of HA1. Antibodies 
with broader specificity have also been identified, and these are known as FI6v3 
(Corti, Voss et al. 2011) and CR9114 (Dreyfus, Laursen et al. 2012).  
The FI6v3 antibody was isolated using a single plasma cell culture method, where 
supernatants were screened for the presence of antibodies able to neutralize both 
H5 and H7. The antibody was isolated from a donor, following a seasonal 
vaccination, and after infection with the 2009 pandemic SOIV (swine-origin 
influenza virus). The FI6v3 antibody recognizes an epitope similar to that 
recognized by CR9114, but binds at a different angle (90° rotation compared to 
CR9114) (Corti, Voss et al. 2011). The FI6v3 uses both heavy and light chain in its 
binding to HA, mainly by HCDR3 (heavy-chain variable complementarity 
determining region 3), and with LCDR1 (light-chain variable complementarity 
determining region 1), crosslinking two monomers of one haemagglutinin trimer by 
interacting with helix A of one HA monomer, and the fusion peptide of the 
neighbouring monomer (Corti, Voss et al. 2011). In the future, cross-reactive 
antibodies may be used for passive immunization as prophylaxis or therapy, and 
characterization of the conserved epitopes on HA, which may play a critical role in 
membrane fusion, can enable the development of broad influenza vaccines and 
antibody-based antiviral agents. The FI6 antibody bound to a trimer of prefusion 
H3 HA is shown in Figure 1.16. 
 53 
 
 
 
 
 
 
Figure 1.16 The FI6 antibody bound to a trimer of prefusion H3 HA.  The 
antibody binds to the stem region using both light and heavy variable 
chains (LCVD and HCVD), crosslinking two HA monomers and interacting 
with helix A of one monomer and the fusion peptide of the neighbouring 
monomer (PDB: 3ZTJ) (Corti, Voss et al. 2011). Light and heavy constant 
domains (LCCD and HCCD) of FI6 are also shown. Antibody domains are 
shown in green and blue. 
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1.9 Current treatments 
 
Infection can be prevented by acquisition of protective immunity through 
vaccination. Vaccine types currently available worldwide include: inactivated 
whole virion, split-products, purified surface antigens, and LAIV. The split-
products vaccine is produced by disruption of the viral envelope with a detergent, 
followed by inactivation using formaldehyde. The surface purified surface antigen 
vaccine is composed of purified viral glycoproteins. Live attenuated influenza 
vaccine (LAIV) contains influenza A H1N1, influenza A H3N2 and two strains of 
influenza B virus (George, Farooq et al. 2010) (Kahn, Santibanez et al. 2015). The 
evolving nature of influenza virus, together with a reduction of vaccine-induced 
antibody response over time, result in a decline in vaccine-induced immunity, 
which last ~1 year. While immunity resulting from infection with the virus can last 
a lifetime (Yu, Tsibane et al. 2008), the seasonal inactivated vaccines need to be 
updated every year (Couch 2008), and their composition depends on the 
recommendations made by WHO Global Influenza Surveillance and Response 
System.  
Antiviral drugs can reduce and shorten symptoms of viral infection when taken 
within two days of the onset of influenza symptoms (Montalto, Gum et al. 2000). 
Neuraminidase inhibitors, such as zanamivir and oseltamivir, block the receptor-
destroying enzymatic activity of NA, by binding to the highly conserved enzyme 
active site, thus preventing the release of the newly assembled viruses from 
infected cells (Colman 1994). These competitive inhibitors of NA were developed 
using structure-based drug design, and closely resemble binding of the sialic acid. 
Oseltamivir (Lew, Chen et al. 2000) (Tamiflu) is taken orally, and zanamivir 
(Relenza) is administered by inhalation. Low frequency of viral resistance to NA 
inhibitors is associated with high conservation of NA active site, and resistance-
causing mutations would most likely affect enzyme’s activity (Ward, Small et al. 
2005).  Arbidol is a drug that inhibits viral membrane fusion by stabilizing the 
prefusion conformation of HA molecule, and thus preventing its low pH-induced 
structural rearrangement and blocking viral membrane fusion (Boriskin, Leneva et 
al. 2008) (Leneva, Russell et al. 2009). 
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1.10 Objectives for thesis 
 
As described in Section 1.5, in order to assist viral membrane fusion, influenza 
virus HA must undergo a significant, low pH-induced structural rearrangement 
(Skehel, Bayley et al. 1982). The structural information concerning this 
conformational transition of influenza HA, has so far only been gained for subtype 
H3 of the 1968 pandemic virus (Bullough, Hughson et al. 1994) (Chen, Skehel et al. 
1999), and this HA subtype belongs to the phylogenetic group 2 HA.  
Group- and clade-specific structural differences between the prefusion HA 
molecules from the two groups, are the basis for classification of the emerging HA 
subtypes (Russell, Gamblin et al. 2004) and are summarized in Section 1.7.  
Thus the primary objective for this thesis was to obtain a crystal structure of 
postfusion HA2 from group 1 HA. The obtained postfusion viral and recombinantly- 
expressed structures of HA2 representing the two phylogenetic groups will be 
compared to assess, whether group-specific characteristic features of prefusion HA 
cause structural differences in their postfusion form. Differences between the 
postfusion form of group 1 and group 2 HA molecules could be correlated to 
potential differences in function. Subtype H1 was chosen to represent group 1 HA, 
and crystallisation trials were performed using a low pH-activated viral, and 
recombinantly-expressed H1 HA2 derived from A/Brisbane/59/07 (B59) and 
A/PuertoRico/8/34 (PR8) H1N1 viruses.  
In addition, the aim was to test the cross-reactive FI6 antibody (Corti, Voss et al. 
2011) for its ability to disrupt the low pH-induced conformational change of HA, 
and for its effect on the infectivity of viruses containing HA from the two groups. 
Methods used for this part of the study included electron microscopy, circular 
dichroism, biolayer interferometry, limited proteolysis and in vitro MDCK1 cell 
infection. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Virus strains 
1. A/Aichi/2/68 (H3N2) (X31)-recombinant influenza A virus (Kilbourne 1969). 
X31 is a reassortant that contains six internal genes of PR8, and the surface 
haemagglutinin and neuraminidase of the H3N2 virus  
2. A/Brisbane/59/07 (H1N1) (B59)-influenza A vaccine strain 
3. A/Puerto Rico/8/34 (H1N1) (PR8)-influenza A laboratory vaccine strain 
4. A/Tokyo/3/67 (H2N2)- influenza A virus 
Viruses were obtained from the WHO Influenza Centre (NIMR, London). 
2.1.2 Antibodies 
1. FI6–a cross-reactive anti-HA antibody obtained from Antonio Lanzavecchia 
(Institute for Research in Biomedicine, Bellinzona, Switzerland) (Corti, Voss 
et al. 2011) 
2. Hc31-strain-specific anti-HA antibody obtained from Alan Douglas (NIMR, 
London) (Daniels, Douglas et al. 1983) 
2.1.3 Reagents 
Reagents used in this study were purchased from Sigma, Abgene, Fluka, GE 
Healthcare, Promega, Qiagen, Roche, Invitrogen, Hampton Research, Roche, Jena 
Bioscience and Molecular Dimensions. Specific chemicals and reagents are detailed 
in the relevant sections of this thesis. 
2.1.4 Cell lines 
MDCK1- cells from the kidney of a normal female adult Cocker Spaniel, which 
support growth of wide range of animal viruses. MDCK1 cells used in this study 
were obtained from Dr Nicole Friedrich (Marburg). 
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2.2 Protein expression 
 
2.2.1 Viral H1 HA2 in a postfusion conformation 
 
2.2.1.1 Virus infection and growth in embryonated eggs 
 
The 9-10 day old embryonated chicken eggs were incubated at 37°C before infection 
with influenza viruses, diluted using 1X phosphate-buffered saline (PBS), 
containing 1% penicillin and 1% streptomycin, and 0.1 ml of a diluted inoculum 
was injected into the allantoic cavity using a 1 ml needle. The inoculation site was 
sealed with a melted wax/paraffin mixture, and the infected eggs were placed into 
an incubator, and left at 37 °C, for 48 h, at 60-65% humidity, in order to maintain 
moisture and prevent death of the embryos. Virus replicates in cells that make up 
the chorioallantoic membrane attached to the embryo, and which acts to remove 
soluble, insoluble and gaseous waste products of the developing embryo. New viral 
particles are released by budding into the allantoic fluid located in the allantoic 
cavity. Eggs were then placed into a cold room (4°C) for 12-24 h, according to The 
Code of Practice for the Humane Killing of Animals under Schedule 1 to the 
Animals (Scientific Procedures) Act 1986. 
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2.2.1.2 Virus purification 
 
Viruses were purified by the procedure of Skehel and Schild (Skehel and Schild 
1971). To harvest the virus, the top of the egg was smashed with a knife handle to 
open the eggshell. The top of the eggshell covering the air sac was removed with 
tweezers. The air sac at the rounded end of an egg is responsible for respiration 
and pressure adjustments. The shell and chorioallantoic membranes were pierced 
with a pair of tweezers, and the allantoic fluid (~10 ml/egg) was aspirated using a 
vacuum pipette. The allantoic fluid was clarified by centrifugation at 3,000 rpm, for 
15 min, at 4°C, in a Beckman swinging bucket centrifuge. The pellet composed of 
red blood cells was discarded, and the supernatant containing virus particles was 
centrifuged overnight at 6,000 rpm, 4°C, in a Beckman Aventi J25 centrifuge (rotor 
F10 or JLA 10500). The supernatant was decanted, and virus pellets were 
recovered and resuspended PBS buffer. Resuspended virus was homogenized using 
a glass homogenizer, and then sonicated for 1 min in a sonication bath. Virus (up to 
8 ml/gradient) was layered on top of continuous 15-40% [v/v] sucrose density 
gradients, and centrifuged at 25,000 rpm, for 45 min, at 4°C, using a L90K or XL90 
centrifuge with a SW32Ti rotor. In these gradients, virus particles travel through 
the gradient, until they reach a point, at which their density matches that of the 
surrounding sucrose. As influenza viruses have densities of ~1.1 g/cm3 in an 
aqueous solution (Sharp 1945), the density of sucrose used for virus purification 
was 1.06-1.17 g/cm3, corresponding to 15-40% sucrose [v/v]. Virus-containing 
fractions were removed with a pipette, diluted with resuspension buffer containing 
10 mM Tris pH 8.0 and 150 mM NaCl, to dilute the remaining sucrose, and 
centrifuged at 25,000 rpm, for 90 min, at 4°C, in a SW32Ti rotor. The supernatant 
was decanted, and virus pellets were diluted with a resuspension buffer (10 mM 
Tris pH 8.0, 150 mM NaCl). 
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2.2.1.3 Release of HA from purified virus with bromelain 
 
Digestion of viral particles with bromelain releases a fragment of the HA 
ectodomain (Brand and Skehel 1972) (Waterfield, Espelie et al. 1979) by digesting 
once after Gly175 of HA2, and the released molecule is a soluble trimer (Dopheide 
and Ward 1981). After digestion with the enzyme, and centrifugation to remove 
virus cores, the soluble protein is present in the supernatant, and can be purified 
by sucrose density gradient centrifugation, or alternatively, by size-exclusion 
chromatography (Waterfield, Espelie et al. 1979). This enzymatically-released 
molecule is a transmembrane anchor-less fragment of prefusion HA, and therefore 
does not aggregate in solution (Waterfield, Espelie et al. 1979). This method has 
been used successfully on different virus strains, and susceptibility of HA to 
bromelain digestion was shown to be strain-dependent. 
 
Experimental details: 
Bromelain extract from Pineapple stem (Sigma) at 2% [w/w] in the presence of 10 
mM βME was added to virus suspensions, and incubated at 37°C, for 90 min, in a 
water bath. Proteolytic digestions were stopped by the addition of protease 
inhibitor cocktail tablets. Viruses were transferred to 3 ml polycarbonate 
centrifuge tubes, and centrifuged at 55,000 rpm, for 10 min, at 4°C, in a Beckman 
TL-100 ultracentrifuge with TLA 100.3 rotor. The supernatant containing BHA 
was purified by sucrose density gradient centrifugation followed by ion-exchange 
chromatography (2.3.4), or by ion exchange (2.3.4) and gel filtration (2.3.5).  
In case of PR8 H1 BHA, the supernatant containing BHA was layered on top of a 
continuous 5-25% sucrose gradient [v/v], in 25 mM Tris pH 8.0, and centrifuged at 
38,000 rpm, for 18 hours, at 10°C. Protein-containing fractions were identified 
using SDS-PAGE (2.3.3), and purified using ion-exchange chromatography (2.3.4). 
The amount of the bromelain-released protein was estimated using SDS-PAGE 
(2.3.3). As different virus strains vary in susceptibility of their HA to bromelain 
digestion (Waterfield, Espelie et al. 1979), some protein preparations required 
multiple bromelain digestions. Additional digestions were performed by incubating 
the resuspended pellets with bromelain as previously described, until enough BHA 
was released from virus particles and subsequent digestions were typically ~2 h, at 
37°C. 
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2.2.1.4 Detergent extraction 
 
An entire haemagglutinin molecule can be released from the viral particle by 
disruption of the lipid envelope with a detergent (Waterfield, Espelie et al. 1979). 
In this case, the released molecule contains the hydrophobic transmembrane (TM) 
anchor located at the C-terminus of HA2, and thus aggregates in solution. In order 
to obtain a soluble fragment of HA for structural studies, detergent extraction is 
usually followed by digestion of HA with trypsin, to remove the hydrophobic TM 
anchor (HA2 residues 185-211), and the resulting molecule is known as THA. 
 
Experimental details: 
Purified viruses were resuspended in 10 mM Tris pH 8.0, 150 mM NaCl, and 2% 
[v/v] Lauryldimethylamine-oxide (LDAO) or n-Octyl-β-D-Glucoside (BOG). Viruses 
were incubated with a detergent at 4°C, for 30 min. Following incubation with a 
detergent, virus was centrifuged at 55,000 rpm, for 10 min, at 4°C, using a 
Beckman TL-100 ultracentrifuge with TLA 100.3 rotor, in order to remove virus 
cores. The HA-containing supernatant was collected and subjected to protein 
purification. Detergent-released HA was layered on top of a continuous 5-25% 
sucrose density gradient [v/v], containing 0.1% BOG [v/v], and centrifuged at 
38,000 rpm, for 18 hours, at 10°C. Protein-containing fractions were identified by 
SDS-PAGE (2.3.3), pooled, and purified using ion-exchange chromatography (2.3.4) 
with a HiTrap Mono-Q HP column (GE Healthcare). Protein samples were 
concentrated using 50K MWCO concentrators (Vivaspin), and digested with 
trypsin, at a ratio 1:10 [w/w], trypsin: protein, for 1 hour, at RT, in order to remove 
the TM anchor at the C-terminus of H1 HA2. Digestions were stopped with an 
equal amount of soybean trypsin inhibitor (Sigma), and digestion products were 
separated on 5-25% sucrose gradients [v/v] in 10 mM Tris pH 8.0, at 38,000 rpm, 
for 18 hours, at 4°C. Protein samples were dialyzed into 25 mM Tris pH 8.0, 150 
mM NaCl, concentrated using 6 ml 50K MWCO concentrators (Vivaspin), and 
subjected to a low pH treatment as described in Section 2.3.6. 
Alternatively, following detergent solubilisation, the supernatant was diluted with 
25 mM Tris pH 8.0, to contain 25mM NaCl, and the TM anchor removal was 
carried out directly by the addition of trypsin. Depending on virus strain and batch, 
removal of the TM anchor would last from 1.5 h to overnight. After the addition of 
the soybean trypsin inhibitor, the protein-containing solution was centrifuged at 
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25,000 rpm, for 15 min, at 4°C, in a BV52 rotor, and the collected supernatant was 
subjected to ion-exchange chromatography (2.3.4) and gel filtration (2.3.5). 
 
 2.2.2 Recombinant H1 HA2 in a low pH conformation 
 
Recombinant baculovirus (Autographa californica multiple nuclear polyhedrosis 
virus) was used to express the ectodomain of H1 HA2 in cultured Sf9 (Spodoptera 
frugiperda) cells. The cDNA encoding HA2 residues 38-175 of A/Brisbane/59/07 
H1N1 HA was subcloned into a modified pAcGP67A (BD Biosciences) baculovirus 
transfer vector (pHAEM) that carries a TEV protease cleavage site, and a 6x His 
tag (Lin, Xiong et al. 2012), and subcloning was performed by GeneArt. Cys137, 
which forms a disulphide bond with Cys14 of HA1 (H3 numbering) (Wilson, Skehel 
et al. 1981), was changed to Ser for expression (to prevent aggregation of HA2) 
(Chen, Wharton et al. 1995), and two cysteines (Cys144 and Cys148) that form 
disulphide bonds within HA2 were preserved. TEV protease cleavage sequence was 
included between the spacer and the N-terminus of HA2 (residue 38), to allow for a 
removal of the 6x His tag at the extreme N-terminus of the expressed polypeptide 
sequence, for use in affinity purification (Figure 2.1). Recombinant baculovirus was 
generated by cotransfection of BD BaculoGoldTM Linearized Baculovirus DNA (BD 
Biosciences) and recombinant plasmid into Sf9 cells. Following virus amplification 
under ampicillin selection, large-scale expression was performed in 2.5 L of Sf9 
insect cells suspension cultures, and the expressed protein is secreted into the cell 
culture medium. Protein expression was kindly carried out by Dr Phil Walker at 
NIMR. Cells were removed by centrifugation, 72 h post-infection, and the 
supernatant was concentrated using a large-scale concentration unit with a 10K 
MWCO membrane, and loaded onto a Talon cobalt column (2.3.8). Fractions 
containing recombinantly-expressed Bac B59 H1 HA2 were pooled, and protein 
buffer was exchanged, by concentrating into 20 mM Tris pH 8.0, 150 mM NaCl. 
Concentrated protein was digested with TEV protease [10:1 HA: TEV w/w, RT, 
overnight] to cleave the spacer and the 6x His tag. The His tag was removed by 
passage over the Ni-NTA resin (Qiagen), and Bac B59 H1 HA2 was further purified 
by size-exclusion chromatography (2.3.5) using the Superdex-200, 16/60-gel 
filtration column (GE), equilibrated with 20 mM Tris-HCl pH 8.0, 150 mM NaCl. 
Fractions containing Bac B59 H1 HA2 were collected, and protein buffer was 
exchanged to contain 10 mM Tris-HCl pH 8.0 and 50 mM NaCl. The expressed 
protein was concentrated to 6mg/ml (A280) for crystallisation trials (2.3.9).  
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Figure 2.1 Bac B59 H1 HA2 expression construct. Construct containing 
the H1 HA2 gene is shown in A. The amino acid sequence of the encoded 
H1 HA2 fragment (HA2 residues 38-175) is shown in B. The N- and C-
termini of the polypeptide fragment are indicated. Cysteines 144 and 148 
that form a disulphide bond within each HA2 monomer are shown in 
yellow. Cysteine137, which forms a disulphide bond with HA1 and was 
changed to serine for expression and is shown in green.  
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2.3 Protein preparation 
 
2.3.1 Quantification of viruses using SDS-PAGE 
 
Quantification of X31 H3N2 and B59 H1N1 viruses was performed prior to biolayer 
interferometry experiments (2.4.6). Concentration of viruses was calculated from 
the estimated viral nucleoprotein (NP) contents, and standardized by comparison 
of the NP band intensity with the protein standard. The number of NP 
molecules/virion was calculated based on the influenza virion genome, consisting of 
13,588 nucleotides, and binding of 23 nucleotides per one NP monomer (Ruigrok 
1998). Bovine Serum Albumin (BSA) Standards (Sigma) were diluted to 200 µg/ml, 
and the reference samples were prepared by mixing 16, 12, 8 and 4 µl of BSA at 
200 µg/ml with 10 µl of reducing 2X LDS, so the final amount of BSA was 3.2, 2.4, 
1.6 and 0.5 µg, respectively. Virus stocks were diluted 2x with 20 mM Tris pH 8.0, 
150 mM NaCl, and virus samples were prepared by mixing 2, 1 and 0.5 µl of 
viruses with 10 µl of non-reducing 2X LDS.  All samples were boiled at 100˚C, spun 
in the centrifuge, and loaded onto Novex 4-12% Bis-Tris gels (Invitrogen). Gels 
were stained with InstantBlue Coomassie stain (Expedeon), scanned, and images 
were analysed using image-processing software (Image J). Following the addition 
of a correction factor, the intensity of viral NP bands was compared to that of BSA 
standards, and the approximate virus concentrations were calculated in nM. A 
typical quantification of viruses using SDS gel electrophoresis is shown in Figure 
2.2. 
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Figure 2.2 Quantification of viruses using SDS-PAGE. Lanes 1-4 contain 
BSA standards, and lanes 5-7 contain samples of B59 H1N1 virus. Virus 
concentration is determined by comparison of viral NP band intensity 
with the intensity of BSA standards. Details of SDS-PAGE are included in 
Section 2.3.3. 
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2.3.2 Determination of protein concentration 
 
Protein concentration measurements were routinely carried out on the purified 
protein fractions, pooled, and concentrated using Vivaspin 20 50K, 30K and 10K 
MWCO concentrators (Sartorius) at various stages of protein preparation. Prior to 
measurements samples were usually centrifuged at 4,000 rpm, for 10 min, at 4°C. 
Protein concentration was determined using UV-Vis spectrophotometry, and the 
absorbance of protein samples was measured at a wavelength of 280 nm, using a 
NanoDrop Spectrometer (ND-1000) (Thermo Scientific).  
 
2.3.3 SDS-PAGE 
 
All Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
experiments were performed using Novex 4-12% Bis-Tris gels (Invitrogen), in 1X 
MES running buffer (Invitrogen), unless stated otherwise. Protein molecular 
weight was visualized using the SeeBlue® Plus2 Prestained Protein Standard 
(Invitrogen). Samples for non-reducing gels were prepared by mixing protein 
solutions (15 µl) with 5 µl of NuPAGE LDS sample buffer (Thermo Fisher 
Scientific). For reducing gels, 1 µl of 1M TCEP (tris (2-carboxyethyl) phosphine) at 
pH 8.0 was added to the samples. Samples were heated to 95°C, for 5 min, and 
loaded onto a gel. Gels were run in an XCell SureLock mini-cell (Invitrogen), at a 
constant 200 V, for 43 min, and stained with InstantBlue Coomassie stain 
(Expedeon). Throughout the thesis, gel electrophoresis images show SDS-PAGE 
under non-reducing (NR) and reducing (R) conditions. 
 
2.3.4 Ion-exchange chromatography 
 
Ion-exchange chromatography (IEX) was used in preparation of postfusion viral H1 
HA2 following the release/extraction of H1 HA from viral envelope using the two 
methods (2.2.1.3 and 2.2.1.4). HA (pI 6.74) was selectively separated from NA (pI 
6.09) and other contaminating viral proteins, using anion exchange 
chromatography. A HiTrap Mono-Q HP column (GE Healthcare) was first 
equilibrated with an equilibration buffer, containing 25 mM Tris pH 8.0 and 25 
mM NaCl. Protein buffer was exchanged to 25 mM Tris pH 8.0, 100 mM NaCl, and 
protein sample was applied to the column using a P1 peristaltic pump (GE 
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Healthcare), at a flow rate of 2 ml/min. The column was attached to the AKTA 
purifier (GE Healthcare), and washed with 2 column volumes (CV) of binding 
buffer, to remove all non-bound proteins. HA was eluted by increasing the ionic 
strength of the elution buffer (25 mM Tris pH 8.0 and 1 M NaCl; 0-100% linear salt 
gradient), over a total volume of 250 ml. The 10 ml fractions were analysed using 
SDS-PAGE (Section 2.3.3), and HA-containing fractions were collected for further 
purification using size-exclusion chromatography (2.3.5). 
 
2.3.5 Size-exclusion chromatography 
 
Size-exclusion chromatography (SEC) was employed to separate contaminants and 
protein aggregates at various stages of protein preparation, as well as a final 
protein purification step prior to protein crystallisation. A Superdex S200 16/60 
size exclusion column (GE Healthcare) was equilibrated with a gel filtration buffer, 
containing 25 mM Tris pH 8.0 and 150 mM NaCl, on the AKTA purifier (GE 
Healthcare), at a flow rate of 1.5 ml/min. Protein samples were concentrated to a 
volume of < 5 ml, injected onto the gel filtration column, and eluted at a flow rate 
of 1.5 ml/min, over a total volume of 120 ml (1.5 ml fractions). Fractions were 
analysed using SDS-PAGE (2.3.3), and the appropriate fractions were pooled for 
further analysis. 
 
 67 
2.3.6 Low pH treatment 
Background: 
It is known, that the low pH treatment (~pH 5.0) results in an induction of 
structural refolding of influenza virus HA, which as part of this process, exposes its 
hydrophobic fusion peptide (FP) at the N-terminus of each HA2 monomer (residues 
1-23) (Skehel, Bayley et al. 1982). Exposure of the FP subdomains of HA2 causes 
aggregation of multiple HA trimers (~8) into rosettes (Ruigrok, Aitken et al. 1988). 
Another feature of this low pH-induced refolding is the observed extension of the 
trimeric coiled coil (Bullough, Hughson et al. 1994) (Chen, Wharton et al. 1995) 
(Chen, Skehel et al. 1999), which exposes the protease cleavage sites normally 
buried at neutral pH, and the rearranged molecule becomes susceptible to 
proteolytic digestion (Skehel, Bayley et al. 1982). These two features of the 
observed structural reorganization of HA at low pH were exploited in preparation 
of postfusion viral H1 HA2, specifically in proteolytic removal of HA1 and the FP 
regions from the low pH-treated HA prior to crystallisation. 
 
Experimental details: 
The conformational change of viral, bromelain-released BHA (2.2.1.3) and 
detergent-extracted THA (2.2.1.4), was typically induced by incubation of 
BHA/THA samples at pH ~5.0. Incubation at low pH was preceded by purification 
of BHA/THA samples using ion-exchange chromatography (2.3.4) and gel filtration 
(Section 2.3.5). Purified BHA/THA samples were transferred to Sterilin™ 7 ml 
Polystyrene Bijou Containers (Thermo Scientific), and the pH of the samples was 
lowered to pH ~5.0 using 0.1 M citric acid, or alternatively, 0.1 M Sodium citrate 
pH 3.5. Following incubation of HA at pH ~5.0, the pH was readjusted to pH 7.8, 
using 1 M Tris pH 8.0. The progress of the expected conformational rearrangement 
of HA was monitored using limited proteolysis (2.3.7), and SDS-PAGE (2.3.3), 
utilizing the acquired susceptibility of the low pH-activated molecule to proteolytic 
cleavage, and samples containing the rearranged protein were pooled and 
subjected to further purification steps. 
The procedure was also performed on purified viruses, and virus-antibody 
complexes prior to electron microscopy (2.4.5). The conformational change of virus-
bound HA was induced by incubation of viruses and virus-antibody complexes at 
pH 4.8, and the pH was lowered using 0.1 M Sodium citrate pH 3.5, for 45 min, at 
RT. The low pH treatment was stopped by adjusting the pH of virus suspensions to 
pH 7.8, using 1 M Tris pH 8.0. 
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 2.3.7 Limited proteolysis 
 
Limited proteolysis was used at various stages of the presented research on the low 
pH-induced rearrangement of influenza virus HA: 
• Bromelain from pineapple stem  
o to release HA from purified viruses (2.2.1.3) 
• Trypsin 
o to remove the hydrophobic TM anchor at the C-terminus of HA2 
(2.2.1.4) 
o to remove the HA1 domains from the refolded HA (3.4) 
o to remove the hydrophobic FP at the N-terminus of HA2 (3.5) 
o to assess the conformational state of Bac B59 H1 HA2 (4.2) 
o to assess the conformational state of virus-bound HA and to confirm 
the ability of the FI6 antibody to prevent the conformational change 
of virus-bound HA using electron microscopy (2.4.5) 
• Thermolysin  
o to remove the hydrophobic FP at the N-terminus of HA2 (3.5) 
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Experimental details: 
 
With the exception of thermolysin, all proteolytic digestions were preceded by 
adjusting the pH of protein solutions to pH 7.8, using 1 M Tris pH 8.0. Enzymes 
tested for the ability to remove the globular HA1 domains and the hydrophobic 
fusion peptide were: 
• Trypsin, TPCK treated from Bovine Pancreas (Sigma). Trypsin was tested 
at concentrations of 0.1-10% [w/w], over 2.5 h, at RT. Samples were collected 
every 10 min, for the first 60 min, and every 30 min afterwards. Digestions 
were stopped by the addition of an equal amount of soybean trypsin 
inhibitor (Sigma). 
• Thermolysin, from Bacillus thermoproteolyticus (Sigma). Thermolysin 
dissolved in PBS was tested at 2% [w/w], at 37°C, in the presence of 1 mM 
CaCl2. The pH of the samples was adjusted to pH 5.0 using 0.1 M Sodium 
citrate, and the typical time course was 1.5-7 h. Reactions were stopped by 
the addition of 20 mM EDTA. 
• α-Chymotrypsin, Elastase, Papain, Subtilisin and Endoproteinase Glu- C 
(Proti-Ace, Hampton Research). Used according to manufacturer’s 
instructions. 
• Proteinase K, Endoproteinase-Arg-C, Pepsin and Actinase E (Proti-Ace 2, 
Hampton Research). Used according to manufacturer’s instructions. 
• Endoproteinase Lys-C, sequencing grade (Promega). Endoproteinase Lys-C 
was used at 0.1-5% [w/w], for 30 min, at RT. 
• Bromelain from pineapple stem (Sigma). Bromelain was used at 1% [w/w], 
for 30 min, at RT. 
 
The Proti-Ace and Proti-Ace 2 proteases were solubilized in 10 mM Hepes pH 7.5, 
500 mM NaCl, and tested at 0.1% [w/w], for 30 min, at RT. Papain, Elastase, 
Endoproteinase-Arg-C and Pepsin were additionally tested at 1% [w/w], for 1 hour, 
at 37°C. Reactions were stopped by the addition of 10 µl SDS-PAGE (10 µl). 
Assessments of the conformational state of low pH-treated viral H1 HA2, and 
recombinantly-expressed Bac B59 H1 HA2, were carried out using 2% [w/w] 
trypsin (Sigma). 
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2.3.8 Immobilized metal affinity chromatography (IMAC) 
 
IMAC is a group-specific affinity technique for separating proteins (Porath, 
Carlsson et al. 1975) based on a reversible interaction between certain amino acid 
side chains, here His, and immobilized divalent metal ions, in this case Co2+. As 
Cobalt-based BD TALONTM IMAC Resin (Clontech) displays a reduced affinity for 
host proteins containing exposed His residues, it was used as an initial step in 
purification of recombinant polyhistidine-tagged Bac B59 H1 HA2. 
 
Experimental details: 
Baculovirus-infected cell extract was clarified by centrifugation at 4,000 rpm, for 
30 min, at 4°C, in a Beckman swinging bucket centrifuge. The supernatant was 
concentrated to 100 ml using a 10K MWCO membrane. A solution containing 5 
mM Imidazole pH 8.0, 10 mM Sodium phosphate pH 8.0, and 300 mM Sodium 
chloride was added to the cell extract. Following the addition of the complete, 
EDTA-free protease inhibitor tablets (Sigma), the concentrated supernatant was 
clarified by centrifugation at 25,000 rpm, for 30 min, using a BV52 rotor. Four 25 
ml TALON Superflow Resins packed into HisTALON FPLC Cartridges (Clontech) 
were connected, and equilibrated with a binding buffer (5 mM Imidazole, 25 mM 
Sodium phosphate pH 8.0, 300 mM NaCl and 10% [v/v] glycerol). The soluble 
protein extract was loaded onto the Cobalt column using a peristaltic pump with a 
continuous flow, at a rate of 5 ml/min. The TALON column was attached to the 
AKTA purifier and the uncleaved protein was eluted in 10 ml fractions, using a 
gradient of an elution buffer, containing 500 mM Imidazole, 25 mM Sodium 
phosphate, 300 mM NaCl and 10% [v/v] glycerol (final pH adjusted to pH 8.0). 
Eluted protein fractions were analysed using SDS-PAGE (2.3.3), pooled, and 
concentrated, and the protein buffer was exchanged into 10 mM Tris pH 8.0, 150 
mM NaCl, lowering the concentration of salt.  
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Polyhistidine-tag removal: 
The His tag was removed using TEV protease at a ratio of 1:100 [w/w], at RT, O/N. 
The cleaved protein was recovered by passing the protein-containing solution 
through the Ni-NTA Agarose nickel-charged resin (Qiagen), pre-washed with PBS. 
While His tag residues bind to the nickel ions, cleaved HA passes through the 
affinity chromatography matrix in a gravity-flow column. His tag cleavage was 
confirmed using SDS-PAGE (2.3.3), and the cleaved protein was concentrated 
using a 10K MWCO concentrator (Sartorius) to < 5 ml, and further purified by gel 
filtration (2.3.5). The recombinantly-expressed Bac B59 H1 HA2 was present in 1.5 
ml fractions D5-E8 eluted from the gel filtration column. The protein buffer was 
exchanged into 10 mM Tris pH 8.0 and 50 mM NaCl post-purification, and protein 
sample was concentrated to ~10 mg/ml (A280) and subjected to crystallisation trials, 
as described in Section 2.3.9. 
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2.3.9 Protein crystallisation and crystal freezing 
 
Protein crystallisation requires soluble, highly pure, homogenous, stable and 
concentrated (~10 mg/ml) protein samples, which in a typical crystallisation 
experiment are separated from a solution, in a process driven by a reduction in 
their solubility, driven by the addition of precipitants to the protein-containing 
solution. When a protein-precipitant drop is placed over a precipitant-containing 
well solution within a sealed compartment, concentration of the precipitant in the 
crystallisation drop will increase over time, in the process called vapour diffusion. 
This decrease in the availability of water in the equilibrating drop mimics an 
increase in the concentration of protein, and when its solubility limit is reached, 
and given correct conditions, protein molecules can separate from the 
supersaturated solution and form a crystal. Changes in protein solubility are 
temperature dependent, and can be described using a phase diagram (Figure 2.3). 
The solubility line defines the region below which crystallisation will not occur, and 
corresponds to a thermodynamic equilibrium between the concentrations of protein 
and the precipitating agent. Region above the solubility line is divided into three 
zones. Metastable zone (1) is a region, where crystals can grow however, a 
spontaneous nucleation does not occur, and induction of crystal growth may 
require seeding. Nucleation zone (2) is an area where protein molecules aggregate 
in a crystalline form. Precipitation zone (3) is a region where proteins separate 
from a solution, forming amorphous protein aggregates. Crystallisation techniques 
have been widely discussed in other sources (Bergfors 2009).  
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Figure 2.3 Protein solubility phase diagram for a given temperature. 
Zones 1-3 represent the metastable, nucleation and precipitation zones, 
respectively. Undersaturation and precipitation zones are indicated. 
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Experimental details: 
Purified proteins were concentrated to ~5.5, 7.5 and ~10 mg/ml (A280) using 
Vivaspin 6 ml and 500 µl concentrators (Sartorius), 10K MWCO, at 3,000 g, 4°C, in 
a benchtop centrifuge (Thermo Scientific). Homogeneity of protein samples was 
assessed using DLS (2.4.2) and SDS-PAGE (2.3.3). Protein crystallisation trials 
were set up at 18°C, using the commercially available crystallisation screens 
(Hampton Research, Qiagen, Molecular Dimensions and Jena Bioscience), as well 
as homemade screens designed by Dr Lesley F. Haire (NIMR). Proteins were 
crystallized using a sitting drop vapour diffusion technique. The volume of 
reservoir solution was typically 75 µl. Screen solutions were transferred from 96-
well deep well blocks (Abgene) using the Liquidator 96 (Anachem), and dispensed 
into the MRC 2-well crystallisation plates (Swissci). Crystallisation droplets 
containing 100 nl of protein solution mixed with 100 nl of different reservoir 
solutions were set up using the Oryx liquid handling robot (Douglas Instruments). 
Crystallisation plates were sealed with Crystal Clear Sealing Tape (Hampton 
Research), and transferred to the Rock Imager 1000 automated imaging system 
(Formulatrix). The incubation temperature was set to 18°C, and high-resolution 
images were acquired according to the specified schedule, and over the course of a 
few weeks. Details of specific crystallisation trials are described in Sections 3.6 and 
4.4. In order to improve the size and quality of the initially obtained crystals, the 
initial hits were optimised, and these trials included microseeding. Seed stocks 
were prepared from the initial crystalline material, by transferring the initially 
obtained crystals to 50 µl of the hit reservoir solution. The Seed Bead tube 
(Hampton Research) was vortexed for a minute, stopping to cool the seed stock on 
ice. Seeding was implemented robotically using the Oryx robot (Douglas 
Instruments), by simultaneously pipetting protein, reservoir solution and 
undiluted seed stocks, using a three-bore dispensing micro tip. Crystallisation drop 
contained 0.15 µl of protein, 0.10 µl of reservoir solution and 0.05 µl of undiluted 
seed stock. The reservoir solutions used in the microseeding experiments were 
closely related to the solutions from which the seeds were derived, typically 
varying the concentration of successful precipitant and in the pH of the 
accompanying buffer. The described procedure is based on the method of Allan 
D’Arcy (D'Arcy, Villard et al. 2007) (Luft and DeTitta 1999). In addition, seeding 
into unrelated crystallisation conditions was performed. This strategy, known as 
microseed matrix screening (MMS), can be used to obtain new crystal forms of 
different space groups, and better diffracting crystals (D'Arcy, Bergfors et al. 2014).  
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Crystals that grew to a suitable size of at least 50 µm in all dimensions, were 
selected for freezing. Crystals were cryoprotected using a two-step method, where 
the initial step was the addition of a cryoprotectant solution into the crystallisation 
drop, resulting in a cryoprotectant solution at half of its final concentration. 
Crystals were then transferred into the final, full-strength cryoprotectant solution. 
Crystals were harvested using an 18 mm Mounted CryoLoopTM - 20 micron 
(Hampton Research), plunged into liquid nitrogen, and stored under liquid 
nitrogen for data collection. 
 
2.4 Analytical techniques 
 
 
2.4.1 Haemagglutination assay 
 
Haemagglutination assays were performed according to the standard protocol, 
using 0.5% suspensions of Turkey red blood cells (RBCs). Turkey red blood cells 
were obtained from Public Health England, under procedures regulated by the 
Animals (Scientific Procedures) Act 1986.  In a V-bottom 96-well plate, 50 µl of 10-2- 
10-5 allantoic fluid dilutions were added to 50 µl of PBS, and serially diluted 2-fold 
across the plate. Following the addition of 50 µl of 0.75% RBCs, the plate was 
incubated for 30 min, at RT, and HA titre for each virus dilution was calculated as 
the reciprocal of the last virus dilution where agglutination was observed. 
 
2.4.2 Dynamic Light Scattering (DLS) 
 
Polydispersity of protein samples was measured using DLS, which measures the 
size distribution profile of molecules in solution. This information was used to 
assess suitability of purified protein samples for the crystallisation trails (2.3.9). 
Prior to a DLS measurement, protein samples (~20 µl) at a concentration of ~0.5 
mg/ml, were centrifuged at 10,000 g, at 20°C, for 10 min. Fluctuations in scattered 
light intensity due to the diffusing particles were measured using a Viscotek-802 
instrument, with Omnisize 3.0 software (Malvern). The particle population was 
determined by calculating an average from 10 separate measurements, and 
samples containing a population of particles with a larger hydrodynamic radius, 
and indicating particle aggregation, were discarded. Samples, for which the 
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calculated molecular weight was within ~20% of the expected molecule size, and 
with polydispersity of less than 20%, were subjected to crystallisation trials.  
As shown in Figure 2.4 and Table 2.1, the intensity distribution of B59 H1 TTHA2 
sample shows a single peak with 100% contribution to the intensity-weighted 
scattering signal. The peak is slightly asymmetric, resulting in the position of the 
mean at 3.31nm Rh. The relative percentage standard deviation (% RSD) indicates 
the width of the peak relative to its height, at the half-height point. The estimated 
molecular weight of B59 H1 TTHA2 trimer (~63 kDa) correlates with the size of the 
molecule estimated using SDS-PAGE (2.3.3), and monodisperse samples were 
subjected to crystallisation trials (2.3.9).  
 
 
 
 
Figure 2.4 DLS profile for purified B59 H1 TTHA2. Mass distribution 
profile was derived from the raw intensities recorded during a DLS 
measurement using Viscotek-802. 
 
 
 
 
Table 2.1 Summary of a DLS measurement using B59 H1 TTHA2. 
 
 
Peak %"Area Rh"(nm) Position %"RSD MW"(kDa)
1 100 3.49 3.31 10.9 63.41
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2.4.3 Circular dichroism (CD) spectroscopy 
 
CD measurements were used for estimation of the secondary structure content, 
and for assessment of thermal stability of Bac B59 H1 HA2, described in Chapter 
4. Bac B59 H1 HA2 samples (2.2.2) were purified using IMAC (2.3.8) and diluted to 
~0.15 mg/ml in two different dilution buffers. The two dilution buffers were:  
• 10 mM phosphate pH 7.2, 150 mM NaCl 
• 10 mM phosphate pH 5.2, 150 mM NaCl (titrated with citric acid) 
CD measurements were performed using Jasco J-715 spectropolarimeter. The far-
UV spectra were recorded at λ 195-260 nm, at 10°C and 25°C, using a 2 mm path 
length quartz cuvette, and the acquired spectra were used to estimate the 
secondary structure content of the expressed protein. Thermal denaturation 
measurements were performed at a fixed λ of 222 nm, over a 40-100°C range, at a 
rate of 2 °C/min. The final spectra were averages of 10 separate scans. The CD 
spectra were acquired and processed with the help of Dr Elizabeth Underwood 
(NIMR), and the results were analysed using software written by Dr Steve Martin. 
The recorded intensities (S) for far-UV data were expressed as: 
 
ΔεMRW = S x MRW/32980 x C mg/ml x L 
 
Where:  
ΔεMRW - mean residue CD extinction coefficient 
S - CD signal (millidegrees)  
MRW - Mean Residue Weight (Da)= !"#$%&#'(	*$+,-.	/01&!2$(	"3	4$4.+5$	2"156	7 
C mg/ml - concentration (mg/ml) 
L - path length (cm) 
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2.4.4 N-terminal sequencing 
 
N-terminal sequencing was used to identify trypsin digestion products of PR8 H1 
HA. Protein samples were digested with trypsin at 2% [w/w], as described in 
Section 2.3.7, and separated using SDS-PAGE (2.3.3). A ProBlottTM PVDF 
membrane (Applied Biosystems) was soaked in MeOH, and placed in a dish 
containing the electroblotting buffer (1X 100 mM CAPS, pH 11 in 10% v/v MeOH). 
The 4-12% Novex Bis-Tris gels (Invitrogen) were removed from the electrophoresis 
cell, and soaked in the electroblotting buffer for 5 min. The transblotting sandwich 
was assembled, and blotting of proteins onto the membrane was carried out using a 
BioRad Mini Trans-Blot Electrophoretic Transfer Cell, at a constant voltage of 50 
V, RT, 45 min). The ProBlottTM was then removed from the transblotting sandwich, 
and rinsed with deionized water, prior to staining. The membrane was saturated 
with 100% MeOH for a few seconds and stained with 0.1% Coomassie® Blue R-250, 
in 40% MeOH/1% acetic acid [v/v]. The membrane was removed from the staining 
solution, destained using 50% [v/v] MeOH, and rinsed with deionized water. The 
membrane was dried between two sheets of filter paper and sent for N-terminal 
sequencing (Pepceuticals Ltd., Leicester, UK), and the obtained results are 
summarized in Section 3.3 and Figure 3.5. 
 
 2.4.5 Electron microscopy (EM) 
 
Background: 
The previously observed structural changes in molecular structure of HA at the pH 
of membrane fusion, include elongation and thinning of HA in its stem region, 
resulting from dissociation of HA1 domains and relocation of the amino-terminal 
fusion peptides of HA2 (residues 1-23) towards the target membrane (Ruigrok, 
Wrigley et al. 1986) (Ruigrok, Aitken et al. 1988). Exposure of these hydrophobic 
subdomains of HA2 causes aggregation of several HA trimers (~8) into rosettes 
(Skehel, Bayley et al. 1982) (Doms, Helenius et al. 1985). A radius of ~15 nm 
(Ruigrok, Aitken et al. 1988) and a terminal knob (Ruigrok, Martin et al. 1986) 
(Ruigrok, Wrigley et al. 1986) have been previously observed using EM. Removal of 
HA1 domains and the hydrophobic fusion peptides (HA2 residues 1-23) by limited 
proteolysis have also been previously observed using EM, and removal of these 
regions with trypsin or thermolysin resolubilizes the ectodomain of viral HA, and is 
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manifested by dissociation of rosettes (Daniels 1983). Dissociation usually starts 
after 10 min of incubation with thermolysin (2% w/w), and proteolytic digestion 
was previously shown to be complete after 40 min (Ruigrok, Aitken et al. 1988). In 
this thesis, EM was one of the techniques used to examine the effect of the FI6 
antibody (Corti, Voss et al. 2011) on the low pH-induced conformational change of 
both virus-bound, and isolated viral HA of H1 and H3 subtypes. The obtained 
results are discussed in Sections 6.1.2 and 6.2, respectively. 
 
Experimental details: 
Virus-antibody complexes were prepared by mixing 50 µl of purified X31 (H3N2) 
and B59 (H1N1) viruses at ~10 mg/ml with 150 µl of the FI6 antibody at 9.8 mg/ml, 
O/N, at 4°C. A buffer containing 150 µl of 20 mM Tris pH 8.0, 150 mM NaCl was 
added to the samples, which were then pelleted at 55,000 rpm, for 10 min, at RT, to 
remove the excess antibody. Pellets were gently resuspended to the final volume of 
350 µl, using 20 mM Tris pH 8.0, 150 mM NaCl. The pH of viral suspensions was 
lowered to pH 4.8, using 0.1 M Sodium citrate pH 3.5, for 5 min, at 37°C. The pH 
was then readjusted to pH 7.8, using 1 M Tris pH 8.0. The virus-antibody 
complexes were digested with 2% trypsin [w/w], for 45 min, at RT, and reactions 
were stopped by the addition of the same amount of the soybean trypsin inhibitor. 
Conformation of virus-bound HA was assessed using both SDS-PAGE (2.3.3) and 
EM. Samples were taken for analysis at each step of virus-antibody complex 
preparation, and control virus samples (without antibody) were included.  
The effect of the FI6 antibody binding on the structural reorganization of HA at 
low pH by EM was also studied using detergent-extracted molecules at 0.5 mg/ml 
(A280). Various FI6 concentrations were tested, and the optimum concentration 
determined by observation was 0.16 mg/ml.  
All samples for EM were prepared on copper discs (grids) cast with a fine mesh. A 
thin layer of carbon was deposited onto mica sheets by evaporating carbon 
graphite, using the EMITECH K950X High Vacuum Carbon Evaporator with a 
small graphite rod. Current applied across the graphite rod caused it to incandesce, 
and carbon was evaporated off the rod and deposited on the surface. Protein 
samples were pipetted between the mica and carbon film, and placed (carbon film 
on top) into a float, containing 1% neutral SST (Sodium silicotungstate) negative 
stain. Sticky copper grids prepared by soaking in chloroform with sellotape were 
placed on top of the carbon film, and grids were blotted dry using filter paper, 
placed into vacuum sample holder and viewed using a JEOL 1200 EX TEM. Digital 
images of protein samples and protein-antibody complexes were recorded using 
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TECNA1, with 150000x magnification. EM experiments were carried out with the 
help of Dr Lesley Calder, and the obtained results are included in Section 6. 
 
2.4.6 Biolayer interferometry 
 
Biolayer interferometry measures the interference from the reflection of white 
light, as a function of the optical layer thickness at the biosensor surface. A shift in 
the interference pattern is caused by binding of molecules to the tip of the 
biosensor, resulting in a change in the wavelength (l) of light. The technique was 
used to measure binding of H1N1 and H3N2 viruses to human and avian receptor 
analogs in the presence of the FI6 (Corti, Voss et al. 2011) and Hc31 (Daniels, 
Douglas et al. 1983) antibodies. In order to account for the host-determined 
preference for sialic acid receptors, sugars with both linkages to galactose (α-2,3- or 
α-2,6-) were used, and measurements were recorded using the Octet RED biolayer 
interferometer (Pall ForteBio Corp.). The technique was used to quantize binding 
of the two influenza viruses to the immobilized sialic acid receptor analogs in real 
time, and the obtained results are shown in Section 6.3. 
 
Experimental details: 
Biotinylated α-2,3- (α-2, 3-SLN) and α-2,6- (α-2, 6-SLN)- linked sialyl lactosamine 
sugars linked to a polyacrylamide backbone and composed of 30 kDa polymers, 
containing 20% sugar and 5% biotin [w/w], were obtained from Lectinity Holding, 
Inc. (Moscow, Russia). The polymers were immobilized on streptavidin biosensors 
(ForteBio), at a concentration of ~0.5 µg/ml. Four sensors were used to test the 
effect of each antibody (FI6 and Hc31) on binding of viruses to the sialic acid 
receptor analogs. The streptavidin sensors (ForteBio) were rinsed with water, and 
sugars at concentrations of 0.01-0.5 µg/µl were applied onto the sensors for 5 min.  
The sensors were washed with a buffer containing 10 mM Hepes pH 7.4, 150 mM 
NaCl, 3 mM EDTA and 0.005% [v/v] Tween 20. In order to prevent viral NA from 
cleaving the sensor-bound receptor analogs, oseltamivir carboxylate at 10 µM 
(Roche, Welwyn Garden City, UK), and zanamivir at 10 µM (GSK, Stevenage, UK) 
were added to the buffer. The initial concentrations of viruses were 62 nM for X31 
(H3N2), and 34 nM for B59 (H1N1), as determined using virus quantification 
based on SDS-PAGE (2.3.1). Viruses were diluted to 0.1-1 nM using the same 
buffer, and after an initial measurement, the desired concentration of viruses was 
determined to be ~100 pM. Binding of the two viruses was measured in the 
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presence of the two antibodies at different concentrations. Stock concentrations of 
the FI6 and Hc31 antibodies were 8.5 and 14.6 mg/ml, respectively. The FI6 and 
Hc31 antibody solutions (2-8 µl) were added to the wells containing a buffer, α-2,3- 
and α-2,6- sugar analogs and virus samples. Contents of the wells were mixed, and 
measurements were repeated. Binding of viruses to the immobilized sialic acid 
analogs was measured in real time, over 30-50 min association step, at 25˚C. The 
relative amounts of viruses bound to the sensors in the presence of varying 
concentrations of the two antibodies, were calculated from the amplitude of the 
response at the end of the association step, and normalized by dividing by the 
maximum response (usually 5-6 nm). The normalized response was plotted as a 
function of antibody concentration. Biolayer interferometry experiments were 
performed with Dr Steve Martin, and the obtained results are summarized in 
Section 6.3. 
 
2.4.7 MDCK1 cell infection  
2.4.7.1 Estimation of the amount of infectious virus in the 
prepared samples using the plaque assay 
 
The ability of the cross-reactive F16 antibody (Corti, Voss et al. 2011) to neutralize 
the infectivity of the X31 (H3N2) and B59 (H1N1) viruses in vitro was tested using 
the MDCK1 cell infection assay. A parallel cell infection assay using the H3 specific 
Hc31 antibody (Daniels, Douglas et al. 1983) was carried out as a control. Cells 
were infected with viruses in the presence and absence of the two antibodies, and 
viral replication was assessed by quantification of viral NP production. The X31 
and B59 viruses from frozen stocks were diluted in a ten-fold dilution series, from 
10-1 to 10-5 in PBS buffer, containing 100 U/ml Penicillin-Streptomycin (Sigma), 
and viruses were propagated as described in Section 2.2.1.1. Allantoic fluid was 
harvested, and centrifuged at 3,000 rpm, for 30 min, at 4°C. The supernatant was 
collected, and HA titre was determined using the HA assay (2.4.1). The allantoic 
fluid samples (0.5 ml) with best HA titres were stored at -80°C to be used in future 
experiments. Confluent monolayers of MDCK1 cells (70-80%), grown in 6-well or 
12-well plates were washed with a pre-warmed PBS to remove the foetal calf 
serum (FCS). Cells were then washed again three times with 200 µl of virus growth 
medium (VGM), and 50 µl of VGM was dispensed into the plate. Cells were infected 
with 50 µl of allantoic fluid (10-1-10-8) dilutions, for 3 hours, at RT. Plates were 
placed briefly onto a platform shaker (30-50 rpm), every 10 min, to avoid drying. 
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Compositions of media used in the plaque assay are shown in Table 2.2. Following 
removal of the inoculum, cells were overlaid with an avicel overlay (200 µl), 
containing 1.25 µg/ ml trypsin (Sigma) (2.5 ml/well for a 6-well plate, and 1 ml/ well 
for a 12-well plate), and incubated at 37°C, 5% CO2, for up to 22 hours. Avicel 
(FMC Biopolymer) provides a semi-solid environment, and prevents the spread of 
the virus to the surrounding cells. The overlay was prepared by mixing the plaque 
medium and avicel 1:1 [v/v], with the addition of 1.25 µg/ml [w/v] trypsin, TPCK 
treated (Sigma). While avicel overlay enables quantification of individual plaques, 
addition of trypsin is essential for cleavage of HA into HA1 and HA2, and therefore 
infectivity of influenza virus. The overlay was removed at various time points, and 
cells fixed using 4.1% [v/v] formaldehyde (Fisher) in PBS, for 30 min, at 4°C. 
Initially, the number of plaques at different time points was assessed by staining 
with toluidine blue (Sigma), which was added to 4.1% [v/v] formaldehyde in PBS, 
at 0.2% [v/v]. Plaques were stained overnight at RT. Stain-containing solution was 
then removed, and plaques counted using a light microscope.  
Having determined the appropriate concentration of X31 and B59 viruses to be 
used in the cell infection assay (based on the ability to resolve individual plaques), 
the experiments were repeated using determined time points. After removal of the 
avicel overlay, cells were fixed, washed three times with PBS, and incubated at 
4°C, O/N. In order to detect viral NP, cells were permeabilized with 0.2% Triton-
100 [v/v] in PBS (100 µl/well, 30 min, RT, shaking), and washed with PBS, 
containing 0.1% Tween 20 [v/v]. Plaques were then visualized by immunostaining 
for influenza NP (Table 2.3). Primary and secondary antibodies used for 
immunostaining were prepared in ELISA buffer, containing 10% horse serum and 
0.1% Tween 80 [v/v]. Plaques were visualized using the HRP on tetra methyl 
benzidine (TMB) based substrate (TrueBlueTM), counted (Sullivan, Kloess et al. 
2012), and their size determined to 0.1 mm by Dr Yan Gu, using a house-assembled 
scanner, with IX70 Olympus microscope and Surveyor software, by counting the 
number of pixels in positively stained areas of 20 single NP positive cells, and 
determination of a mean pixel number.  
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Table 2.2 Composition of media and reagents used in the plaque assay.  
 
 
 
 
 
 
Table 2.3 Immunostaining for influenza NP. 
 
 
 
 
Plaque medium (500 ml) 100 ml 10X MEM (Sigma) (2X final)
5 ml 200mM Glutamax (Sigma)
5 ml Penicillin-Streptomycin (Sigma)- 
(10000 U/ml penicillin, 10 mg streptomycin/ml)
25 ml 7.5% [v/v] Na2CO3 
10 ml 7% [v/v] Bovine serum albumin (BSA) 
355 ml dH2O
Avicel 2.4% [w/v] avicel (FMC Biopolymer) in dH2O
MDCK cell growth medium Minimum essential medium (MEM) (Sigma)
10%  [v/v] Foetal Calf Serum (Perbio)
100 U/ml Penicillin/Streptomycin (Sigma)
100 U/ml Glutamax (Sigma)
Virus growth medium (VGM) Minimum essential medium (MEM) (Sigma)
 0.14% [w/v] Bovine serum albumin (BSA)
100 U/ml Penicillin/Streptomycin (Sigma)
100 U/ml Glutamax (Sigma)
1- addition of primary antibody mouse monoclonal influenza A NP-specific (AbCam)
1:4000 [v/v],1 h, RT, 50 µl/well
2- cell washing 3X with PBS, 0.1% [v/v] Tween 20
3- addition of secondary antibody goat anti-mouse IGG, HRP conjugate (Biorad)
1:1000 [v/v], 1 h, RT, 50 µl/well
4- cell washing 3X with PBS, 0.1% [v/v] Tween 20
5- substrate addition TrueBlue™ Peroxidase Substrate (KPL)
1:1000 [v/v]in 30% Hydrogen peroxide, 10 min, RT
6-substrate removal and plate drying 2X 200 µl H20/well
Immunostaining for influenza NP
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MOI calculation: 
 
The appropriate multiplicity of infection (MOI) to be used in influenza virus cell 
infection assays was previously determined to 0.1 PFU/cell by Dr Yan Gu, and 
after determination of the infectious virus using the plaque assay, the number of 
PFU/ml of virus inoculum was calculated. A well of a 96-well plate containing a 
confluent monolayer of MDCK cells was previously determined to have ~5.6 x 104 
cells by Dr Saira Hussain (NIMR). The concentration of viruses at 10-6 dilution, 
required for preparation of 50 µl of inoculum/well was calculated, and inocula were 
prepared by diluting virus stocks with serum-free media. MOI calculations were 
performed according to the example: 
 
Determination of the infectious virus titre of X31 by plaque assay: 
 
Average number of plaques from replicate wells at 10-6 dilution (PFU): 17 
200 µl of inoculum used to infect a 12-well plate contains 17x 106 plaques 
To calculate PFU/ml: 17 x 106 x 5= 8.5 x 107 PFU/ml 
Infect cells at MOI= 0.1 PFU/cell 
Confluent monolayer of cells has ~5.6 x 104 cells/ well 
Therefore, for 0.1 PFU/ml, 5.6 x 103 PFU/ well 
For a 96-well plate use 50µl inoculum: 5.6 x 103 PFU/ 50 µl 
As the infectious X31 stock has a titre of 8.5 x 107 PFU/ml, therefore 50 µl 
inoculum has 8.5x 107/ 20= 0.425 x 107 PFU/ 50 µl. 
For MOI of 0.1 PFU/ cell, the X31 virus needs to be diluted 0.425 x 107/ 5.6 x 103= 
1:760. 
Virus was diluted 1:10 (100 µl virus: 900 µl serum-free medium) initially, and then 
1:76. 
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2.4.7.2 Infection of MDCK1 cells in the presence of FI6 and 
Hc31 antibodies 
 
The MDCK1 cells were seeded into 96-well plates containing the cell growth 
medium. The X31 (H3N2) and B59 (H1N1) viruses were pre-incubated with serial 
dilutions of the FI6 and the Hc31 antibodies, for 1 h, at RT. The initial 
concentration of the FI6 antibody was 8.5 mg/ml, and the antibody was diluted 1:2 
with virus growth medium to the final concentration of 4.25 mg/ml. The initial 
concentration of the Hc31 antibody was 14.6 mg/ml, and the antibody was diluted 
1:100 to the final concentration of 0.146 mg/ml. Virus growth medium (100 µl) was 
dispensed into the deep well blocks. Final antibody stocks (50 µl) were added to the 
first well, and serially diluted across each plate. The X31 and B59 viruses were 
added to the wells (150 µl), for 1 hour, at RT. Viruses were pre-incubated with the 
two antibodies and then used for infection of MDCK1 cells. Cells were infected with 
100 µl of viruses pre-incubated with the two antibodies, in a series of two-fold 
dilutions across the plate. Viral control was prepared by mixing 150 µl of virus 
growth medium with 150 µl of viruses. Plates were incubated at 37°C and 5% CO2, 
fixed at different time points (3, 4 and 6 h), and immunostained for influenza NP 
(Table 2.3). Cell infection assays were performed with Dr Yipu Lin. Inhibition of 
viral infection following the addition of the two antibodies was compared using the 
average number of NP positive cells at the corresponding antibody dilution. Cell 
counting analysis was performed by Dr Yan Gu, and the obtained results are 
shown in Section 6.4. 
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3 Crystal structure of viral H1 TBHA2 
 
3.1 Virus growth and purification 
 
Details of virus infection, growth in embryonated eggs, purification and isolation of 
viral H1 HA from purified viruses are included in Section 2.2.1. Typically, the yield 
of virus from 2000 eggs was 80-100 mg. 
 
3.2 Isolation of H1 HA 
 
Bromelain release: 
The TM anchor-less H1 BHA was typically released from the H1N1 viruses using 
2% [w/w] bromelain. Release of H1 BHA required several bromelain digestion 
steps, and majority of BHA was released only after a second bromelain digestion 
(2.2.1.3). The released soluble fragment was purified using sucrose density 
gradient centrifugation. The supernatant containing H1 BHA was layered on top of 
a 5-25% [v/v] sucrose density gradient, and centrifuged at 38,000 rpm, for 18 h, at 
10°C, in a Beckman XL-90 ultracentrifuge with a SW41 rotor. A tube connected to 
a peristaltic pump was gently inserted into the gradient, and 1 ml fractions were 
collected starting from the bottom of each sucrose density gradient. Purification of 
H1 BHA by sucrose density gradient centrifugation is shown in Figure 3.1. The 
protein-containing fractions were pooled and subjected to ion exchange 
chromatography (2.3.4) in order to remove bromelain. Protein eluted at 150-200 
mM NaCl, and the supernatant containing H1 BHA was further purified by ion-
exchange chromatography (2.3.4) followed by gel filtration (2.3.5). The yield of H1 
BHA obtained using the enzymatic method was typically ~15 mg from ~100 mg of 
virus.  
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Figure 3.1 Purification of H1 BHA by sucrose density gradient 
centrifugation. Shown are 1ml fractions 1-9 of 5-25% [v/v] sucrose density 
gradient (10ml) analysed by non-reducing SDS-PAGE. Details of SDS-
PAGE are included in Section 2.3.3. Soluble H1 BHA was purified from 
fractions 4-7. 
 
 
Detergent extraction: 
Detergent extraction of viral H1 HA with LDAO or BOG (Section 2.2.1.4) was 
typically followed by purification of the released protein using detergent-containing 
sucrose density gradients. Detergent-released H1 HA was purified from 1 ml 
fractions (4-7) of 5-25% [v/v] sucrose density gradients at 38,000 rpm, 18 h, and 
10°C.  
 
Transmembrane anchor removal 
Prior to the removal of the hydrophobic TM anchor with trypsin, the HA-containing 
fractions (4-7, Figure 3.2, A) were pooled, and H1 HA were further purified by ion-
exchange chromatography (2.3.4). The TM insert was successfully removed with 
trypsin (1:10 w/w, trypsin: A) after 1 h, at RT, and digestions were stopped with an 
equal weight of soybean trypsin inhibitor (Sigma). Removal of the hydrophobic TM 
anchor is very difficult to observe using SDS-PAGE under non-reducing conditions, 
due to the small size of this subdomain of HA2. The progress of TM anchor removal 
can only be observed under reducing conditions. The observed decrease in the size 
of the band corresponding to HA2 correlates with the removal of the ~ 3 kDa TM 
anchor (Figure 3.2, B, lane 4), and the TM-less HA molecules (H1 THA) were 
further purified by either sucrose density gradient centrifugation (5-25% sucrose 
gradient without detergent, at 38,000 rpm, 18 h and 10°C), or ion-exchange 
chromatography (2.3.4) and gel filtration (2.3.5). In case of sucrose density gradient 
centrifugation, the final preparation step involved removal of sucrose from the H1 
THA sample by centrifugation and buffer exchange. Alternatively, the TM anchor 
was removed by adding trypsin to the diluted supernatant, directly after 
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solubilisation of the virus with a detergent. H1 THA was then subjected to ion-
exchange chromatography (2.3.4) and gel filtration (2.3.5). As this method proved 
to be very effective and less time consuming, it was used routinely in H1 THA 
preparations. Figure 3.2, C, shows a H1 THA band of ~63 kDa. Experimental 
details related to detergent extraction can be found in Section 2.2.1.4. For protein 
released from the virus using detergent extraction, the yield of the protein was 
higher, typically ~40 mg. The two methods for isolation of viral H1 BHA/THA were 
used with both, PR8 and B59 H1N1 viruses, and in combination with various 
purification techniques used in this study. 
 
 
 
 
Figure 3.2 Release of viral H1 HA with BOG. The release of B59 H1 HA 
with 2% BOG is shown in A. B59 H1 HA is present in fractions 5-8 (1 ml) of 
a 5-25% sucrose density gradient. The TM anchor removal is shown in B. C 
shows purification of B59 H1 THA (fractions 6-10 of a 5-25% v/v sucrose 
density gradient). Details of non-reducing (NR) and reducing (R) SDS-
PAGE are included in Section 2.3.3.  
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3.3 Induction of H1 BHA conformational change by 
incubation at low pH 
 
Low pH treatment: 
Conformational change of H1 HA was induced by incubation at pH 5.0 (Section 
2.3.6), and the release of the hydrophobic fusion peptides at the N-termini of HA2 
(residues 1-23) is known to cause aggregation. The aggregated molecules are 
normally present in the bottom fractions of a 5-25% [v/v] sucrose density gradient, 
with a 1ml sucrose cushion at 60% [w/v] (Bullough, Hughson et al. 1994). This FP-
mediated aggregation of the TM anchor-less molecule was not observed for PR8 H1 
BHA. Only a fraction of PR8 H1 BHA molecules aggregated in the bottom fractions 
of a sucrose density gradient. However, more protein was present in middle 
fractions, where soluble BHA would normally be present (Figure 3.3). This 
suggested that either not all of the PR8 H1 BHA molecules have undergone the low 
pH-induced conformational change, or that the protein was contaminated with 
proteases that cleaved the N-terminal fusion peptide of HA2 (residues 1-23) after 
exposure of the molecule to low pH (~5.0). In order to compare the unusual 
solubility of the low pH-treated PR8 H1 BHA to that of other HA subtypes, the 
conformational change of HA of subtypes H3 (X31 strain) and H2 (Tokyo strain) 
was induced in a similar manner, and the low pH-activated proteins were 
separated on a 5-25% sucrose density gradients, with a 1ml 60% [w/v] sucrose 
cushion. Figure 3.3 shows that in contrast to PR8 H1 HA, the low pH-treated X31 
H3 BHA (A) and Tokyo H2 BHA (B) molecules aggregate at the bottom of a 
continuous 5-25% sucrose density gradient as previously expected. 
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Figure 3.3 Induction of the conformational change of influenza virus HA. 
Figures A-C show 1 ml fractions of a 5-25% v/v sucrose density gradient 
(with a 60% w/v sucrose cushion), containing low pH-treated X31 H3 BHA 
(A), Tokyo H2 BHA (B) and PR8 H1 BHA (C), analysed by SDS-PAGE. The 
H3 and H2 rosettes aggregate in the bottom fraction of a sucrose density 
gradient (A and B). C shows the presence of both, aggregated (fractions 1 
and 2) and soluble (fractions 5 and 6) PR8 H1 BHA, after low pH 
activation. Details of SDS-PAGE are included in Section 2.3.3. 
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Determination of a conformational state of low pH-treated H1 BHA by limited 
proteolysis: 
In order to assess the conformational state of bromelain-released, low pH-treated 
PR8 H1 BHA (Figure 3.3, C) the protein was tested for its susceptibility to 
proteolytic cleavage. Trypsin digestions were carried out both before and after the 
low pH treatment (pH ~5.0). Limited proteolysis was carried out using 10:1 BHA: 
trypsin [w/w], for 20 min, at RT. Results confirmed, that prior to the low pH 
treatment, H1 BHA was not susceptible to trypsin digestion, and that protein 
became susceptible to trypsin only after incubation of the sample at pH ~5.0. 
Trypsin digestion products of low pH-treated H1 HA are present in fractions 11-15 
(0.5 ml) of a continuous 5-25% [v/v] sucrose density gradient (10 ml) (Figure 3.4, B). 
This observation was consistent with the results previously reported for H3 BHA 
(Ruigrok, Martin et al. 1986), and suggested, that the obtained protein was in fact 
a fusion peptide-less PR8 H1 TBHA2. 
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Figure 3.4 Assessment of a conformational state of low pH-treated H1 BHA 
by limited proteolysis. Trypsin digestion of neutral pH H1 BHA is shown 
in A. Trypsin digestion of low pH- treated H1 BHA shown in B. Fractions 
1-18 are 0.5 ml fractions of a 10 ml 5-25% [v/v] sucrose density gradient, 
with fraction 1 being the bottom fraction. Details of non-reducing (NR) 
and reducing (R) SDS-PAGE are included in Section 2.3.3. 
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N-terminal sequencing: 
In order to identify the trypsin digestion products of low pH-treated (pH ~5.0), viral 
PR8 H1 BHA, samples were transferred onto a ProBlottTM membrane and analysed 
by N-terminal sequencing according to a protocol described in Section 2.4.4. The N-
terminal sequencing results confirmed that the obtained product was in fact a 
fusion peptide-less PR8 H1 TBHA2. Bands 1 and 2 gave the same sequences and 
showed the presence of both HA1 and HA2 disulphide-linked fragments (Figure 
3.5). Band 1 is likely to be a fusion peptide-less HA2 (residue 40 onwards) with a 
larger fragment of HA1. Under reducing conditions (Figure 3.5, band 4) the protein 
band contains only the HA2 fragment, which corresponds to a removal of 
disulphide-linked HA1 domains (Figure 3.5). The N-terminal sequencing results 
presented in Figure 3.5, show, that the low pH-activated H1 BHA isolated from 
PR8 H1N1 virus is very susceptible to proteolytic cleavage, and digestion with 
trypsin results in a removal of both, the hydrophobic fusion peptide (at the extreme 
N-terminus of HA2) and most parts of HA1 domains, at the same time. The 
obtained fragment was named PR8 H1 TBHA2, and following a final purification 
by sucrose density gradient centrifugation and gel filtration (2.3.5), the purified 
protein was subjected to crystallisation trials (Sections 2.3.9 and 3.6). 
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A)  
 
 
B) 
 
MKANLLVLLC ALAAADADTI CIGYHANNST DTVDTVLEKN VTVTHSVNLL 050 
EDSHNGKLCR LKGIAPLQLG KCNIAGWLLG NPECDPLLPV RSWSYIVETP 100 
NSENGICYPG DFIDYEELRE QLSSVSSFER FEIFPKESSW PNHNTNGVTA 150 
ACSHEGKSSF YRNLLWLTEK EGSYPNLKNS YVNKKGKEVL VLWGIHHPSN 200 
SKEQQNLYQN ENAYVSVVTS NYNRRFTPEI AERPKVRDQA GRMNYYWTLL 250 
KPGDTIIFEA NGNLIAPMYA FALSRGFGSG IITSNASMHE CNTKCQTPLG 300 
AINSSLPYQN IHPVTIGECP KYVRSAKLRM VTGLRNIPSI QSRGLFGAIA 350 
GFIEGGWTGM IDGWYGYHHQ NEQGSGYAAD QKSTQNAING ITNKVNTVIE 400 
KMNIQFTAVG KEFNKLEKRM ENLNKKVDDG FLDIWTYNAE LLVLLENERT 450 
LDFHDSNVKN LYEKVKSQLK NNAKEIGNGC FEFYHKCDNE CMESVRNGTY 500 
DYPKYSEESK LNREKVDGVK LESMGIYQIL AIYSTVASSL VLLVSLGAIS 550 
FWMCSNGSLQ CRICI 565 
 
C) 
  
Band 1 DTICIGYHANN STQNAINGITN 
Band 2 DTICIGYHANN STQNAINGITN 
Band 3 IVGGYTXAA- TRYPSIN  
Band 4 DFVLDNEGN-TRYPSIN INHIBITOR STQNAINGITN 
 
Figure 3.5 Identification of trypsin digestion products of low pH-treated 
H1 BHA by N-terminal sequencing. Digestion of low pH-treated H1 BHA 
with trypsin is shown in A. Details of SDS-PAGE are included in Section 
2.3.3. B shows the primary sequence of PR8 H1 HA: the signal peptide 
(green), HA1 (blue), the N-terminal HA2 fusion peptide (yellow) the rest of 
HA2 (red). Sequences corresponding to HA2 identified by N-terminal 
sequencing are underlined. Composition of bands 1-4 (A) identified by N-
terminal sequencing is shown in C. 
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3.4 Removal of HA1 domains by limited proteolysis 
 
Following the low pH treatment (pH ~5.0), the dissociated HA1 domains of B59 H1 
BHA and B59 H1 THA were removed using trypsin at a range of 0.1–5% [w/w] 
(protein: trypsin), for 1 h, at RT. Digestions were stopped using an equal amount of 
soybean trypsin inhibitor (Sigma). Removal of HA1 domains was successful using 
5% [w/w] trypsin. The fusion peptide-aggregated protein (Bullough, Hughson et al. 
1994) required for further protein preparation steps was purified on a continuous 
5-25% [v/v] sucrose density gradient, with a 60% [w/v] sucrose cushion (1ml) at 
35,000 rpm, 16 h, 20°C, or by ion-exchange chromatography (2.3.4) and subsequent 
gel filtration (2.3.5). Figure 3.6 shows B59 H1 THA before activation by low pH (A), 
and B59 H1 THA2 aggregates (rosettes) following removal of HA1 domains with 
5% [w/w] trypsin (B and C).  
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Figure 3.6 Purification of H1 THA2 aggregates. Detergent-released B59 H1 
THA before the low pH treatment is shown in A. B and C show the 
removal of HA1 domains from the low pH-activated H1 THA using trypsin. 
Protein aggregates are present in the bottom fractions of 5-25% sucrose 
density gradient with a 60% sucrose cushion. Details of SDS-PAGE are 
included in Section 2.3.3. 
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3.5 Removal of the fusion peptide by limited 
proteolysis 
 
High susceptibility of PR8 H1 HA to proteolytic cleavage resulted in a removal of 
both, HA1 domains, and the hydrophobic fusion peptide at the N-terminus of HA2 
in a single digestion step. At the N-terminus of HA2 residues 1-39, which include 
the fusion peptide, were removed, as determined by N-terminal sequencing 
(Section 3.3 and Figure 3.5). The soluble H1 TBHA2 isolated from this virus strain 
using the enzymatic method was subjected directly to crystallisation trials 
(Sections 2.3.9 and 3.6). 
In case of B59 H1 HA, digestion using 0.1-1% [w/w] trypsin, for 30 min, at RT, did 
not remove the fusion peptide. Removal of the fusion peptide using 2-10% [w/w] 
trypsin, for 10-20 min, at 37°C, resulted in an incomplete digestion, with 
approximately half of the protein still aggregating in the bottom fractions of a 5-
25% [v/v] sucrose density gradient, following centrifugation at 38,000 rpm, for 18 h, 
at 4°C. Digestion with 10% trypsin [w/w], for 1 h, at 37°C resulted in a removal of 
the hydrophobic fusion peptides. The truncated protein can be observed using SDS-
PAGE (2.3.3) under reducing conditions, as presented in Figure 3.7, lane 4. 
Solubility of the obtained B59 H1 TTHA2 was confirmed using sucrose density 
gradient centrifugation, and the size of the observed band (~17 kDa) (Figure 3.7, 
lane 4) is the same, as the size of a fusion peptide-less product of proteolytic 
digestion of PR8 H1 TBHA2, the sequence of which was confirmed to start with 
STQNAINGITN (HA2 residue 40 onwards) by N- terminal sequencing (Section 3.3, 
Figure 3.5). Because the resulting band was the same size, regardless of the 
concentration of trypsin used to remove the fusion peptide at 37°C, all future 
preparations of postfusion H1 HA2 were carried out using 10% [w/w] trypsin, at 
37°C, which removed both HA1 domains and the fusion peptide at the same time, 
and resulted in a consistent fragment of postfusion viral H1 HA2. Both B59 H1 
TBHA2 and B59 H1 TTHA2 were the same size as that of PR8 H1 TBHA2, as 
determined by SDS-PAGE (2.3.3). Thermolysin removed the fusion peptide at a 
concentration of 2% [w/w], at pH 5.0, in the presence of 1mM CaCl2. The pH was 
adjusted to 5.0 using 0.1 M Sodium citrate pH 3.5. Digestion was set up at 37°C, 
over a 1.5-7 h time course. Thermolysin removed the fusion peptide only after a 7 h 
digestion at 37°C, and the resulting TTHA2 band can be observed by SDS-PAGE 
under reducing conditions. The size of the obtained TTHA2 band is similar to that 
obtained using trypsin (~17 kDa) and is shown in Figure 3.8, lane 2. 
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Figure 3.7 Removal of the fusion peptide from H1 rosettes with trypsin. 
Fusion peptide-less B59 H1 TTHA2 is shown in lanes 2 and 4, under non-
reducing and reducing conditions. Details of SDS-PAGE are included in 
Section 2.3.3. 
 
 
 
 
Figure 3.8 Removal of the fusion peptide from H1 rosettes with 
thermolysin. Fusion peptide-less B59 H1 TTHA2 is shown in lane 2. Details 
of SDS-PAGE are included in Section 2.3.3. 
1 2 3 4
28 kDa
38 kDa
49 kDa
17 kDa
THA2 TTHA2
lanes 1 & 2- non-reducing SDS-PAGE
lanes 3 & 4- reducing  SDS-PAGE
THA2
TTHA2
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Testing of other proteases for the ability to remove the fusion peptide: 
In an attempt to obtain a longer fusion peptide-less fragment of B59 H1 TTHA2, 
proteolytic screening was carried out as described in Section 2.3.7. Limited 
proteolysis of aggregated H1 THA2 was performed versus a number of proteases. 
The proteases were selected based on their ability to cleave hydrophobic amino 
acids, and included: α-Chymotrypsin, Papain, Elastase, Subtilisin, Endoproteinase 
Glu-C, Proteinase K, Clostripain (Endoproteinase-Arg-C), Pepsin and Actinase. 
Proteases (Proti-Ace Kit and Proti-Ace 2 Kit, Hampton Research) and used 
according to manufacturer’s instructions at 0.01 mg/ml. The analysis of protein 
digests using SDS-PAGE (2.3.3) presented in Figure 3.9 shows, that while α-
Chymotrypsin, Subtilisin and Proteinase K completely digested B59 H1 THA2, 
enzymes such as Endoproteinase Glu-C and Actinase partially degraded the 
protein at 0.01 mg/ml. Digestions with Papain, Elastase, Clostripain and Pepsin 
(Figure 3.10, lanes 3, 4, 8 and 9) were repeated using a higher concentration of 
proteases (0.1 mg/ml), over a period of 60 min, at 37°C. Figure 3.10 shows, that 
none of the enzymes removed the fusion peptide at 0.1 mg/ml. Endoproteinase Lys-
C was tested for its ability to remove the fusion peptide at 0.1-5% [w/w], for 30 min, 
at RT. Reactions resulted in a complete digestion of H1 THA2.  
 
 
Summary of protein digestion experiments: 
Viral H1 HA2 in a postfusion conformation has been challenging to prepare 
proteolytically. Only trypsin and thermolysin were successful in removing the 
hydrophobic fusion peptide at the N-terminus of HA2 (HA2 residues 1-23). 
Thermolysin removed the fusion peptide at 2% [w/w], and digestion was complete 
after 7 h, at 37°C. Removal of the fusion peptide and HA1 domains with trypsin 
required at least 5% [w/w] of the enzyme, and 1 h, at 37°C. Both activities resulted 
in a similar fragment of ~17 kDa. This proteolytically prepared fragment of 
influenza virus HA (H1 subtype) in a postfusion conformation was subjected to 
crystallisation trials as described in Section 3.6. 
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Figure 3.9 Removal of the hydrophobic fusion peptide using Proti-Ace 
proteases. Proteases (Hampton Research) were used at 0.1% [w/w], for 30 
min, at 37°C . Completely degraded B59 H1 THA2 is shown in lanes 2, 5 
and 7. Partially degraded protein is shown in lanes 6 and 10. No 
degradation is observed in lanes 1, 3, 4, 8 and 9. Reducing SDS-PAGE 
(2.3.3). 
 
 
 
Figure 3.10 Removal of the hydrophobic fusion peptide using other 
enzymes. Papain, Elastase, Clostripain and Pepsin at 1% [w/w] (Hampton 
Research) were used for 30-60 min, at 37°C. Reducing SDS-PAGE (2.3.3). 
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3.6 Crystallisation 
 
Crystals of PR8 H1 TBHA2: 
Suitability of the prepared H1 TBHA2 and TTHA2 samples for crystallisation 
trials was assessed using DLS as described in Section 2.4.2. The PR8 H1 TBHA2 
sample was concentrated to ~5 mg/ml (A280), using a Vivaspin 10K MWCO 
concentrator (Sartorius) at 3,000 g, 4°C, in a benchtop centrifuge (Thermo 
Scientific). Crystallisation experiments were set up using a vapour diffusion 
technique as described in Section 2.3.9. Protein crystallized from various PEGs at 
pH 6.0-7.5, with seeding. Microseed stock was prepared from an initial crystalline 
material grown from 16% PEG 3350 and 0.1M MES pH 6.5. Conditions successful 
in producing crystals of PR8 H1 TBHA2 contained 0.1M buffers, such as: Bis-tris 
pH 5.5, MES pH 6.0-6.5, Hepes pH 7.5, Pipes pH 6.8-7.0, Sodium citrate pH 6.5, 
Sodium malonate pH 6.0, and 8% tacsimate pH 6.0. Initial hits were obtained from: 
12-25% PEG 3350 (pH 6.0-7.5), 20% PEG 4000 (pH 6.5), 16% PEG 8000 (pH 5.5), 
20-30% PEG 600 (pH 6.0-7.0), 25% PEG 550MME (pH 6.5). Although crystals were 
of suitable size and good morphology (Figure 3.11), they diffracted weakly, with 
best crystal diffracting to about ~5 Å. In order to shrink the crystal lattice and 
improve crystal packing, dehydration experiments were performed (by serial 
transfer into drops with an increasing concentration of precipitant), prior to crystal 
freezing. Despite extensive optimisation trials and testing of various 
cryoprotectants (Ethylene glycol, Glycerol and PEG 400), no improvement in 
diffraction resolution was observed. Details related to protein crystallisation 
including preparation of the seed solution and crystal freezing, are included in 
Section 2.3.9. 
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Figure 3.11 Crystals of PR8 H1 TBHA2. Crystals were grown from 12 % 
PEG 3350, 0.1M Bis-tris pH 5.5 (A), 16% PEG 3350, 0.1M citrate pH 6.5 (B), 
15% PEG 3350, 0.1M Pipes pH 6.8 (C) and 12% PEG 3350, 0.1M Hepes pH 7.5 
(D). Crystal dimensions are shown in µm. Images were obtained using 
Rock Imager 1000 with Rock Maker software (Formulatrix). 
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Crystals of B59 H1 TBHA2: 
B59 H1 TBHA2 and B59 H1 TTHA2 were concentrated to ~7.5 mg/ml (A280), and 
~5.5 mg/ml (A280), respectively, using a Vivaspin 10K MWCO concentrator 
(Sartorius) at 3,000 g, 4°C, in a benchtop centrifuge (Thermo Scientific). The 
concentrated protein was subjected to crystallisation trials (2.3.9). Protein 
crystallized from conditions containing various PEGs. Buffers successful in 
producing crystals of B59 H1 TBHA2 and B59 H1 TTHA2 included 0.1M solutions 
of Pipes pH 6.8, Hepes pH 7.5, MES pH 6.0, Potassium phosphate monobasic and 
Bicine pH 9.0. The initial crystals obtained from 25% PEG 3350 and 0.1M Hepes 
pH 7.5 were used to prepare a microseed solution. Although microseeding resulted 
in crystals with improved size and morphology, crystals of B59 H1 TBHA2 and 
TTHA2 were generally smaller (Figure 3.12), and took longer to grow than those of 
PR8 H1 TBHA2 (Figure 3.11). Initial hits were obtained from: 15-25% PEG 3350 
(pH 5.5-7.5), 10% PEG 6000 (pH 9.0), 20% PEG 600 (pH 6.0). Diffraction quality 
crystals of B59 H1 TBHA2 were obtained from 16% PEG 3350, 0.1M MES pH 6.0 
with seeding (Figure 3.12, C), and from 15% PEG 3350, 0.1M MES pH 6.0+1.5% 
[v/v] MPD, 0.01M Hepes pH 7.5 and 0.02M Sodium citrate (Figure 3.12, D).  
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Figure 3.12 Crystals of B59 H1 TTHA2 and B59 H1 TBHA2. Crystals of 
TTHA2 were grown from 20% PEG 3350, 0.1M Pipes pH 6.8 (A), and from 
20% PEG 3350, 0.1M MES pH 6.0 (B). Crystals of TBHA2 were obtained 
from 16% PEG 3350, 0.1M MES pH 6.0 (C), and from 15% PEG 3350, 0.1M 
MES pH 6.0+1.5% v/v MPD, 0.01M Hepes pH 7.5, 0.02M Sodium citrate (D). 
Images obtained using Rock Imager 1000 with Rock Maker Software 
(Formulatrix). 
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3.7 Data collection and processing 
 
Thirteen crystals of B59 H1 TBHA2 in a postfusion conformation were tested. Two 
crystals gave good diffraction and datasets were collected. Dataset A was from a 
crystal grown from 15% PEG 3350 and 0.1M MES pH 6.0, with the addition of 1.5% 
MPD, 0.01M Hepes pH 7.5, 0.02M Sodium citrate. The cryoprotectant solution was 
identical to the crystallisation condition with a slightly higher concentration of 
PEG (~2% v/v), and 20% [v/v] glycerol. Dataset B was from a crystal grown from a 
condition containing 16% PEG 3350, 0.1M MES pH 6.0, with seeding. In this case 
the crystal was cryoprotected with a solution containing 20% PEG 3350, 0.1M MES 
pH 6.0, and 20% [v/v] ethylene glycol as a cryoprotectant. Details related to protein 
crystallisation and crystal freezing are included in Sections 2.3.9 and 3.6. 
Diffraction data were collected using an oscillation method (angle increment 
0.5°/frame, exposure period 0.5 sec/frame, λ=0.97 Å), and recorded using a Pilatus 
detector by Dr Phil Walker (NIMR), at the IO4 beam line at Diamond Light Source 
Synchrotron (Harwell, UK). The two datasets were indexed and integrated using 
Xia2 system (Kabsch 2010) (Winter, Lobley et al. 2013). The indicated space group 
for both data sets was P 3 2 1 (150). Dataset A diffracted to 3.4 Å, and dataset B to 
3.3 Å. However, analysis of dataset B indicated an issue with anisotropy.  The 
Aimless (Evans 2006) (Evans and Murshudov 2013) log file output prepared using 
Loggraph (CCP4) (Figure 3.13) shows the anisotropy of dataset B. Analysis of 
signal/noise (I/σ) against resolution for dataset B is shown in Figure 3.14. In 
contrast, the equivalent analysis of dataset A indicated that there was no issue 
with anisotropy. Anisotropy analysis of dataset A is shown in Figure 3.15. Analysis 
of signal/noise (I/σ) against resolution is shown in Figure 3.16. Therefore, dataset A 
was used to solve the structure of B59 H1 TBHA2. 
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Figure 3.13 Anisotropy analysis of dataset B obtained from a crystal 
grown from 20% PEG 3350 and 0.1M MES pH 6.0. Graph prepared from 
Aimless log file (Evans and Murshudov 2013) using Loggraph (CCP4) 
(Winn 2003). Shown is the half-dataset correlation coefficient (CC1/2) for 
the directions d12 and d3 versus resolution. 
 
 
 
 
 
Figure 3.14 Analysis of I/sigma and Mean (I/sd) versus resolution for 
dataset B obtained from a crystal grown from 20% PEG 3350 and 0.1M 
MES pH 6.0. Graph prepared from Aimless log file (Evans and Murshudov 
2013) using Loggraph (CCP4) (Winn 2003). 
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Figure 3.15 Anisotropy analysis of dataset A obtained from a crystal 
grown from 15% PEG 3350, 0.1M MES pH 6.0, 1.5% MPD, 0.01M Hepes pH 
7.5 and 0.02M Sodium citrate. Graph prepared from Aimless log file 
(Evans and Murshudov 2013) using Loggraph (CCP4) (Winn 2003). Shown 
is the half-dataset correlation coefficient (CC1/2) for the directions d12 and 
d3 versus resolution. 
 
 
 
Figure 3.16 Analysis of I/sigma and Mean (I/sd) versus resolution for 
dataset A obtained from a crystal grown from 15% PEG 3350, 0.1M MES pH 
6.0, 1.5% MPD, 0.01M Hepes pH 7.5 and 0.02M Sodium citrate. Graph 
prepared from Aimless log file (Evans and Murshudov 2013) using 
Loggraph (CCP4) (Winn 2003). 
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Molecular replacement and model refinement: 
 
The unmerged XDS ASCII reflection file was used for space group assignment 
using Pointless (CCP4) (Evans 2006) (Evans 2011) (Winn, Ballard et al. 2011). 
Pointless confirmed that the most likely space group was P 3 2 1 (150). Space group 
P 3 2 1 was assigned with a total space group probability estimate of 0.999, and 
systematic absences-based estimate of 1.00. Scores for the possible Laue groups are 
shown in Table 3.1, which includes scores for a likelihood measure (Lklhd), a 
“significance” score (Z-score), a correlation coefficient (CC) and the multiplicity-
weighted R factor (Rmeas). 
 
Table 3.1 Scores for possible Laue groups for the B59 H1 TBHA2 crystal. 
Scores obtained using Pointless (CCP4).  
 
 
 
 
The molecular weight of each B59 H1 TBHA2 monomer was estimated to ~10,000 
Da by N-terminal sequencing (Section 3.3). The number of molecules in the 
asymmetric unit of the P 3 2 1 unit cell was calculated using Matthews-Coeff 
(CCP4) (Kantardjieff and Rupp 2003). Based on the calculated % solvent content, 
there is most likely one monomer of postfusion B59 H1 TBHA2 in the asymmetric 
unit of the P 3 2 1 crystal (Table 3.2). Data collection and refinement statistics are 
shown in Table 3.3. 
 
Table 3.2 Number of B59 H1 TBHA2 monomers in the asymmetric unit of 
the P321 (150) unit cell and the corresponding % solvent content. The 
Matthews coefficient (Vm) is calculated as 𝒗𝒐𝒍𝒖𝒎𝒆	𝒐𝒇	𝒖𝒏𝒊𝒕	𝒄𝒆𝒍𝒍𝑴𝒘×𝒁×𝐗  , where Z is the 
number of asymmetric units in the unit cell, and X is the number of 
molecules in the asymmetric unit. 
 
 
 
Laue Group Lklhd NetZc CC Rmeas
1 P -3 m 1 0.999 8.43 0.97 0.06
2 C 1 2/m 1 0.00 5.40 0.98 0.04
3 C 1 2/m 1 0.00 5.19 0.97 0.05
4 C 1 2/m 1 0.00 5.20 0.97 0.05
5 P -3 0.00 5.24 0.97 0.06
6 P -1 0.00 4.78 0.99 0.03
Nmol/asym Matthews Coeff % solvent P (tot)
1 3.28 62.56 0.98
2 1.64 25.11 0.02
Cell volume: 196972.97  ~10kDa/monomer  P321 (150) 
 109 
 
 
Molecular replacement using a monomer of recombinantly-expressed H3 HA2 
(residues 33-173) (PDB: 1QU1) (Chen, Skehel et al. 1999) or viral postfusion H3 
HA2 (residues 40-162) (PDB: 1HTM) (Bullough, Hughson et al. 1994) as a search 
model using MOLREP (Vagin and Teplyakov 2010) and PHASER (McCoy, Grosse-
Kunstleve et al. 2007), did not find a solution initially. Given the length of the 
shorter molecular replacement model (PDB: 1HTM), which is ~98 Å long (Ser40-
Gln105), and the dimensions of the unit cell: 59.60, 59.60, 64.03 (a, b, c), it was 
concluded, that even the shorter molecule (1HTM) would not fit into the P 3 2 1-
unit cell. For this reason, the original model (1HTM) was truncated, according to 
trypsin cleavage sites predicted by PeptideCutter (ExPASy). The subsequent 
deletions from the N-terminus of H3 HA2 (1HTM) model are shown in Figure 3.17. 
A corresponding number of residues running antiparallel to the main α-helix were 
removed from the C-terminal region of the search model. The final trimmed model 
of H3 TBHA2 contained one H3 HA2 monomer (residues 69-156). The trimmed 
postfusion helix of H3 TBHA2 was pruned to carbon beta using CHAINSAW (CCP4 
suite) (Winn, Ballard et al. 2011). In this procedure, a PDB file was mutated 
according to an input sequence alignment between target and model sequences, by 
pruning non-conserved residues to Cβ atoms. Pruned H3 TBHA2 monomer (PDB: 
1HTM) was used as a new search model for molecular replacement using MOLREP 
(Lebedev, Vagin et al. 2008) (Vagin and Teplyakov 2010) and PHASER (McCoy, 
Grosse-Kunstleve et al. 2007) (CCP4 suite).  
Molecular replacement was successful using a model of viral H3 TBHA2 (PDB: 
1HTM), trimmed to contain HA2 residues 69-159 (Figure 3.17) and pruned to beta 
atom using CHAINSAW (Winn, Ballard et al. 2011). Both MR programs predicted 
the same packing of molecules in the crystal lattice. Molecular replacement was 
also carried out using a monomer of postfusion B59 H1 TBHA2, solved previously 
in a lower symmetry space group. This strategy resulted in lower R factors than 
those obtained using H3 TBHA2 monomer (1HTM) (Bullough, Hughson et al. 
1994), thus a monomer of H1 TBHA2 was used as a search model for molecular 
replacement. 
The model of postfusion B59 H1 TBHA2 was built into the σ- weighted 2FO-FC 
electron density map using Coot (Emsley and Cowtan 2004), and refined using 
Buster (Bricogne G. 2011). Figures for structural snapshots were generated using 
PyMol (Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.). Data 
collection and refinement statistics are presented in Table 3.3. Ramachandran 
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analysis of the final refined model is shown in Figure 3.18. Only two residues, Arg 
106 and Asp 146, lie outside the preferred regions. 
 
 
 
 
Figure 3.17 Truncations of a search model for molecular replacement. 
Trimmed H3 TBHA2 monomers (PDB: 1HTM) (Bullough, Hughson et al. 
1994) are shown in blue, and a model of B59 H1 TBHA2 solved in P 3 2 1 
space group is shown in red (A). The primary sequence of H3 TBHA2 
(residues 40-162) aligned to the corresponding fragment of H1 HA2 is 
shown in B. Molecular replacement model truncations are indicated. The 
non-conserved residues were additionally pruned to carbon beta using 
Chainsaw (CCP4) (Winn, Ballard et al. 2011). Sequences were aligned 
using PRALINE (IBIVU Server) (Simossis and Heringa 2003).  
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Table 3.3 Data collection and refinement statistics for B59 H1 TBHA2 
(molecular replacement). 
 
B59 H1 TBHA2 
Data collection 
Space group P 3 2 1 
Cell dimensions   
a, b, c (Å) 59.60, 59.60, 64.03 
a,	b,	g (∘) 90.00, 90.00, 120.00 
Resolution (Å) 40.18-3.41 (3.50-3.41)* 
Rmerge 0.069 (0.465)* 
Mean I/s(I) 23.3 (2.9)* 
Completeness (%) 97.7 (84.1)* 
Redundancy 13.2 (6.1)* 
Refinement 
Resolution (Å) 32.01-3.41 
No.reflections 1912 
Rwork/Rfree 0.31/0.33 
No. protein atoms 613 
Protein B-factors 120.5 
Rms deviations   
Bond lengths (Å) 0.009 
Bond angles (Å) 1.09 
 
*Values in parentheses are for the highest-resolution shell. 
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Chain Residue Score Phi Psi 
A ARG 106 0.01 41.7 19.2 
A ASP  146 0.01 50.5 -52.3 
 
 
Figure 3.18 Ramachandran plot for B59 H1 TBHA2 model. The plot was 
prepared using Phenix GUI, Comprehensive validation (Afonine, Grosse-
Kunstleve et al. 2012).  
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3.8 Crystal structure of B59 H1 TBHA2 
 
The refolded B59 H1 TBHA2 was prepared by releasing HA from viral particles 
using bromelain (2.2.1.3) and incubation at pH ~5.0 to induce the conformational 
change of HA (3.3), after which the HA1 domains and the fusion peptide were 
removed by digestion with trypsin. Crystals grew from 15% PEG 3350, 0.1M MES 
pH 6.0, with the addition of 1.5% [v/v] MPD, 0.01M Hepes pH 7.5 and 0.01M 
Sodium citrate, and the structure was solved by molecular replacement using a 
monomer of H1 TBHA2 solved previously in a lower symmetry space group, as a 
search model. There is one monomer of postfusion B59 H1 TBHA2 in the 
asymmetric unit of the P 3 2 1-unit cell. The postfusion structure of B59 H1 
TBHA2 is 62.29 Å long, and the central stem comprises HA2 residues Ala65-
Glu105. The HA2 chain was labelled A and is a continuous polypeptide chain 
containing HA2 residues 65-155. The connecting loop (HA2 residues 106-112) turns 
the long central helix (Ala65-Glu105) into an antiparallel shorter α-helix (HA2 
residues 113-130), which then extends to form a loop. Within this loop residues 
131-140 of HA2 form a β-hairpin, and together with a short strand of HA1 
containing Asp11-Tyr17 (H3 numbering), this region of the molecule folds into an 
antiparallel β-sheet. The HA1 chain was named D. Most parts of the extended C-
terminal fragments of the postfusion molecule are unobserved in the crystal 
structure of B59 H1 TBHA2. Figure 3.19 shows a trimeric (A) and monomeric (B) 
cartoon representation of the obtained structure. Loop containing the β-hairpin 
(Lys131- Phe140) with a disulphide-linked fragment of HA1 (Asp11-Tyr17) is 
magnified in Figure 3.19 C. The obtained structure of postfusion viral B59 H1 
TBHA2 is compared to other known structures of postfusion HA2 in Chapter 5. 
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Figure 3.19 Crystal structure of B59 H1 TBHA2. A trimer of postfusion B59 
H1 TBHA2 is shown in A. A B59 H1 TBHA2 monomer is shown in B. Loops 
at HA2 residues 132-143 are shown in C. HA1 chains are shown as sticks 
and S-S bond is indicated (H3 numbering). 
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4 Crystal structure of recombinant H1 HA2  
 
Summary: 
Two fragments of postfusion H3 HA2 (group 2 HA), containing HA2 residues 38-
175 and 23-185, referred to as EBHA2 and EHA2, respectively, and a fragment of 
postfusion influenza B HA2, have been previously expressed in E.coli (Chen, 
Wharton et al. 1995) (Ni, Chen et al. 2014). 
In an attempt to prepare a longer than enzymatically prepared (Chapter 3) 
fragment of postfusion H1 HA2, HA2 residues 38-175 of A/Brisbane/59/07 H1 HA 
were expressed using Baculovirus/insect cell system (Section 2.2.2). 
Conformational assessment of the recombinantly-expressed protein was carried out 
using limited proteolysis (2.3.7). The secondary structure content and thermal 
stability of the expressed protein were estimated using circular dichroism (2.4.3). 
The recombinantly-expressed postfusion H1 HA2 (residues 38-175) spontaneously 
folded into the postfusion conformation, and after a final purification by gel 
filtration (2.3.5), the protein was subjected to crystallisation trials (2.3.9). 
Diffraction quality crystals were obtained from 18% PEG 3350, 0.1M Sodium 
citrate pH 5.6 and 2% tacsimate. Crystals were cryoprotected with the 
crystallisation solution containing 25% [v/v] Ethylene glycol.  
 
4.1 Protein expression and purification 
 
 
Recombinant H1 HA2 (residues 38-175) was expressed using Baculovirus/insect 
cell system as described in Section 2.2.2. The expressed protein was purified using 
IMAC and size-exclusion chromatography, as described in Sections 2.3.8 and 2.3.5, 
respectively. Protein containing fractions A12-B5 (10 ml) eluted from a cobalt 
column are shown in Figure 4.1, A. Cleavage and removal of the polyhistidine tag 
using TEV protease and Ni beads are shown B and C, respectively. The expressed 
protein folded into a soluble trimer of ~48 kDa (calculated Mw) as determined by a 
final size-exclusion chromatography (2.3.5) and SDS-PAGE (2.3.3) (Figure 4.2).  
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Figure 4.1 Purification of Bac 59 H1 HA2. Fractions A12-B5 (10 ml) eluted 
from a cobalt column and analysed using SDS-PAGE, under non-reducing 
(NR) and reducing (R) conditions, are shown in A.   Removal of the 
polyhistidine tag using TEV protease is shown in B, under non-reducing 
(lanes 1 and 2), and reducing (lanes 3 and 4) conditions. Removal of TEV 
using nickel beads (Qiagen) is shown in C. Details of SDS-PAGE are 
included in Section 2.3.3. 
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Figure 4.2 Chromatogram from final size-exclusion chromatography of 
Bac B59 H1 HA2. Recombinantly-expressed H1 HA2 is shown in red, and 
H1 THA is shown in yellow. The y-axis plots the relative absorbance at 280 
nm. The x-axis plots the retention times in ml. Vertical lines indicate 
fractions pooled for crystallisation trials and electron microscopy. The 
reference curve for a THA trimer is shown in blue (H5 subtype).  
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4.2 Conformational assessment of recombinantly-
expressed H1 HA2 
 
Limited proteolysis: 
 
Conformation of the recombinantly-expressed Bac B59 H1 HA2 (residues 38-175) 
was assessed using limited proteolysis, as described in Section 2.3.7. The 
recombinantly-expressed protein at 0.15 mg/ml, was digested with trypsin at 2% 
[w/w] and 5% [w/w], for 30min, at RT. Digestions were stopped using an equal 
amount of soybean trypsin inhibitor (Sigma), and tryptic digestion products were 
analysed using SDS-PAGE, as described in Section 2.3.3. As presented in Figure 
4.3, digestion of the expressed Bac 59 H1 HA2 with trypsin, resulted in a ~6 kDa 
fragment as observed using SDS-PAGE (2.3.3). The observed trypsin digestion 
product is smaller (~6 kDa) than those previously obtained by proteolytic digestion 
of H3 TBHA2 and H3 EBHA2, and the size of the previously obtained fragments 
was ~10 kDa (Wharton, Calder et al. 1995) (Chen, Wharton et al. 1995). Fragments 
of similar size (~6 kDa) were obtained by proteolytic digestion of viral B59 H1 HA2 
using α-Chymotrypsin, Subtilisin, Endoproteinase Glu-C and Proteinase K at 0.1% 
[w/w], as observed using SDS-PAGE (2.3.3), and the obtained fragments are shown 
in Figure 3.9. 
 
 
 
 
 
Figure 4.3 Assessment of the conformational state of Bac B59 H1 HA2 by 
limited proteolysis. Details of SDS-PAGE are included in Section 2.3.3. 
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Circular dichroism and thermal stability measurements: 
 
Conformation of the recombinantly-expressed Bac B59 H1 HA2 (residues 38-175) 
was also assessed using circular dichroism spectroscopy (CD). Experimental details 
relating to CD are included in Section 2.4.3. Far UV spectra recorded at λ 195-260 
nm allowed estimation of the secondary structure content. No significant 
differences in secondary structure at pH 5.2 and pH 7.2 were detected (Figure 4.4), 
suggesting a stable secondary structure in different buffer conditions. The observed 
high α-helical content (Tables 4.1 and 4.2) is characteristic of the extended α-helical 
coiled coil of postfusion H3 HA2 (Ruigrok, Aitken et al. 1988) (Chen, Wharton et al. 
1995). The secondary content predictions shown in Tables 4.1 and 4.2 were 
calculated using three different algorithms: SELCON3 (Sreerama, Venyaminov et 
al. 1999), CONTINLL (van Stokkum, Spoelder et al. 1990), and CDSSTR 
(Sreerama and Woody 2000), and then averaged. The averaged content of 
secondary structure elements, turns and unstructured regions estimated for the 
recombinantly-expressed H1 HA2 (residues 38-175) is shown in % (Tables 4.1 and 
4.2). 
 
 
 
 
 
Figure 4.4 Far UV CD spectrum of Bac B59 H1 HA2. CD spectra obtained 
at pH 5.2 (red) and pH 7.2 (blue). Minima at 208 and 222 nm are 
characteristics of α-helices. 
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Table 4.1 Secondary structure content predictions for Bac B59 H1 HA2 at 
pH 5.2 by CD spectroscopy at λ=195-260 nm. 
 
 
 
 
 
 
Table 4.2 Secondary structure content predictions for Bac B59 H1 HA2 at 
pH 7.2 by CD spectroscopy at λ=195-260 nm. 
 
pH 7.2 
a-helix b-sheet turn unstructured algorithm 
30.9 18.6 21 30.08 selcon 3 
33.3 7.3 20.5 38.8 continll 
40.9 17.1 15.6 26.5 cdsstr 
35.03 14.33 19.03 32.03 average 
 
a-helix b-sheet turn unstructured algorithm
26.9 18.6 21.3 32.3 selcon 3
25.8 12.4 18.6 43.2 continll
34.5 17.3 17.5 30.2 cdsstr
29.07 16.10 19.13 35.23 average
pH 5.2
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Thermal denaturation experiments performed at a fixed λ=222 nm, as described in 
Section 2.4.3, allowed assessing protein stability at pH 5.2 and pH 7.2, by 
observing protein unfolding transitions in relation to thermal denaturation. The 
melting temperature (Tm) was determined as a midpoint between folded and 
unfolded conformation. As presented in Figure 4.5, the expressed protein is more 
stable with respect to thermal denaturation at pH 5.2 (protein unfolds at Tm=72 °C) 
than pH 7.2 (Tm=67 °C). The temperature ranged from 40 to 100 °C. High thermal 
stability and pH dependence of unfolding transitions are also characteristics of H3 
HA2 in a low pH conformation (Ruigrok, Aitken et al. 1988) (Chen, Wharton et al. 
1995). 
 
 
 
 
Figure 4.5 Thermal denaturation of Bac B59 H1 HA2. Denaturation curves 
at pH 5.2 (red) and pH 7.2 (blue) were obtained by CD spectroscopy at a 
fixed λ=222 nm over a temperature range 40-100 °C. 
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4.3 Comparison of recombinantly-expressed 
postfusion H1 HA2 and H3 HA2 using CD  
 
4.3.1 Secondary structure 
 
The far UV (λ 195-260 nm) spectra of recombinantly-expressed Bac B59 H1 HA2 
(residues 38-175) (Section 4.2) predicted a high α-helical content associated with 
the extension of the trimeric stem of HA at low pH, and corresponding with the 
characteristic CD profile obtained for an equivalent fragment of E.coli-expressed 
H3 HA2 (residues 38-175) referred to as EBHA2 (Chen, Wharton et al. 1995), and 
for enzymatically prepared H3 TBHA2 (HA2 residues 40-162) (Ruigrok, Aitken et 
al. 1988). 
 
4.3.2 Thermal stability and pH dependence of unfolding 
transitions 
 
Thermal stability measurements described in Section 4.2 and shown in Figure 4.5 
indicate, that Bac B59 H1 HA2 has high thermal stability, characteristic of EBHA2 
(Chen, Wharton et al. 1995) and TBHA2 (Ruigrok, Aitken et al. 1988). Melting 
temperatures of unfolding transitions for the three constructs are compiled in 
Table 4.3.  
 
Table 4.3 Melting temperatures for X31 H3 EBHA2, X31 H3 TBHA2 and Bac 
B59 H1 HA2 by CD spectroscopy at λ= 222 nm. Melting temperatures (Tm) 
for the three constructs, obtained at low (5.0-5.2) and high (7.0-7.2) pH are 
shown. 
 
 
 
The X31 H3 EBHA2 is more stable to thermal denaturation at pH 5.2 than pH 7.2 
by 14°C. Viral X31 H3 TBHA2 denatures at a temperature 19°C higher at pH 5.0 
than at pH 7.0. In contrast, Bac B59 H1 HA2 unfolds at a temperature only 5°C 
higher at pH 5.2 than at pH 7.2. Although the high thermal stability of Bac B59 H1 
HA2, and the observed pH dependence of unfolding transitions (Figure 4.5) are 
similar to those of X31 H3 EBHA2 and X31 H3 TBHA2, the recombinantly-
Construct pH 5.0/5.2 pH 7.0/7.2
EBHA2 Tm=84°C Tm=70°C
TBHA2 Tm=95°C Tm=76°C
H1 HA2(38-175) Tm=72°C Tm=67°C
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expressed postfusion H1 HA2 was shown to be less stable than H3 HA2 with 
respect to thermal denaturation. 
 
4.4 Crystallisation 
 
The expressed Bac B59 H1 HA2 was concentrated to ~10 mg/ml (A280), using a 
Vivaspin 10K MWCO concentrator (Sartorius) at 3,000 g, 4°C, in a benchtop 
centrifuge (Thermo Scientific), and crystallized using a sitting drop vapour 
diffusion technique, as described in section 2.3.9. Crystals grew from conditions 
containing 12-20% PEG 3350, 0.1M Sodium citrate pH 5.6 and 2-7% [v/v] 
tacsimate. Optimisation trials involving varying the concentration of protein and 
precipitant resulted in diffraction quality crystals. Diffracting crystals were 
obtained from 18% PEG 3350, 0.1M Sodium citrate pH 5.6 and 2% [v/v] tacsimate 
pH 5.0 (Hampton Research). Concentration of protein varied between 5.6-8 mg/ml, 
and drops were seeded with a microseed solution, obtained from 15% PEG 3350 
and 0.1M MES pH 6.0. Crystals are shown in Figure 4.6. Crystals were 
cryoprotected with a crystallisation solution containing 25% [v/v] ethylene glycol, 
and frozen by direct immersion in liquid nitrogen. 
 
 
 
 
Figure 4.6 Crystals of Bac B59 H1 HA2. Crystals grown from 18% PEG 
3350, 0.1M Sodium citrate pH 5.6, 2% [v/v] tacsimate are shown in A, and 
crystals grown from 14% PEG 3350, 0.1M Sodium citrate pH 5.6 and 7% 
tacsimate are shown in B. 
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4.5 Data collection and processing 
 
Diffraction data were collected using an oscillation method (angle increment 0.15° 
and 0.5°/frame, exposure period 0.1 and 0.5 sec/frame, wavelength (λ) 0.9200, 
0.96861 and 0.97625 Å), and recorded using a Pilatus detector by Dr Phil Walker 
(NIMR), at the IO4 beam line at Diamond Light Source Synchrotron (Harwell, 
UK).  
Five complete datasets were collected, four of these were indexed and integrated 
using Xia2 system (Kabsch 2010)  (Winter, Lobley et al. 2013). One dataset could 
not be indexed due to the poor quality of data and low resolution (~5.6 Å). The four 
other crystals gave an indicated space group of R 3 2 (155). The dimensions of the 
R 3 2-unit cell were: 55.97, 55.97, 431.16 (a, b, c) and 90.00, 90.00, 120.00 (α, β, γ). 
The best dataset was chosen based on crystallographic statistics and data analysis 
using Aimless and Loggraph (CCP4) (Winn 2003). 1834 frames were collected 
(angle increment 0.15°/frame, exposure 0.1s/frame, λ=0.97625 Å), and the crystal 
diffracted to 3.4 Å. Resolution estimate and the anisotropic half-dataset correlation 
coefficient (CC1/2) calculated by Aimless (CCP4), and shown graphically using 
Loggraph (CCP4) (Winn, Ballard et al. 2011), are shown in Figures 4.7 and 4.8, 
respectively. Data collection statistics are shown in Table 4.6. 
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Figure 4.7 Resolution estimate for data collected from a crystal of Bac B59 
H1 HA2 grown from 18% [v/v] PEG 3350, 0.1M Sodium citrate pH 5.6 and 
2% [v/v] tacsimate. Data collected by oscillation method (0.15°/frame, 
exposure 0.1s/frame, λ=0.97625). Shown is the graphical output from 
Pointless log file obtained using Loggraph (CCP4) (Winn, Ballard et al. 
2011). 
 
Figure 4.8 Anisotropy analysis of the 3.4 Å dataset obtained from a crystal 
of Bac B59 H1 HA2 grown from 18% PEG 3350, 0.1M Sodium citrate pH 5.6 
and 2% [v/v] tacsimate. Graph prepared from Aimless log file (Evans and 
Murshudov 2013) using Loggraph (CCP4) (Winn 2003). Shown is the half-
dataset correlation coefficient (CC1/2) for the directions d12 and d3 
versus resolution. 
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Figure 4.9 Distribution of Rmerge over 1834 frames collected at 
0.15°/frame, 0.1s/frame exposure and λ=0.97625 from a crystal of Bac B59 
H1 HA2, grown from 18% PEG 3350, 0.1M Sodium citrate pH 5.6 and 2% 
[v/v] tacsimate. Shown is the Rmerge versus batch calculated using 
Aimless and displayed using Loggraph (CCP4) (Winn, Ballard et al. 2011). 
 
 
Figure 4.10 Data completeness versus the 1834 frames collected at 
0.15°/frame, 0.1s/frame exposure and λ=0.97625 from a crystal of Bac B59 
H1 HA2 grown from 18% PEG 3350, 0.1M Sodium citrate pH 5.6 and 2% 
[v/v] tacsimate. Shown is the % completeness versus batch N calculated 
using Aimless and displayed using Loggraph (CCP4) (Winn, Ballard et al. 
2011). 
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Molecular replacement and model refinement: 
 
The merged XDS ASCII reflection file was used for space group assignment using 
Pointless (CCP4) (Evans 2006) (Evans 2011) (Winn, Ballard et al. 2011). Pointless 
confirmed that the most likely space group was R 3 2 (155). Space group R 3 2 was 
assigned with a total space group probability estimate of 1.00, and systematic 
absences-based estimate of 1.00. Scores for the H -3 m Laue group are shown in 
Table 4.4, which includes scores for a likelihood measure (Lklhd), a “significance” 
score (Z-score), a correlation coefficient (CC), and the multiplicity-weighted R factor 
(Rmeas). 
 
 
Table 4.4 Scores for H-3 m Laue group for a crystal of Bac B59 H1 HA2 
calculated using Pointless (CCP4) (Winn, Ballard et al. 2011).  
 
 
 
 
The number of molecules in the asymmetric unit of the R 3 2 unit cell was 
calculated using Matthews-Coeff program (CCP4) (Kantardjieff and Rupp 2003).  
Based on the molecular weight, estimated from the number of residues in the PDB 
file (137 residues/monomer), and the calculated % solvent content there are most 
likely one or two monomers of postfusion H1 HA2 in the asymmetric unit of the R 3 
2 crystal (Table 4.5). 
 
 
Table 4.5 Number of Bac B59 H1 HA2 monomers in the asymmetric unit of 
the R 3 2 (155) unit cell and the corresponding % solvent content.  
 
 
 
 
 
 
 
 
Laue Group Lklhd NetZc CC Rmeas
1 H -3 m 1.00 3.49 1.00 0.00
Nmol/asym Matthews Coeff % solvent P (tot)
1 4.84 74.60 0.01
2 2.42 49.2 0.99
3 1.61 23.79 0
Cell volume: 1166135.5  13388 Da/monomer  H32 (155) 
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Molecular Replacement was initially attempted using a monomer of the E.coli-
expressed H3 EHA2 (HA2 residues 33-173) (PDB: 1QU1) (Chen, Skehel et al. 1999) 
as the search model using MOLREP (Vagin and Teplyakov 2010) and PHASER 
(McCoy, Grosse-Kunstleve et al. 2007) however, no unique solution was found. A 
partial solution was found in a lower symmetry space group (P1), using a search 
model of H1 HA2 (residues 42-166), which gave interpretable density. This model 
was edited using the electron density as a guide to prepare a new search model for 
molecular replacement with the data processed in R 3 2. The new search model 
contained one long (HA2 residues 45-164), and one short (HA2 residues 75-128) 
monomer of H1 HA2, Figure 4.11. Molecular replacement with this search model 
was successful using both, PHASER and MOLREP (CCP4) (Winn, Ballard et al. 
2011). The model of postfusion Bac B59 H1 HA2 was completed by building into 
the σ-weighted 2FO-FC electron density map using Coot (Emsley and Cowtan 2004), 
and refined using Buster (Bricogne G. 2011). Figures for structural snapshots were 
generated using PyMol (Molecular Graphics System, Version 1.2r3pre, 
Schrödinger, LLC.). Data collection and refinement statistics are presented in 
Table 4.6. Ramachandran analysis of the final refined model is shown in Figure 
4.12. Only three residues, Asn 154, Thr 156 and Thr 107 are outside the preferred 
regions. 
 
 
 
Figure 4.11 Model of postfusion H1 HA2 used as a search model for 
molecular replacement. The model was prepared after investigation of the 
electron density map obtained using PHASER and MOLREP (CCP4). 
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Table 4.6 Data collection and refinement statistics for Bac B59 H1 HA2 
(molecular replacement). 
 
 
Bac B59 H1 HA2 
Data collection 
Space group R 3 2  
Cell dimensions   
a, b, c (Å) 59.97, 59.97, 431.19 
a,	b,	g (∘) 90.00, 90.00, 120.00 
Resolution (Å) 71.86-3.17 (3.25-3.41)* 
Rmerge 0.168 (3.36)* 
Mean I/s(I) 8.6 (0.7)* 
Completeness (%) 100.0 (100.0)* 
Redundancy 14.3 (14.4)* 
Refinement 
Resolution (Å) 15.59-3.40 
No.reflections 4809 
Rwork/Rfree 0.29/0.30 
No. protein atoms 1213 
Protein B-factors 147.40 
Rms deviations   
Bond lengths (Å) 0.009 
Bond angles (Å) 1.18 
 
*Values in parentheses are for highest-resolution shell. 
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Figure 4.12 Ramachandran plot for the model of Bac B59 H1 HA2. Model 
obtained using Phenix GUI, Comprehensive validation (Afonine, Grosse-
Kunstleve et al. 2012).  
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4.6 Crystal structure of Bac B59 H1 HA2 
 
The sequence identity between influenza H3 and H1 HA2 is 52.5 % as calculated 
using ClustalW2 (Larkin, Blackshields et al. 2007). The aligned sequences of HA2 
domains from the two HA subtypes are shown in Figure 4.13 A.  
There are two monomers in the asymmetric unit of the R 3 2-unit cell, labelled A 
and B. Chain A is ordered from Ile45 (N-terminus of HA2) onwards. Chain B is 
shorter and starts at Arg75. The postfusion H1 HA2 adopts the hairpin-like 
conformation observed previously for H3 HA2 (Bullough, Hughson et al. 1994) 
(Chen, Wharton et al. 1995) (Chen, Skehel et al. 1999). The N-terminal region 
(residues 31-37), which forms an N-cap domain in the crystal structure of E.coli-
expressed H3 HA2 (residues 31-37) (Chen, Skehel et al. 1999), and part of helix A 
(residues 38-41), are unstructured in the obtained crystal structure. Three 
segments form the postfusion stem of H1 HA2. These are: prefusion helix A (HA2 
residues 42-58), prefusion loop B (HA2 residues 59-74), and prefusion helix C (HA2 
residues 75-105). As for the postfusion H3 HA2 structures (Bullough, Hughson et 
al. 1994) (Chen, Skehel et al. 1999), region constant between the pre- and 
postfusion structures of H1 HA2 is helix C (HA2 residues 75-105). The long central 
stem of the refolded molecule is followed by a loop (D) (HA2 residues 106-112). This 
fragment is helical in the prefusion H1 HA2, and connects the central stem of the 
molecule to helix E (HA2 residues 113-127). A fragment of a loop (F) (HA2 residues 
130-145) is unstructured in the crystal structure of Bac B59 H1 HA2, and weaker 
electron density for this fragment (HA2 residues 129-139) indicates greater 
structural flexibility. These fragments are present in the proteolytically prepared 
B59 H1 TBHA2 described in Chapter 3, and are stabilized by disulphide-linked 
fragments of HA1 domains (HA1 residues 11-17) (Figure 3.19). Loop F of the 
postfusion H1 HA2 extends to form another short helix G (HA2 residues 146-155), 
which runs in an antiparallel orientation to the central stem of the molecule. The 
C-terminal residues observed in the postfusion monomers of H1 HA2 are Glu164 in 
chain A, and Asn128 in chain B.  
The core of Bac B59 H1 HA2 trimer is formed by a number of hydrophobic 
residues, which are either identical, or conserved in hydrophobicity between the 
two HA subtypes. One exception is Phe88, which is buried in postfusion H1 HA2. 
The corresponding residue in H3 HA2 is Lysine, the side chain of which appears to 
be exposed to solvent (PDB: 1QU1). The side chain of Phe88 in postfusion H1 HA2 
points towards the 3-fold axis of H1 HA2 trimer, and is surrounded by two large 
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hydrophobic residues, Ile91 and Trp92. Trp92 appears to make a hydrophobic 
interaction with Val122 of the antiparallel helix E (HA2 residues 113-127), possibly 
stabilizing the six-helix-bundle. Hydrophobic interactions in the core of postfusion 
H1 HA2, and in the region of the six-helix-bundle are shown in Figure 4.13. 
 
 
 
Figure 4.13 Crystal structure of Bac B59 H1 HA2. (A) Sequence alignment 
of H3 and H1 HA2 fragments containing residues 31-180. Residues are 
coloured by segments, which undergo refolding at low pH. (B) A trimer of 
H1 HA2 generated by symmetry operations using PyMol. (C) Burial of 
Phe88 in the protein core of refolded Bac B59 H1 HA2 (residues 38-175). 
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5 Postfusion H1 HA2 and its comparison to 
other HA2 structures 
 
5.1 Viral and recombinantly-expressed H1 HA2 
 
The crystal structure of postfusion viral B59 H1 TBHA2 is described in Chapter 3. 
One monomer (chain A) in the asymmetric unit (space group P 3 2 1) contains a 
fragment of a postfusion molecule (HA2 residues 65-155). Loop F (HA2 residues 
128-145) is ordered, and connected to a short fragment of HA1 domain. The two 
domains are linked via a disulphide bond, formed between Cys137 of HA2 and 
Cys14 of HA1.  
The crystal structure of postfusion, recombinantly-expressed Bac B59 H1 HA2 is 
described in Chapter 4. There are two monomers in the asymmetric unit (space 
group R 3 2). Electron density is discontinuous for both longer (chain A, residues 
45-164), and shorter (chain B, residues 75-128) monomer, and the unobserved 
fragment comprises residues 129-139. 
Differences in lengths of the observed fragments in the two crystal structures of 
postfusion H1 HA2, result most likely from proteolytic cleavage of the prepared 
protein post purification. Enzymatically prepared B59 H1 TBHA2 was most likely 
cleaved at Lys58. Although missing in the obtained structure of B59 H1 TBHA2, 
the crystal structure of Bac B59 H1 HA2 suggests, that the side chain of HA2 
Lys58 points out from the trimer surface, and does not seem to be protected by the 
extended C-terminal fragment of the refolded molecule (Figure 5.1, A). 
Superposition of the longer monomer (chain A) of the Bac B59 H1 HA2 and a 
monomer of B59 H1 TBHA2 gives an overall rmsd of 0.6 Å (Figure 5.1, C).  
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Figure 5.1 A model of postfusion influenza H1 HA2. A monomer of Bac B59 
H1 HA2 is shown in A. A monomer of B59 H1 TBHA2 is shown in B. 
Superposition of the two monomers gives and overall rmsd of 0.6 Å and is 
shown in C. Key residues are indicated. 
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Segments for structural comparison of viral and recombinantly-expressed H1 HA2 
in a postfusion conformation are shown in Table 5.1. Conformational changes of 
segments A to G, and the extended C-terminal fragment of H1 HA2 are 
summarized in Table 5.1. The appropriate residue range is shown. Segment A 
(residues 45-58) is helical in both pre- and postfusion H1 HA2, and is recruited to 
the central coiled coil following the structural refolding at low pH. Segment B 
(residues 59-74) is a random coil in prefusion H1 HA2 and adopts a helical 
structure at low pH. The constant region C (HA2 residues 75-105) is shown in 
green, and fragment of H1 HA2 that undergoes a 180° helix-to-turn transition 
(HA2 residues 106-112) is shown in yellow. 
The corresponding regions of postfusion H1 HA2, which undergo the low pH-
induced structural refolding, were aligned, and rmsd between the two structures 
was calculated using PyMol (Molecular Graphics System, Version 1.2r3pre, 
Schrödinger, LLC.). The calculated rmsd values are shown in Table 5.2.  
 
 
Table 5.1 Refolding of H1 HA2 in response to low pH. Both pre- and 
postfusion conformations of segments A-G, and the extended C-terminal 
fragment of H1 HA2 are shown. 
 
 
 
 
Table 5.2 Structural comparison of B59 H1 TBHA2 and Bac B59 H1 HA2. 
Rmsd between the corresponding fragments A-G, and the extended C-
terminal fragment was calculated using PyMol.  
 
 
 
H1	HA2	segment	(residue	range) H1	prefusion H1	postfusion
A	(38-58) α-helix α-helix
B	(59-74) random	coil α-helix
C	(75-105) α-helix α-helix
D	(106-112) α-helix turn
E	(113-127) α-helix α-helix
F	(128-145) loop loop
G	(146-153) α-helix α-helix
extended	C-term	(154-167) random	coil random	coil
Viral&to&recombinantly&expressed&H1&HA2&segments&(residue&range) Rmsd&(Å)
A!(45%58) missing!in!TBHA2
B!(65%74) 0.536
C!(75%105) 0.388
D!(106%112) 0.357
E!(113%127) 0.258
F!(130%145) missing!in!recombinant
G!(146%153) 0.887
extended&CCterm!(154%164) missing!in!TBHA2
central&helices&(65C105) 0.437
Overall&rmsd&(monomers) 0.6
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The overall reorganisation of H1 HA2 after its exposure to low pH is similar to that 
observed previously for H3 HA2 (Bullough, Hughson et al. 1994) (Chen, Skehel et 
al. 1999). Figure 5.2 shows a monomer of prefusion H1 HA2 (PDB: 1RUZ) and the 
two obtained structures of postfusion H1 HA2. Regions that undergo transition at 
the pH of membrane fusion are coloured according to colour scheme used in Tables 
5.1 and 5.2. A short fragment of HA1 remains disulphide-linked to HA2, and the 
disulphide bond is between Cys14 of HA1 and Cys137 of HA2. Relocation of helix A 
to the top of the central coiled coil extends the structure towards the target 
membrane. Loop B characterized by a tall turn at residue 75 in the prefusion 
structure of group 1 HA, is also recruited to the central coiled coil. Short helical 
fragment D (HA2 residues 106-112), which makes contacts with the fusion peptide 
in the prefusion conformation, refolds to form a loop, which reverses direction of 
the HA2 polypeptide chain by 180°, and results in positioning of the C-terminal 
fragment of postfusion H1 HA2 near the N-terminus of the postfusion molecule 
(Figures 5.1 and 5.2). 
 
Figure 5.2 The low pH-induced refolding of H1 HA2. A prefusion monomer 
of H1 HA2 (PDB: 1RUZ) is shown on the left, a monomer of recombinantly-
expressed H1 HA2 is shown in the middle, and a monomer of viral 
postfusion H1 HA2 is shown is on the left. Segments A-G, which undergo 
refolding at low pH are shown as cylinders. 
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5.2 Postfusion viral H1 and H3 TBHA2  
 
A monomer of postfusion viral H1 HA2 (residues 65-155) present in the crystal 
structure of B59 H1 TBHA2 and described in Chapter 3, is 25 amino acid residues 
shorter at its N-terminus than the previously solved structure of X31 H3 TBHA2, 
which starts at residue 40 of HA2, and contains residues 1-27 of HA1 (Bullough, 
Hughson et al. 1994). Helix A, together with first ~5 residues of postfusion helix B 
are unobserved in the crystal structure of low pH-activated B59 H1 TBHA2. The 
unstable nature of the N-terminal fragment of the refolded B59 H1 TBHA2 may be 
related to the exposure of additional, previously hidden protease cleavage sites 
after exposure of the molecule to low pH (~5.0). The appropriate cleavage sites at 
the N- and C-termini of H1 HA2 are shown in Appendix 2. The pre- and postfusion 
conformations of segments A-G and the C-terminal fragment of H3 HA2 (Bullough, 
Hughson et al. 1994) (Chen, Skehel et al. 1999) (Gamblin, Haire et al. 2004) are 
summarized in Table 5.3. Four helices and three β-strands are conserved between 
the pre- and postfusion H1 and H3 TBHA2 (Bullough, Hughson et al. 1994). Helix 
A of prefusion H3 HA2 (Table 5.3) is three amino acids shorter than that of H1 
HA2 (Table 5.1). In prefusion H1 HA2, Ile56, Glu57 and Lys58 belong to helix A, 
and are then recruited to the top of the postfusion molecule. Structural alignments 
were carried out using PyMol (Molecular Graphics System, Version 1.2r3pre, 
Schrödinger, LLC.), and alignments were preceded by a removal of the atomic 
coordinates corresponding to fragments of HA1 from the two PDB files. The root-
mean-square deviation (rmsd) between the equivalent atoms was calculated 
according to the formula: 
 
 
𝑅𝑀𝑆𝐷 = 	 𝑆𝑈𝑀	(𝑑𝑖𝑖)T𝑁  
Where: 
RMSD- root-mean-square deviation of the Cα atomic coordinates after rigid body 
superposition 
dii- distance between equivalent atoms 
N- number of atoms matched in each structure 
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Alignment of prefusion H3 and H1 monomers gives an rmsd of ~1 Å and is shown 
in Figure 5.3. Structural alignment of prefusion H3 and H1 HA2 monomers and 
the corresponding rmsd values are presented in Table 5.4. Rmsd for the given 
regions was calculated by superposing the specified residues of prefusion H3 HA2 
(PDB: 1HGF) (chain B) and prefusion H1 HA2 (PDB: 1RUZ) (chain I).  
Due to differences in lengths of helices A between the prefusion monomers of H3 
(PDB:1HGF) and H1 HA2 (PDB:1RUZ) shown in Figure 5.3, and the lengths of 
enzymatically prepared X31 H3 TBHA2 (PDB: 1HTM) (Bullough, Hughson et al. 
1994) and B59 H1 TBHA2 presented in this thesis (Chapter 3), the postfusion 
structures of viral HA2 from the two groups HA were compared, by calculating 
rmsd for the corresponding regions present in both crystal structures (HA2 
residues 65-155). Structural alignment of postfusion H3 (PDB: 1HTM) (chain F) 
and B59 H1 TBHA2 (chain A) monomers, and the corresponding rmsd values, are 
presented in Table 5.5. With rmsd of ~4 Å, loops B that connect helices A to central 
helices C in prefusion HA2, are structurally different between the two HA subtypes 
(Table 5.4), and adopt a very similar conformation (rmsd=0.46 Å) after refolding of 
the molecules at low pH (Table 5.5 and Figure 5.4). Helices C (HA2 residues 76-
105) remain similar after the low pH-induced conformational change, with a slight 
increase in the rmsd value from ~0.4 Å to ~0.6 Å. Segments D (HA2 residues 106-
112) are helical in the prefusion structures, and can be aligned very well between 
prefusion H3 and H1 HA2 (rmsd=~0.3 Å). Turns formed by a helix-to-turn 
transition of these residues are different in the two postfusion viral HA2 
structures, which is reflected by an increase in rmsd to ~0.8 Å (Tables 5.4 and 5.5). 
Threonine at position 107 of H1 HA2 packs towards the 3-fold axis of the HA2 
trimer, and may form weak hydrogen bonds with carbonyl oxygen atom of Thr107 
belonging the neighbouring HA2 subunit (Figure 5.5). Leucine at position 108 of 
H1 TBHA2 is located in the middle of two adjacent helices C and E of each 
monomer. Although the exact orientation of all amino acid side chains in this 
region of the refolded B59 H1 TBHA2 cannot be determined precisely due to low 
resolution, it appears, that this part of the rearranged molecule is held mainly by 
hydrophobic interactions between methyl groups of Threonine residues of the 
neighbouring monomers and weak hydrogen bonds. Interhelical loops D (HA2 
residues 106-112) change the direction of the polypeptide chain in crystal 
structures of both H3 (Bullough, Hughson et al. 1994) and H1 TBHA2. The 
observed postfusion structures of these regions of viral, enzymatically prepared, 
and low pH-activated H3 and H1 TBHA2, are compared in Figure 5.5. 
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Figure 5.3 Structural alignment of prefusion H3 and H1 HA2. Monomers of 
H3 HA2 (PDB: 1HGF) and H1 HA2 (PDB: 1RUZ) are shown in blue and red, 
respectively. Segments A-G, key residues and group-specific differences in 
turns are indicated. Alignment of the corresponding fragments gives an 
overall rmsd of 1 Å.  
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Figure 5.4 Structural alignment of postfusion X31 H3 TBHA2 and B59 H1 
TBHA2. Alignment of X31 H3 TBHA2 (PDB: 1HTM) and B59 H1 TBHA2 
monomers gives an overall rmsd of 1 Å. The X31 H3 TBHA2 monomer was 
trimmed at its C-terminus. 
 
 
Postfusion H3 TBHA2
  (PDB:1HTM)
 Postfusion H1 TBHA2
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Table 5.3 Refolding of H3 HA2 in response to low pH. Both pre- and 
postfusion conformation of segments A-G and the extended C-terminal 
fragment of H3 HA2 are shown. 
 
 
 
 
Table 5.4 Structural comparison of prefusion H3 HA2 (PDB: 1HGF) and H1 
HA2 (PDB: 1RUZ). Rmsd between the corresponding fragments A-G was 
calculated using PyMol.  
 
 
 
 
 
Table 5.5 Structural comparison of X31 H3 TBHA2 (PDB: 1HTM) and B59 
H1 TBHA2. Rmsd between the corresponding fragments A-G was 
calculated using PyMol.  
 
 
 
 
 
 
 
H3	HA2	segment	(residue	range) H3	prefusion H3	postfusion
A	(38-55) α-helix α-helix
B	(56-75) random	coil α-helix
C	(76-105) α-helix α-helix
D	(106-112) α-helix turn
E	(113-129) α-helix α-helix
F	(130-145) loop loop
G	(146-153) α-helix α-helix
extended	C-term	(154-185) random	coil random	coil
H3#to#H1#prefusion#HA2#segments#(residue#range) Rmsd#(Å)
A!(38%55) 0.508
B!(59%74) 4.138
C!(76%105) 0.423
D!(106%112) 0.299
E!(113%127) 0.314
F!(130%145) 0.880
G!(146%153) 0.398
extended#CCterm!(154%160) 0.993
Overall#rmsd#(monomers) 1.005
H3#to#H1#postfusion#TBHA2#segments#(residue#range) Rmsd#(Å)
B!(65%74) 0.458
C!(76%105) 0.650
D!(106%112) 0.812
E!(113%127) 0.408
F!(130%145) 1.541
G!(146%155) 0.647
central#helices#(65E105) 0.492
Overall#rmsd#(HA2#monomers+#HA1#chains) 1.056
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Figure 5.5 Comparison of turns in X31 H3 TBHA2 and B59 H1 TBHA2. 
View down the 3-fold symmetry axis of H3 (PDB: 1HTM) and H1 TBHA2 
trimers generated by symmetry operations in PyMol. Key residues are 
indicated. Alignment of equivalent regions comprising the C-terminal 
part of helix C, loop D (HA2 residues 106-112) and the N-terminal end of 
helix E is shown. Threonine 107 packs closely towards the 3-fold axis of 
both refolded molecules indicating, that this region is held mainly by 
hydrophobic interactions. Superposition was carried out by an alignment 
of HA2 residues 106-112 of the two monomers. 
 
Postfusion H3 TBHA2
  (PDB:1HTM)
 Postfusion H1 TBHA2
(presented in this thesis)
rmsd= 0.8 Å
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The antiparallel helices E comprise residues 113-129 in H3 TBHA2, and residues 
113-127 in B59 H1 TBHA2. These helices pack into the groove of two neighbouring 
helices C in both structures (Figure 5.5). The structural deviation between helices 
E of viral, pre- and postfusion H3 and H1 HA2 is low (~0.3 and ~0.4 Å, 
respectively), when calculated by superposing the entire HA2 monomers. 
Alignment of central helices (HA2 residues 65-105), revealed, that angles between 
helices E and helices C in the postfusion structures of H3 and H1 TBHA2 are 
different, and that helices E of postfusion B59 H1 TBHA2 sit above the equivalent 
helices in postfusion viral X31 H3 TBHA2. The observed relative position of helices 
E in the two structures of postfusion viral TBHA2 is shown in Figure 5.6.  
Residues 130-145 form a loop (F) in postfusion HA2 of both subtypes, and these 
loops are disulphide linked to short fragments of HA1. The connecting loops F are 
different in both pre- (rmsd ~0.9 Å), and postfusion (rmsd ~1.5 Å) viral H3 and H1 
HA2 structures, indicating a flexible nature of these fragments. The disulphide 
bond is formed between Cys137 of HA2 and Cys14 of HA1 in both subtypes (H3 
numbering). Loops at residues 130-145 of HA2, and the attached fragments of 
HA1, are shown in Figure 5.6.  
The shortest helices G (HA2 residues 146-153) observed in the two postfusion 
TBHA2 (H3 and H1) monomers can be aligned with an rmsd of ~0.65 Å. Residues 
beyond residue 155 are disordered in the B59 H1 TBHA2 structure, and were 
excluded from the structural comparison. While the rmsd value obtained by 
superposing the entire monomers of postfusion H1 and H3 TBHA2 (Bullough, 
Hughson et al. 1994) is ~1.06 Å, alignment of central helices (HA2 residues 65-105) 
reduces this value to ~0.5 Å. 
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Figure 5.6 Loops at residues 130-145 of X31 H3 TBHA2 and B59 H1 TBHA2. 
Monomers of H3 TBHA2 (PDB: 1HTM) and B59 H1 TBHA2 are shown in 
blue and red, respectively. Loops at HA2 residues 130-145 are shown as 
cartoon (purple and yellow), HA1 chains are shown as sticks, and S-S 
bonds are indicated (H3 numbering). The two monomers superposed by 
aligning residues HA2 residues 65-105 (main helices) of the two HA 
subtypes are shown on the right. 
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A monomer of enzymatically prepared B59 H1 TBHA2 (Chapter 3) contains HA2 
residues 65-155. The polypeptide chain starts at Ala65 (N-terminus), indicating 
cleavage by trypsin at Lys58 or cleavage by contaminating proteases near Thr64. 
In prefusion H1 HA2, Lys58 belongs to helix A, which is three amino acids longer 
than helix A of prefusion H3 HA2 (Figure 5.3). The proteolytically-prepared 
postfusion B59 H1 TBHA2 may have been cleaved after induction of the 
conformational change of H1 HA by incubation at the pH of fusion, and upon 
exposure of the previously buried protease cleavage sites, or possibly post-
purification. In comparison, a monomer of postfusion X31 H3 TBHA2 (PDB: 
1HTM) (Bullough, Hughson et al. 1994) prepared using a similar method is 25 
amino acids longer than that of B59 H1 TBHA2, and contains HA2 residues 40-
162.  
The observed increased susceptibility of B59 H1 TBHA2 to proteolytic digestion in 
the region of HA2 residues 40-65 was analysed in relation to the probability of 
coiled coil formation. Primary sequences of H1 and H3 HA2 were compared to a 
database of known coiled coils, and the probability of their formation was 
calculated using COILS/PCOILS (Bioinformatics Toolkit; Max-Planck Institute for 
Developmental Biology). The program uses a matrix specific for left-handed coiled 
coils, and produces a set of probabilities of coiled coil forming potential for a given 
sequence. As shown in Figure 5.7, coiled coil prediction profiles for both H3 and H1 
HA2, correlate directly with the lengths of the monomers observed in crystal 
structures of X31 H3 TBHA2 (PDB: 1HTM) (Bullough, Hughson et al. 1994) and 
B59 H1 TBHA2 (Chapter 3). The predicted propensity of HA2 residues 65-90 to 
form a stable coiled coil correlates with the length of the molecules observed in the 
crystal structures of both enzymatically-prepared TBHA2. The observed length of 
B59 H1 TBHA2 (Ala65-), is consistent with the low coiled coil propensity predicted 
based on the primary sequence of this fragment of H1 HA2 (residues 1-64). 
Surprisingly, a relatively low coiled coil forming potential calculated for the 
equivalent fragment of H3 HA2, is sufficient for H3 HA2 residues 1-64 to remain 
folded as a stable super helix, as observed in the crystal structure of X31 H3 
TBHA2 (PDB: 1HTM)  (Bullough, Hughson et al. 1994).  
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Figure 5.7 Coiled coil prediction profiles for H1 and H3 HA2. The helical 
propensity of H1 HA2 is shown in A, and coiled coil prediction for H3 HA2 
is shown in B. An overlap of coiled probability for H1 and H3 HA2 
(window=14) is shown in C. Figure prepared using COILS/PCOILS 
(Bioinformatics Toolkit; Max-Planck Institute for Developmental Biology).  
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As shown in Figure 5.8, the N-terminal region of H3 HA2 (residues 38-86), 
comprising helix A, loop B and part of helix C, contains more hydrophobic (green), 
more charged (grey), and less polar (red) amino acids, than the equivalent 
fragment of H1 HA2. The overall distribution of amino acids in this fragment of H3 
HA2 a higher coiled coil forming potential than that of the equivalent fragment of 
H1 HA2, which may be related to the observed differences in lengths of the two 
molecules when prepared proteolytically. Amino acid substitutions that may be 
responsible for differences in strengths of the hydrophobic component of H3 and H1 
HA2 in the region of residues 38-64 are marked (*). Residues 52 and 59 of HA2 are 
group-specific, and these are Valine and Methionine in H1, H2 and H5 (group 1 
HA), and Leucine and Threonine in H3, H7 and H10 (group 2 HA). Sequence 
alignments of representative subtypes from two groups HA are included in Figure 
1.13. Differences in amphipathicity of the corresponding regions of H1 and H3 HA2 
(residues 38-64) were also visualized as helical wheels. As presented in Figure 5.9, 
the apolar stripe defined by hydrophobic residues in positions a and d of H3 HA2 
(A), contains a very strong cluster of hydrophobic residues. The opposite face of H3 
HA2 helix contains a strong cluster of hydrophilic residues (Q42, N49, N53 and 
N60), and in total there are four heptad repeats in this fragment of H3 HA2. The 
corresponding residues of H1 HA2 appear to form three heptads, the frame of 
which is shifted by 3 amino acids (B).  
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Figure 5.8 Comparison of H1 and H3 sequences in the region of HA2 
residues 38-86 in terms of their coiled coil forming potential. Sequences 
with coiled coil forming potential are shown in salmon, and sequences 
with no coiled coil forming potential are shown in blue. Polar, 
hydrophobic and charged residues are shown in red, green and grey, 
respectively. Key residues are indicated. Amino acid substitutions, which 
may account for differences in coiled coil propensity of these regions of 
H1 and H3 HA2, are marked (*). The N-termini of enzymatically prepared 
H3 and H1 TBHA2 (Ser40 and Ala65) are marked. Potential cleavage sites 
are indicated (Lys39, Lys58, Thr64). 
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Figure 5.9 Helical wheel representation of H3 and H1 sequences in the 
region of HA2 residues 38-64. H3 HA2 is shown in A, and H1 HA2 is shown 
in B. The most hydrophobic residues are shown in green as diamonds, 
zero hydrophobicity in yellow. The most hydrophilic residues are shown 
in red. Potentially charged residues are shown in blue, with potentially 
negatively charged residues as triangles, and potentially positively 
charged as pentagons (rzlab.ucr.edu/scripts/wheel).  
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Comparison of ~10 kDa H3 and H1 HA2 proteolytic digestion products: 
 
The structural features of B59 H1 TBHA2 appear to be different to those of X31 H3 
TBHA2 when tested proteolytically. Incubation of X31 H3 TBHA2 and X31 H3 
EBHA2 with trypsin and thermolysin yields different ~10 kDa fragments (Ruigrok, 
Aitken et al. 1988) (Chen, Wharton et al. 1995) shown in Figure 5.10. While 
incubation of X31 H3 TBHA2 with thermolysin, yields a fragment of HA2 
containing residues 38-125, digestion of the same fragment with trypsin results in 
two fragments, one containing HA2 residues 40-124, and another containing HA2 
residues 40-127. Incubation of X31 H3 EBHA2 with trypsin results in two 
fragments, identical to those obtained by digestion of X31 H3 TBHA2, and an 
additional intermediate containing HA2 residues 40-139, and as previously 
determined using N-terminal sequencing and mass spectrometry. As the resulting 
fragments are similar after digestion with different enzymes it was proposed, that 
cleavage at these positions is due to the exposure of these parts on the surface of 
H3 HA2. In all cases, the final structure contains the helical hairpin composed of a 
long α-helix (residues 40-105), followed by a turn at residues 106-112 and a short 
helix E (residues 113-128) (Chen, Wharton et al. 1995), and the resulting products 
are all shorter at their C-termini than a monomer of enzymatically-prepared B59 
H1 TBHA2 described in this thesis. As described in Chapter 3, B59 H1 TBHA2 is a 
trimer of postfusion H1 HA2, containing short fragments of disulphide-linked HA1 
domains (residues 11-17). The calculated molecular weight of HA1-less monomer is 
10677.03 Da. Despite being exposed on the molecule, loops at HA2 residues 130-
145 are unaffected by limited proteolysis, and shortening of the postfusion 
molecule results from a removal of amino acid residues from its N- and C-termini.  
Fragments resulting from proteolytic digestion of X31 H3 TBHA2, X31 H3 EBHA2 
and B59 H1 TBHA2 are shown in Figure 5.10.  
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Figure 5.10 X31 H3 TBHA2, X31 H3 EBHA2 and B59 H1 TBHA2 proteolytic 
digestion products. Three postfusion H3 monomers are shown in blue, and 
a monomer of B59 H1 TBHA2 is shown in red.  Molecular weight of each 
monomer was calculated from the primary sequence using Compute 
pI/Mw tool (ExPASy). The sequence alignment of H3 and H1 HA2 in the 
region of interest is shown (PRALINE; IBIVU server), and positions of key 
residues are indicated. 
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5.3 Recombinantly-expressed H1 and H3 HA2  
 
The sequence identity between HA2 domains (residues 1-222) of B59 (UniProt: 
D5F1Q8) and X31 (UniProt: P03437) HA is 55% as calculated using PRALINE 
multiple sequence alignment (IBIVU Server) (Simossis and Heringa 2003) 
(Simossis and Heringa 2005). The crystal structures of Bac B59 H1 HA2 (Chapter 
4) and X31 H3 EHA2 & EBHA2 (Chen, Skehel et al. 1999) were compared, by 
calculating rmsd for equivalent segments (A-G), and according to residue ranges 
given in Table 5.3. Structural alignment of the equivalent regions that undergo the 
low pH-induced refolding was carried out using chain B of X31 H3 EHA2 (PDB: 
1QU1) (Chen, Skehel et al. 1999), and chain A of Bac B59 H1 HA2 (residues 45-
164), present in the asymmetric unit of the R 3 2 unit cell . While the alignment of 
the entire monomers gives an overall rmsd of ~1.1 Å, superposition of the central 
helices (HA2 residues 42-105) reduces the rmsd value to ~0.37 Å. Distribution of 
structural deviation across the HA molecule was calculated as described in 
Chapter 5.2, and the obtained rmsd values are given in Table 5.6. Residues 
unobserved in the obtained structure of Bac B59 H1 HA2 (chains A and B) could 
not be compared to the corresponding fragment of X31 H3 EHA2, and residues 
excluded from structural comparison were HA2 residues 129-139, and the extended 
C-terminal fragment beyond Glu164 of the longer HA2 monomer (chain A). 
Distribution of structural deviation across the prefusion H3 HA2 (PDB: 1HGF) 
(Sauter, Hanson et al. 1992) and H1 HA2 (PDB: 1RUZ) (Sauter, Hanson et al. 
1992, Gamblin, Haire et al. 2004), and across postfusion X31 H3 EHA2 (Chen, 
Skehel et al. 1999) and Bac B59 H1 HA2 structures was calculated, and the 
obtained rmsd values are shown in Table 5.6. With an rmsd of ~4 Å, interhelical 
loops B connecting prefusion helices A to central helices C, are completely different 
in the prefusion structures of H3 and H1 HA2, but adopt an almost identical 
conformation in the refolded molecules, and the structural deviation between them 
decreases to ~0.3 Å. While structural alignment of recombinantly-expressed H1 
and H3 HA2 monomers gives an rmsd of ~0.8 Å, superposition of main helices 
(HA2 residues 45-105) reduces the rmsd value to 0.6 Å. The superposed monomers 
of X31 H3 EHA2 and Bac B59 H1 HA2 are shown in Figure 5.11. Trimers were 
generated by symmetry operations are these are shown in Figure 5.12. The two 
molecules are coloured by segments that undergo refolding at low pH. 
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Table 5.6 Structural comparison of prefusion H3 and H1 HA2 (PDB: 1HGF 
and 1RUZ), and postfusion X31 H3 EHA2 (PDB: 1QU1) and Bac B59 H1 
HA2 fragments. Rmsd between the corresponding fragments A-G was 
calculated using PyMol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prefusion Postfusion
H3-to-H1-HA2-segments-(residue-range) Rmsd-(Å) Rmsd-(Å)
A!(45%55) 0.508 0.484
B!(59%74) 4.138 0.291
C!(76%105) 0.423 0.331
D!(106%112) 0.299 0.704
E!(113%127) 0.314 0.397
F!(130%145) 0.88 missing!in!H1
G!(146%153) 0.398 0.848
extended-CCterm!(154%164) 0.993 1.542
central-helices-(45C105) 0.578
Overall-rmsd-(monomers) 1.005 0.796
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Figure 5.11 Recombinantly-expressed X31 H3 EHA2 and Bac B59 H1 HA2. 
The E.coli-expressed H3 EHA2 (PDB: 1QU1) (Chen, Skehel et al. 1999), is 
shown in green and purple. The Baculovirus/insect cell expressed B59 H1 
HA2 is shown in yellow and salmon. Alignment of central helices (HA2 
residues 45-105) gives an overall rmsd of ~0.6 Å. Position of helices E in 
both refolded HA2 is shown. 
Postfusion H3 HA2
  (PDB:1QU1)
 Postfusion H1 HA2
(presented in this thesis)
C-term Val176
N-term Gly33
A
B
C
D
E
F
G
N-term Ile45
C-term Glu164
A
B
C
D
E
F
G
rmsd= 0.6 Å
helix E H3
helix E H1
4545
105 105
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Figure 5.12 A symmetry generated trimer of Bac B59 H1 HA2 aligned to a 
trimer of X31 H3 EHA2. Structures are coloured by segments, which 
undergo refolding at low pH. Bac B59 H1 HA2 is shown in salmon, bright 
orange, lime, wheat and violet. X31 H3 EHA2 (PDB: 1QU1) is shown in red, 
orange, green, yellow and purple.  
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5.4 Recombinantly-expressed H1 HA2 and 
Influenza B HA2  
 
The structure of E.coli-expressed influenza B HA2 (PDB: 4NKJ) (Ni, Chen et al. 
2014) has been recently obtained using X-ray crystallography. The structure was 
solved in space group R 3 2. One monomer in the asymmetric unit contains HA2 
residues 34-175. The sequence identity between HA2 fragments (residues 1-222) of 
B59 (UniProt: D5F1Q8) and Influenza B virus (B/Texas/3394/2013) (UniProt: 
S5DRP1) HA is 39%, as calculated using PRALINE multiple sequence alignment 
(IBIVU Server) (Simossis and Heringa 2003) (Simossis and Heringa 2005). The 
rmsd calculated by aligning the two monomers in PyMol is ~1.5 Å. Superposition 
was carried out using chain A of postfusion influenza B HA2 (PDB: 4NKJ) and 
chain A of Bac B59 H1 HA2 (Chapter 4). Alignment of central helices (residues 45-
105) reduces the rmsd value to ~1.1 Å. As shown in Table 5.7, the central 
postfusion helix of influenza B HA2 (up to HA2 residue 105) is almost identical to 
that of Bac B59 H1 HA2. Fragments most similar between the two postfusion 
structures are helices B (HA2 residues 59-74) and helices E (HA2 residues 113-
127), and the respective rmsd values are 0.27 Å and 0.29 Å. The superposed 
monomers labelled by segments (A-G) that undergo transition at low pH are shown 
in Figure 5.13. Differences in structures of turns D at HA2 residues 106-112 (rmsd 
~2 Å) arise most likely from differences in their primary sequence. Structures of 
turns formed by a low pH-induced helix-to-turn transition are compared in Figure 
5.14. 
 
 
Table 5.7 Structural comparison of recombinantly-expressed influenza B 
(PDB: 4NKJ) and Bac B59 H1 HA2. Rmsd between the corresponding 
fragments A-G was calculated using PyMol.  
 
 
 
 
 
H1#to#Flu#B#postfusion#HA2#segments#(residue#range) Rmsd#(Å)
A!(45%55) 0.409
B!(59%74) 0.270
C!(76%105) 0.468
D!(106%112) 2.049
E!(113%127) 0.293
F!(130%145) missing!in!H1
G!(146%153) 0.852
extended#C@term!(154%164) 2.075
central#helices#(45@105) 1.098
Overall#rmsd#(monomers) 1.475
 157 
 
 
 
Figure 5.13 Comparison of recombinantly-expressed influenza B HA2 and 
Bac B59 H1 HA2. Recombinantly-expressed influenza B HA2 (PDB: 4NKJ) 
is shown in blue, and Bac B59 H1 HA2 is shown in yellow. Alignment of 
central helices (HA2 residues 42-105) gives an overall rmsd of 1.1 Å.  
Postfusion infuenza B HA2
     (PDB:4NKJ)
 Postfusion H1 HA2
(presented in this thesis)
N-term Ile45
C-term Glu164
C-term Ala175 N-term Val34
AA
B B
C C
DD
EE
F F
G G
rmsd= 1.1 Å
helix E H1
helix E H3
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Figure 5.14 Comparison of turns at residues 106-112 of recombinantly-
expressed influenza B HA2 and Bac B59 H1 HA2. View down the 3-fold 
symmetry axis of postfusion influenza B HA2 trimer (PDB: 4NKJ) and a 
symmetry generated Bac B59 H1 HA2 trimer. Key residues are indicated. 
Alignment of regions gives an rmsd of ~2 Å. Threonine 107 packs closely 
towards the 3-fold axis of the postfusion H1 HA2 structure. Residues 107 
and 108 of influenza B HA2 are Isoleucine. 
Postfusion influenza B HA2
  (PDB:4NKJ)
 Postfusion H1 HA2
(presented in this thesis)
helix E helix E
helix C
helix C Thr107
Leu108Arg106
His111
Ile107
Ile108 Glu111
rmsd= 2 Å
Thr107
Ile107
helices E
helices C
loop D
loops D
loop D
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6 Characterisation of FI6 antibody binding to 
the two groups HA 
 
The cross-reactive FI6 antibody has been previously shown to bind to a conserved 
region in the fusion (F) subdomain of HA2 present in both HA groups (Corti, Voss 
et al. 2011). In this thesis, the antibody was tested for its ability to prevent the low 
pH-induced conformational change of HA, and therefore viral membrane fusion. 
The specifications of the FI6 with relation to HA binding, and group-specific 
structural features of influenza virus HA, which may play a role in the efficiency of 
the FI6-mediated neutralization, are discussed in Chapters 1.8.2 and 1.7.  
 
6.1 Binding of the FI6 antibody to virus-bound HA 
 
To investigate the ability of the cross-reactive FI6 antibody (Corti, Voss et al. 2011) 
to prevent the conformational change of virus-bound HA, two viruses with HA 
belonging to two distinct HA groups were chosen. Strain B59 was chosen to 
represent group 1 HA, and strain X31 was chosen to represent group 2 HA. In 
order to assess the ability of FI6 to prevent the conformational change of the virus-
bound molecule, virus-antibody complexes were prepared, treated with low pH to 
induce the conformational change of virus-bound HA (Section 2.3.6) and digested 
with trypsin, to confirm the conformation of the low pH-treated molecule. The 
obtained samples were analysed by SDS-PAGE (Section 2.3.3) and electron 
microscopy (Section 2.4.5).  
 
 
 
Preparation of H1N1- and H3N2-FI6 antibody complexes: 
 
The X31 and B59 viruses were grown in embryonated chicken eggs and purified as 
described in 2.2.1.1 and 2.2.1.2. The purified viruses were incubated with an excess 
of the FI6 antibody O/N. Viruses were pelleted to remove the antibody that has not 
bound, and resuspended in 25 mM Tris pH 8.0, 150 mM NaCl.  
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6.1.1 Assessment of the ability of the FI6 antibody to 
prevent the conformational change of virus-bound HA by 
limited proteolysis 
 
Virus-antibody complexes were pre-incubated at 37°C, for 2 min. The pH of virus 
suspensions was lowered to pH 4.8, using 0.1 M citric acid (37°C, 5 min) in order to 
induce the conformational change of virus-bound HA (2.3.6). The pH was then 
readjusted to pH 7.8, using 1 M Tris pH 8.0, and virus-antibody complexes were 
digested with trypsin (50:1 w/w, complex: trypsin), for 45 min, at RT. Digestions 
were stopped by the addition of an equal amount of soybean trypsin inhibitor 
(Sigma), and samples were analysed by SDS-PAGE (Section 2.3.3). The SDS-PAGE 
analysis of tryptic digestion products is shown in Figure 6.1. The analysed samples 
included virus-antibody complexes, complexes treated with low pH, and their 
trypsin digests. The antibody-less virus samples were used as a control. As shown 
in Figure 6.1, A, lane 3, almost all of the antibody-less H3 HA (X31) was digested 
with trypsin after the low pH treatment. In case of H3 with the FI6 antibody 
bound, a proportion of HA stays intact following the low pH treatment and trypsin 
digestion (Figure 6.1, A, lane 6). As shown in Figure 6.1, B, while all of antibody-
less H1 HA was digested with trypsin after low pH treatment (lane 3), H1 HA 
complexed with the FI6 antibody stays intact after exposure to trypsin. The 
obtained results confirm that binding of the FI6 to the fusion subdomain of H3 
HA2 is not as tight as its binding to the corresponding region of H1 HA2. 
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Figure 6.1 Assessment of the ability of the FI6 antibody to prevent a 
conformational change of virus-bound HA by limited proteolysis. Binding 
of the FI6 antibody (Corti, Voss et al. 2011) to X31 and B59 viruses is 
shown in A and B, respectively. Bands corresponding to influenza 
nucleoprotein (NP) and influenza matrix protein (MP) are labelled. 
Details of SDS-PAGE are included in Section 2.3.3. 
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6.1.2 Binding of the FI6 antibody to virus-bound HA by 
electron microscopy 
 
The X31 and B59 viruses were complexed with the FI6 antibody, treated with low 
pH and trypsin as described in Section 6.1.1, and analysed using electron 
microscopy. The FI6 antibody-less viruses were imaged at each step as a control. 
Experimental details related to electron microscopy are included in Section 2.4.5. 
Figure 6.2 shows electron micrographs of the FI6-bound H3 HA on the surface of 
X31 virus. Images of B59 virus complexed with FI6 could not be obtained at 
satisfactory resolution, due to the observed instability of virus-bound H1 HA. As 
observed, virus particles were separate at pH 7.0, with straight and even HA 
spikes. Following the addition of the FI6 antibody, viral particles appeared more 
crowded, and observation of individual HA spikes became difficult. The excess of 
used FI6 antibody is visible in the background. As opposed to antibodies that bind 
to the globular HA1 domains, causing cross-linking between virus particles, 
binding of the FI6 antibody to the stem region of HA, does not cause aggregation of 
virus particles. Following incubation at pH 5.0, the antibody-less X31 particles 
aggregated, which is consistent with HA on the viral particles undergoing the low 
pH-induced conformational change. Particle aggregation was not observed for X31-
FI6 complexes at pH 5.0, and in this case HA spikes appeared to stay intact, 
suggesting that the conformational change of X31 HA was prevented by the FI6 
antibody binding. Subsequent digestion with trypsin aimed to remove the 
dissociated HA1 domains from the low pH-treated sample, and these were 
successfully removed from the antibody-less X31 HA, which reduced particle 
aggregation. Trypsin digestion of the X31-FI6 complexes did not remove the HA1 
domains, and HA spikes stayed intact. Some short, thin HA spikes were observed, 
which indicated, that a fraction of X31 HA on the virus surface had undergone a 
conformational change in the presence of FI6. The obtained results suggested that 
sufficient amount of the FI6 antibody binds to H3 HA on the surface of the X31 
virus to prevent a proportion of HA from undergoing the low pH-induced 
conformational rearrangement.  
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Figure 6.2 Electron microscopy of the FI6 antibody binding to the X31 
virus. Images acquired by Dr Lesley Calder. 
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6.2 Binding of the FI6 antibody to THA by electron 
microscopy 
 
The number of HA spikes on each viral particle is ~400, and each HA trimer has 
three FI6 binding sites (Corti, Voss et al. 2011). In order to determine, how many 
FI6 molecules need to bind to an individual HA trimer in order to block the 
conformational change of HA, binding of FI6 was studied using a detergent-
extracted THA, released from X31 and B59 viruses using bOG or LDAO. The TM 
anchor-less THA was prepared as described in 2.2.1.4, and purified by gel filtration 
(2.3.5). A chromatogram from a final THA purification is shown in Figure 4.2 
(Chapter 4). The THA-FI6 antibody complexes were prepared as described in 6.1.1. 
Following incubation at pH 5.0, THA molecules would normally aggregate into 
rosettes of 6-8 molecules, due to exposure of the hydrophobic fusion peptides at the 
pH of membrane fusion (Skehel, Bayley et al. 1982) (Doms, Helenius et al. 1985) 
(Ruigrok, Aitken et al. 1988). This property of THA was exploited to examine the 
ability of FI6 to prevent the conformational change of the detergent-released X31 
H3 THA and B59 H1 THA. As expected, THA rosettes were unobserved at pH 7.0 
using electron microscopy, and majority of the observed molecules were THA-FI6 
complexes. The antibody appeared to bind to two binding sites on a THA trimer. 
Some THA trimers had only one binding site occupied by FI6, and very few THA 
molecules had all three sites bound to the antibody. Some single THA molecules 
were also visible. After incubation of THA-FI6 complexes at pH 5.0, mainly 
individual complexes were observed (Figure 6.3, B). As molecules lacking the FI6 
antibody formed rosettes at pH 5.0, it can be concluded, that the FI6 antibody 
prevents the formation of rosettes at the pH of membrane fusion, by blocking the 
conformational change of HA. Individual THA-FI6 complexes of different 
morphology, resulting from the flexibility of variable arms of the FI6 are 
magnified, and presented schematically in Figure 6.3, and the observed complexes 
adopt similar structures at pH 7.0 and pH 5.0. 
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Figure 6.3 Electron microscopy of X31 H3 THA-FI6 antibody complexes. 
Images at neutral pH (A) and at the pH of membrane fusion (B) are shown. 
Images were acquired by Dr Lesley Calder.  
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6.3 Binding of viruses to human and avian 
receptor analogs in the presence of FI6 by 
biolayer interferometry 
 
Binding of X31 and B59 viruses complexed with the FI6 antibody (Corti, Voss et al. 
2011) to human and avian receptor analogs was tested using biolayer 
interferometry. The principles of biolayer interferometry and experimental details 
are described in 2.4.6. The technique was used to estimate the concentration range 
of the FI6 antibody to be used in the MDCK1 cell infection assay described in (6.4) 
and also to verify, whether high concentrations of FI6 interfere with binding of 
viral particles to the sialic acid receptors on the surface of infected cells. The 
results indicate, that binding of FI6 antibody to X31 virus does not stop binding of 
X31 to sialic acid receptor analogs (Figure 6.4, B, yellow). The Hc31 strain-specific 
antibody is expected to completely block binding of X31 virus to sialic acid, and the 
observed weak binding (Figure 6.4, B, blue), at low concentration of Hc31, may 
result from overestimation of the initial antibody concentration. In case of B59 
virus (group 1 HA) neither of the antibodies prevents the virus from binding to 
sialic acid receptor analogs, as shown in Figure 6.4, A, and the results confirm that 
even at very high concentrations, the FI6 antibody does not sterically block binding 
of viruses to sialic acid-containing receptors. 
 
 
Figure 6.4 Binding of B59 H1N1 and X31 H3N2 virus-antibody complexes 
to sialic acid receptor analogs by biolayer interferometry. Shown is a 
response on the sensor (% of the control). Virus-FI6 complexes are shown 
in yellow, and virus-Hc31 complexes are shown in blue. 
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6.4 Determination of infectivity of H1N1 and H3N2 
viruses neutralized by the FI6 antibody 
 
Infectivity of H3N2 and H1N1 viruses neutralized by the broadly neutralizing FI6 
antibody was measured using the MDCK1 cell infection assay, described in 2.4.7. 
Experiments were performed using X31 and B59 viruses. The ability of the 
antibody-bound viruses to enter the infected cells was tested using biolayer 
interferometry (6.3) prior to cell infection. The HA titre in the collected allantoic 
fluid was determined using HA assay (2.4.1). The HA titre in the allantoic fluid 
containing B59 virus was estimated to ~512 HAU for 10-2 – 10-4 inoculum dilutions, 
and 1024 HAU for 10-5 dilution. The HA titre in the allantoic fluid containing X31 
virus was lower (256 HAU for 10-2- 10-3, and 512 HAU for 10-4 – 10-5 initial allantoic 
fluid dilutions). Samples with the highest HA titre were used for cell infection 
experiments. Preparation of allantoic fluid and the FI6 antibody dilutions, as well 
as preparation of the Hc31 antibody dilutions (used as a control), are described in 
2.4.7. Cell infection assay (2.4.7) was carried out over 6 hours to ensure only one 
cycle of viral infection. Results indicate that the Hc31 antibody blocks infection of 
MDCK1 cells with the X31 virus, and as expected, infectivity of B59 virus 
remained unaffected (Figure 6.5). This result is consistent with the specificity of 
Hc31, which specifically binds to the globular head domains of H3 HA, blocking 
receptor-binding (Daniels, Douglas et al. 1983). The FI6 antibody was found to 
reduce viral infection with both viruses. At high concentrations, the FI6 appeared 
to completely block infection of MDCK1 cells with the B59 virus, but was found to 
be less effective in neutralisation of the infectivity of the X31 virus (Figure 6.6).  
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Figure 6.5 Quantification of viral infection in the presence of the Hc31 
antibody. Virus strains include B59 (H1N1) shown in red, and X31 (H3N2) 
shown in blue. Labels on the curve indicate the average number of 
positive cells at corresponding Hc31 dilution. 
 
 
 
Figure 6.6 Quantification of viral infection in the presence of the FI6 
antibody. Virus strains include B59 (H1N1) shown in red, and X31 (H3N2) 
shown in blue. Labels on the curve indicate the average number of 
positive cells at corresponding FI6 dilution. 
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7 Discussion 
 
7.1 Purpose of study 
 
Influenza HA is a molecule with three major functions. These are receptor binding, 
viral membrane fusion and antigenic variation. In this thesis, the molecule was 
studied with respect to its role in viral membrane fusion, which leads to the release 
of viral genome into the host cytoplasm, allowing for its replication. To perform this 
critical step of virus cycle, the molecule must undergo a significant rearrangement, 
which eventually brings the viral and endosomal membranes into proximity. In 
contrast to the abundance of prefusion influenza A HA structures obtained to date 
using X-ray crystallography, the number of available postfusion structures is 
limited. Two crystal structures of postfusion H3 HA2 (group 2 HA) were previously 
obtained, and these are enzymatically-prepared, viral H3 TBHA2 (Bullough, 
Hughson et al. 1994) and E.coli-expressed H3 EHA2 & EBHA2 (Chen, Skehel et al. 
1999) fragments of the ectodomain. 
The purpose of this study was to obtain a structure of postfusion HA2 from group 1 
HA using X-ray crystallography, and its comparison to the previously reported 
structures of postfusion H3 HA2 (Bullough, Hughson et al. 1994) (Chen, Skehel et 
al. 1999), and to the recently reported structure of influenza B HA2 in a postfusion 
conformation (Ni, Chen et al. 2014). The aim of this thesis was to use structural 
comparison of these molecules, in order to investigate, whether group-specific 
structural features of the prefusion molecules (discussed in 1.7), result in 
differences in their postfusion structures. Subtype H1 was chosen to represent 
group 1 HA, and HA of PR8 and B59 H1N1 viruses was used. Subtype H1 is 
responsible for the 1918 pandemic (Gamblin, Haire et al. 2004), and given its place 
in the same HA group as the highly pathogenic H5 subtype, structural information 
related to the low pH-induced structural rearrangement of H1 HA2, could be 
related to other HA subtypes from group 1 HA.  
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7.2 Crystal structure of B59 H1 TBHA2 
 
Postfusion H1 TBHA2 from the PR8 and B59 H1N1 viruses were prepared 
proteolytically, and subjected to crystallisation trials as described in Chapter 3. 
Crystals of best morphology and size were obtained using refolded HA2 released 
from PR8 H1N1 virus with bromelain. Protein crystallized from solutions 
containing various PEGS as precipitants. The pH of buffers ranged from 5.5-7.5. 
Crystals diffracted weakly, despite extensive optimisation trials, testing of 
different cryoprotectants and dehydration experiments. Diffraction quality crystals 
of B59 H1 TBHA2 were obtained from 15% PEG 3350, 0.1M MES pH 6.0, with the 
addition of 1.5% MPD, 0.01M Hepes pH 7.5 and 0.02M Sodium citrate. Crystals 
diffracted to ~3.4 Å, and the structure was solved by molecular replacement in 
space group P 3 2 1. There was one monomer of B59 H1 TBHA2 in the asymmetric 
unit. The triple-stranded, α-helical coiled coil comprises HA2 residues 65-105. This 
trimeric structure is followed by a connecting loop (D), formed by a helix-to-turn 
transition of HA2 residues 106-112, upon exposure of the molecule to acidic pH. 
(Figure 4.3, B). Loop D reverses residues beyond Asp112 by 180°, and results in an 
antiparallel packing of a short helix E (Ser113-Lys127). Residues 130-145 of B59 
H1 TBHA2 are arranged into a loop (F), and majority of residues within this loop 
(Lys131-Phe140) form a β-hairpin structure. Loop F is connected to a short 
fragment of HA1 (Asp11-Tyr17) via a disulphide bond between Cys137 of HA2 and 
Cys14 of HA1. Loop F is followed by a short helix G comprising HA2 residues 146-
155, and the C-terminal residue is Gly155. Preparation of B59 H1 TBHA2 for 
crystallographic studies and the obtained crystal structure are shown in Figure 
7.1. Regions of the molecule that undergo the low pH-induced structural refolding 
are labelled. 
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Figure 7.1 Preparation of B59 H1 TBHA2 for crystallographic studies. 
Shown are: a prefusion trimer of H1 HA (PDB: 1RUZ) (Gamblin, Haire et 
al. 2004), dissociation of HA1 domains in response to low pH, and the 
obtained structure of B59 H1 TBHA2. Structures are coloured by 
segments, which undergo refolding at low pH.  
 
Postfusion H1 TBHA2
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7.3 Analysis of H1 TBHA2 fragment  
 
The N-terminal sequencing of enzymatically-prepared fusion peptide-less PR8 H1 
TBHA2 confirmed its N-terminus to be Ser40 of HA2. The purified protein runs as 
a ~17 kDa band under reducing conditions (Figures 3.7 and 3.8), corresponding to 
the size of HA1-less HA2 monomer. Resuspended crystals of PR8 H1 TBHA2 also 
ran as a ~17 kDa band under reducing conditions, indicating presence of the 
prepared fragment. The B59 H1 TBHA2 prepared using the same method was not 
sequenced, but also ran as a ~17 kDa band, indicating the N-terminus of the 
purified protein to be Ser40, as in case of PR8 H1 TBHA2. However, only residues 
65-155 of HA2, disulphide-linked to a short fragment of HA1 (residues 11-17), can 
be seen in the crystal structure of B59 H1 TBHA2. The molecular weight of B59 H1 
TBHA2 monomer calculated from the built structure is ~10677 Da per monomer. 
Missing electron density for ~25 residues at the N- and C-termini of the prepared 
B59 H1 HA2 would have accounted for the rest of the initial molecular weight of 
the prepared protein (~17 kDa/monomer) (Figures 3.7 and 3.8) indicating, that the 
prepared protein was cleaved post-purification. 
Overall, the HA of B59 H1N1 virus was found to be very unstable and highly 
susceptible to proteolytic cleavage. Conservation of proteolytic cleavage sites 
between HA2 segments of B59 and PR8 influenza virus HA suggests some 
additional instability in B59 HA2 in the region comprising residues 40-64. 
Cleavage of this region and the ~25 residues at the C-terminus, would result in a 
fragment of ~10 kDa, which correlates with the molecular weight of a degradation 
product observed by SDS-PAGE under reducing conditions (Figure 3.7, lanes 2 and 
4), and with the molecular weight of a monomer calculated from the obtained 
structure. Despite cleavage of the postfusion molecule at both N- and C-termini, 
the six-helical bundle and the connecting loops F characteristic of the postfusion 
molecule are present in the obtained crystal structure of B59 H1 TBHA2, and this 
part of the refolded viral molecule can be considered very stable. 
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7.4 Crystal structure of Bac B59 H1 HA2 
 
Due to the difficulties encountered in preparation of postfusion viral H1 TBHA2 
described in Chapter 3, residues 38-175 of B59 H1 HA2 were expressed using 
Baculovirus/insect cell system (2.2.2). Protein was purified using IMAC (2.3.8) and 
gel filtration (2.3.5), and its conformation was assessed in two ways. Firstly, using 
limited proteolysis (2.3.7 and 4.2), and digestion of the purified protein with 
trypsin resulted in a ~6 kDa fragment (Figure 4.3). The susceptibility of the 
expressed fragment to trypsin digestion indicated exposure of previously buried 
trypsin cleavage sites, associated with the low pH-induced refolding of the HA2 
molecule. Secondly, the secondary structure content was determined using CD 
spectroscopy (2.4.3 and 4.2), and far UV spectra recorded at λ=195-260 nm 
indicated a high α-helical content of Bac B59 H1 HA2. The predicted α-helical 
content of the expressed protein containing HA2 residues 38-175 was ~ 30%, and is 
characteristic of the postfusion H3 HA2 (Ruigrok, Aitken et al. 1988) (Chen, 
Wharton et al. 1995). Estimation of the secondary structure content of Bac B59 H1 
HA2 at neutral and acidic pH using CD is shown in Tables 4.1 and 4.2. Another 
feature of postfusion HA2 is its high stability with respect to thermal denaturation 
(Ruigrok, Aitken et al. 1988) (Chen, Wharton et al. 1995).  CD was therefore used 
to monitor the thermal stability of the recombinant protein. The melting 
temperature (Tm) of recombinantly-expressed Bac B59 H1 HA2 was shown to be 
pH-dependent, and the Tm was 72°C for pH 5.2, and 67°C for pH 7.2 (Table 4.3).  
Use of the Baculovirus/insect cell expression system resulted in high levels of 
recombinant protein expression, and spontaneous folding of recombinant H1 HA2 
into a low pH-induced conformation makes it a preferred eukaryotic system for the 
expression of postfusion HA2 for structural analysis. 
Diffraction quality crystals of Bac B59 H1 HA2 were grown from 18% PEG 3350, 
0.1 M Sodium citrate pH 5.6 and 2% tacsimate [v/v].  Crystals diffracted to ~3.4 Å 
and the structure was solved by molecular replacement (4.5) using a specially 
prepared model in space group R 3 2. The obtained crystal structure of Bac B59 H1 
HA2 is described in Chapter 4. There are two monomers of postfusion H1 HA2 in 
the asymmetric unit of the R 3 2 crystal. The two monomers vary in length. Chain 
designated A, contains HA2 residues 45-164, and chain B contains HA2 residues 
75-128. Chain B is even shorter than that observed in the crystal of the 
enzymatically prepared B59 H1 TBHA2 described in Chapter 3. Molecular weight 
calculated from the primary sequence according to the built model is 6511.37 Da, 
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and corresponds to the size of a degradation product (~6 kDa) observed using SDS-
PAGE, and shown in Figure 4.3. Interestingly, ~6 kDa fragments were also 
obtained by treating viral H1 HA2 with various proteases (Figure 3.9). The 
observed six-helix-bundle appears to be stabilized by a hydrophobic interaction 
between Val122 belonging to helix E and Trp92 belonging to the central stem, and 
is shown in Figure 4.13.  
 
7.5 Viral and recombinantly-expressed H1 HA2 
 
The two monomers of postfusion H1 HA2 are compared in Section 5.1. Structural 
comparison between the two molecules was carried out using a monomer of B59 H1 
TBHA2 (chain A; HA2 residues 65-155) present in the asymmetric unit of the P 3 2 
1-unit cell, and the longer monomer of recombinantly-expressed Bac B59 H1 HA2 
(chain A; HA2 residues 45-164) present in the asymmetric unit of the R 3 2-unit 
cell. The overall rmsd of 0.6 Å obtained by aligning the two monomers indicates a 
high overall level of structural similarity. Alignment of just the central helices 
(HA2 residues 65-105) reduces this value to ~0.44 Å. The stems of the two 
molecules, including the six-helical-bundle regions, are almost identical, and this 
part of the postfusion molecule is composed of segments C (HA2 residues 75-105), 
loop D (HA2 residues 106-112) and helix E (HA2 residues 113-127). The most 
variable region between the two structures was helix G (HA2 residues 146-153), 
and differences may be a result of crystal packing. Stability of these fragments may 
have been affected by the observed increased flexibility at the N- and C-termini of 
the postfusion H1 HA2, and the observed progressive shortening of the refolded 
molecule (Chapters 3 and 4). Structural deviations between different regions of the 
postfusion molecules are shown in Table 5.2. Given that viral B59 H1 TBHA2 
contains a disulphide-linked fragment of HA1, and that conformational change of 
HA was induced by its incubation at the pH of fusion (pH ~5.0), this molecule most 
likely represents the conformation of the rearranged H1 HA2 in vivo. As the top 
part (helix A and part of helix B) and the extended C-terminus of the postfusion 
molecule are unobserved in the crystal structure of B59 H1 TBHA2, a model of 
postfusion H1 HA2 was generated, by combining the two postfusion H1 HA2 
structures obtained using X-ray crystallography (Chapters 3 and 4). The composite 
model was generated by superposing central helices (HA2 residues 65-105) of the 
two monomers in Coot (Emsley and Cowtan 2004) and symmetry operations is 
shown in Figure 7.2. The middle and viral membrane-proximal part of the 
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molecule, including the six-helical-bundle and short fragments of HA1 domains, 
corresponds to the structure of B59 H1 TBHA2 obtained at a resolution of 3.4 Å. 
The top part of the postfusion model (HA2 residues 45-64) and regions C-terminal 
to the antiparallel helix G (HA2 residues 146-153) were reconstructed using the 
equivalent fragments of H1 HA2 present in the obtained crystal structure of 
recombinantly-expressed Bac B59 H1 HA2. 
 
 
 
 
Figure 7.2 Composite model of H1 HA2 in a postfusion conformation. A 
trimer of B59 H1 TBHA2 is shown in cyan. The N- and C-terminal residues 
(Ala65 and Gly155) are indicated. The top part of the molecule was 
modelled using HA2 residues 45-64 present in the obtained crystal 
structure of Bac B59 H1 HA2 (green). Fragments of loops unobserved in 
B59 H1 TBHA2 were reconstructed using HA2 residues 156-164 of Bac B59 
H1 HA2. Model prepared using LSQ Superpose (Coot) (Emsley and 
Cowtan 2004). 
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7.6 Comparison of postfusion H3 and H1 HA2 
 
It has been previously suggested, that the acidic pH of endosomes is only required 
for dissociation of HA1 domains, and that subsequent conformational changes 
leading to membrane fusion follow spontaneously (Carr and Kim 1993). It has been 
previously shown, that structural refolding of HA2 can also occur at neutral pH 
(Chen, Wharton et al. 1995), and E.coli-expressed H3 EBHA2 spontaneously folded 
into a low pH-induced conformation (Chen, Skehel et al. 1999). The recombinantly-
expressed fragment of Bac B59 H1 HA2 and described in Chapter 4, spontaneously 
folded into a low pH-induced conformation in the absence of HA1 domains. Bac B59 
H1 HA2 was susceptible to digestion with trypsin, which indicated presence of the 
extended structure in the expressed molecule (4.2 and Figure 4.3). Thermal 
stability of Bac B59 H1 HA2 was evaluated using CD spectroscopy (4.3.2), and the 
recorded elevated melting temperatures confirmed the presence of a postfusion 
super helix (Table 4.3). Although the registered melting temperatures were lower 
than those previously recorded for H3 TBHA2 (Ruigrok, Aitken et al. 1988) and H3 
EBHA2 (Chen, Wharton et al. 1995), this feature of Bac B59 H1 HA2 agrees with 
the idea that a prefusion HA2 is metastable.  
The postfusion structures of viral B59 H1 TBHA2 and X31 H3 TBHA2 are 
compared in 5.2 (Figures 5.3, 5.4, 5.5 and 5.6), and the structural deviations 
calculated for different regions of the two postfusion molecules are shown in Table 
5.5. Although the structure of B59 H1 TBHA2 presented in Chapter 3 is 25 amino 
acids shorter than that of X31 H3 TBHA2 prepared using a similar method 
(Bullough, Hughson et al. 1994), reorganization by a formation of an antiparallel 
six-helix-bundle, characteristic of postfusion X31 H3 TBHA2, is observed in crystal 
structure of viral postfusion B59 H1 TBHA2. Region comprising residues 1-64 of 
H1 HA2 is unstable and prone to proteolytic digestion. This observation correlates 
with a weak coiled coil forming potential predicted for H1 HA2 (residues 1-64) 
calculated based on the primary sequence (Figures 5.7 and 5.8). Despite a very low 
probability of coiled coil formation predicted for an equivalent region of H3 HA2, a 
strong cluster of hydrophobic residues in the region of Leu38-Phe63 of H3 HA2 is 
most likely responsible for the ability of postfusion X31 H3 TBHA2 to retain the 
trimeric conformation of this segment. A shorter length of the enzymatically-
prepared H1 TBHA2 (both B59 & PR8), when compared to X31 H3 TBHA2, most 
likely results from differences in the ability of postfusion H1 HA2 to form a stable 
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super helix, and may indicate an increased flexibility of the N- and C-terminal 
regions of postfusion H1 HA2.  
Interestingly, the equivalent sequences of other subtypes belonging to group 1 HA 
(H2 and H5) show a very similar coiled coil probability profile, when calculated 
using COILS/PCOILS (Bioinformatics Toolkit; Max-Planck Institute for 
Developmental Biology) suggesting, that other enzymatically-prepared fragments 
of postfusion HA2 from group 1 of HA, are also likely to start in the region of HA2 
residue 65. The helical propensity of H1, H2 and H5 HA2 (group 1 HA) is shown in 
Figure 7.3. Coiled coil probability profiles calculated for the same regions of H7 and 
H10 (group 2 HA) are also very similar, and the expected helical propensity of the 
equivalent N-terminal fragments of H7 and H10 HA2 (residues 40-65) is even 
higher, than that of H3 HA2. The sequence-based coiled coil prediction for H7 and 
H10 HA2 (group 2 HA) is shown in Figure 7.4. 
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Figure 7.3 Coiled coil prediction profiles for group 1 HA. Profiles for H1, 
H2 and H5 HA2 are shown. Figure prepared using COILS/PCOILS 
(Bioinformatics Toolkit; Max-Planck Institute for Developmental Biology). 
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Figure 7.4 Coiled coil prediction profiles for group 2 HA. Profiles for H3, 
H7 and H10 HA2 are shown. Figure prepared using COILS/PCOILS  
(Bioinformatics Toolkit; Max-Planck Institute for Developmental Biology). 
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Differences in type and distribution of amino acid residues in group 1 and group 2 
HA within the corresponding HA2 fragments, comprising prefusion helices A, loops 
B and parts of helices C, are shown in Figures 5.8 and 5.9. Distribution of amino 
acids in these fragments of prefusion HA2 appears to affect the size and shape of 
internal cavities, located between loops B and helices C of prefusion H3 and H1 
HA2 (Figures 7.5 and 7.6). The molecular surface areas of H3 and H1 HA are 
165649.563 Å2 and 164987.031 Å2, respectively, as calculated using PyMol 
(Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.). Although the 
overall solvent accessible area is slightly greater for H3 HA (97536.930 Å2) when 
compared to H1 HA (91539.172 Å2), this cavity, together with a high number of 
polar residues in this region of H1 HA2, seem to directly affect the length of 
proteolytically prepared of H1 TBHA2 presented in this thesis. The internal cavity 
at the interface of loop B (HA2 residues 59-74) and helix C (HA2 residues 75-105) 
of H1 HA2 is shown in Figure 7.6, and its presence may also be related to the 
position of HA1 domains with respect to HA2 stem in prefusion H1 HA. Figure 7.5 
shows the conformations of key amino acid residues within helices A and loops B in 
the two prefusion molecules (H3 and H1 HA2). It has been previously shown that 
proteolytically prepared H3 TBHA2 is cleaved at Lys39 (shown in blue), and 
residues at the interface of loop B and helix C (Lys58 and Lys62) are protected 
from proteolytic cleavage, and present in the crystal structure of X31 H3 TBHA2 
(Bullough, Hughson et al. 1994). In case of enzymatically-prepared B59 H1 TBHA2 
described in Chapter 3, these fragments are unobserved, and missing fragments 
are helix A, and fragment of loop B, up to Thr64 (shown in red). Cleavage of these 
residues at the interface of loop B (HA2 residues 59-74) and helix C (HA2 residues 
75-105) resulting in a short length of the obtained B59 H1 TBHA2 fragment, may 
be related to the presence of an internal cavity at the interface of these parts of 
prefusion H1 HA2. Potential proteolytic cleavage sites are shown. 
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Figure 7.5 Interhelical loops in prefusion H3 and H1 HA2 structures. 
Monomer of prefusion H3 HA2 (PDB: 1HGF) is shown in blue, purple and 
salmon. Monomer of H1 HA2 (PDB: 1RUZ) is shown in red, yellow and 
green. Conformation of key residues at the interface of loops B and 
helices C in the two subtypes is shown. 
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Figure 7.6 Solvent accessible areas in prefusion H3 and H1 HA. Molecules 
are coloured by secondary structure elements (helix-sheet-loop). H3 HA 
(PDB: 1HGF) is shown in blue, purple and salmon (A), and H1 HA (PDB: 
1RUZ) is shown in red, yellow and green (B). Internal cavity at the 
interface of HA1 and HA2, and loop B and helix C, present in prefusion H1 
HA is shown.  
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7.7 Final conclusions in relation to the low pH- 
induced refolding of H3 and H1 HA2 
 
The sequence identity between residues 1-222 of B59 H1 HA2 (UniProt: D5F1Q8) 
and X31 H3 HA2 (UniProt: P03437) is 55% as calculated using PRALINE multiple 
sequence alignment (Simossis and Heringa 2003) (Simossis and Heringa 2005). 
The two crystal structures of postfusion H1 HA2 (group 1 HA), described in 
Chapters 3 and 4, were compared to the previously solved structures of postfusion 
H3 HA2 (group 2 HA) (Bullough, Hughson et al. 1994) (Chen, Skehel et al. 1999). 
In addition, the obtained postfusion structures of postfusion H1 HA2 and already 
known structures of postfusion H3 HA2 were analysed in relation to their 
prefusion form (Gamblin, Haire et al. 2004) (Sauter, Hanson et al. 1992), and 
detailed structural analysis is presented in Sections 5.1, 5.2 and 5.3. The data show 
the structures of postfusion HA2 to be conserved between the two HA groups with 
minor differences. Prefusion helices A and interhelical loops B, are recruited to the 
extended trimeric coiled coil, adopting an almost identical conformation in 
postfusion HA2 of the two subtypes. In both cases, the postfusion HA is a trimer of 
molecules arranged into a hairpin-like conformation. Despite variations in lengths 
of the obtained molecules, the central trimeric coiled coil, comprising fragments of 
helices A (HA2 residues 45-55), helices B (HA2 residues 59-74) and helices C (HA2 
residues 76-105) is almost the same in the postfusion HA2 structures of H1 and H3 
HA subtypes. The structural deviation between turns D (HA2 residues 106-112) in 
the two molecules changes from ~0.3 Å in their prefusion form, to ~0.8 Å 
postfusion. These turns change the direction of the polypeptide chain by 180°, and 
the six-helix-bundle is formed by a sideways positioning of helices E (HA2 residues 
113-127). Although when aligned directly these helices are very similar (rmsd ~0.4 
Å) in postfusion H1 and H3 HA2, superposition of main helices revealed that 
helices E of the H1 subtype sit on top of the equivalent helices E in postfusion H3 
HA2. Side chain packing at the interface of helices E (HA2 residues 113-127) and 
helices C (HA2 residues 76-105) in postfusion structures of H1 and H3 HA2 is 
shown in Figure 7.7. Residue 122 of helix E is a polar Threonine in H3 HA2 (Figure 
7.7, A), and a hydrophobic Valine in H1 HA2. A second substitution is at residue 
115, which is Methionine in H3 HA2 and Valine in H1 HA2 (Figure 7.7, A). 
Approximate angles between helices E (HA2 residues 113-127) and helices C (HA2 
residues 76-105) are slightly different in the postfusion structures of H1 and H3 
HA2, and these are shown in Figure 7.7, B. 
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The stabilizing N-cap that holds the C-terminus in the proximity to the N-terminus 
observed previously in the structure of E.coli-expressed H3 EHA2 (Chen, Skehel et 
al. 1999) is absent in both structures of postfusion H1 HA2, described in Chapters 
3 and 4 of this thesis. Some residues implicated in the formation of the helix-
terminating N-cap, are conserved in the primary sequences of H1 and H3 HA2, and 
these are the N-terminal Ala35 and Ser40, and the C-terminal Ile173 and Val176. 
One exception is HA2 residue 174, which in H1 HA2 is Aspartic acid. Nonpolar 
Leu38 at the N-terminus of H3 HA2 is substituted with a polar Glutamine in H1 
HA2. Even though the structural information relating to these fragments of 
refolded H1 HA2 is unavailable, the above substitutions suggest weaker 
interactions between the capping residues and the extended C-terminal fragments 
of H1 HA2.  
 
 
Figure 7.7 Differences in packing of helices E against central helices C in 
postfusion H3 and H1 HA2. Side chain packing at the interface of the two 
helices in H3 EHA2 (PDB: 1QU1) and B59 H1 TBHA2 is shown in A. 
Approximate angles between helices C and E of X31 H3 EHA2 (PDB: 
1QU1), Bac B59 H1 HA2 and B59 H1 TBHA2 are shown in B. 
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7.8 Comparison of postfusion H1 HA2 and 
Influenza B HA2 
 
The sequence identity between the corresponding fragments (residues 1-222) of 
B59 HA2 (UniProt: D5F1Q8) and Influenza B virus (B/Texas/3394/2013) HA2 
(UniProt: S5DRP1) is 39% as calculated using PRALINE multiple sequence 
alignment (IBIVU Server) (Simossis and Heringa 2003) (Simossis and Heringa 
2005). The postfusion structure of recombinantly-expressed Bac B59 H1 HA2 was 
compared to the recently published postfusion structure of influenza B HA2 (Ni, 
Chen et al. 2014) (Section 5.4). Structural deviations between the corresponding 
segments A-G that undergo refolding at low pH are summarized in Table 5.7, and 
the two structures are compared in Figures 5.13 and 5.14. In summary, despite low 
levels of sequence identity, the stems of the two molecules, comprising HA2 
residues 75-105 and spanning helices A, B and C, are almost identical (Table 5.7). 
Superposition of turns D at residues 106-112 of HA2 gives an rmsd of ~2 Å, and the 
observed differences are most likely related to differences in the primary sequence. 
With rmsd of ~0.3 Å, helices E (HA2 residues 113-127) are almost the same in the 
two postfusion structures.  
 
7.9 Implications for viral membrane fusion 
 
Analysis and interpretation of the structural data on postfusion HA2 from group 1 
and group 2 HA in relation to viral membrane fusion is problematic, due to the lack 
of information regarding position of the refolded molecule with respect to the two 
interacting membranes during viral membrane fusion. The two structures of 
postfusion H1 HA2 discussed in this thesis, contain features conserved in the 
postfusion structures of HA2 from the two HA groups, and in the postfusion 
structure of influenza B HA2, which shares a very low level of sequence identity 
with influenza A (~39%). The data show that viral membrane fusion requires 
formation of a trimeric hairpin-like structure, as previously found for the 
rearranged H3 HA2 (Bullough, Hughson et al. 1994) (Chen, Skehel et al. 1999). 
The shorter lengths of the obtained fragments of postfusion H1 HA2 may indicate 
an increased flexibility of the N- and C-termini of postfusion H1 HA2 (Figures 5.10 
and 5.11). As these regions would terminate with the hydrophobic fusion peptide 
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and the transmembrane anchor in vivo, this structural flexibility of the N- and C- 
termini of postfusion H1 HA2 can be considered as beneficial in terms of the ability 
of H1 HA2 to perform viral membrane fusion suggesting, that the observed 
flexibility of these regions of postfusion H1 HA2 may allow for a close apposition of 
the two interacting membranes. The shortest fragment of postfusion B59 H1 
TBHA2 shown in Figure 5.4 may indicate the core of the molecule, which must 
remain trimeric in order to facilitate membrane fusion. The ~6 kDa degradation 
product of postfusion H1 HA2, comprising the six-helical-bundle (HA2 residues 75-
128) was obtained by proteolytic digestion of Bac B59 H1 HA2 (Chapter 4), which 
has not been exposed to proteases (other than TEV), and the obtained fragment 
was observed using SDS-PAGE (Figure 4.3). 
Overall, the viral membrane-distal part of postfusion H1 HA2 of B59 H1N1 virus 
appears less likely to form a tight hydrophobic core characteristic of postfusion H3 
HA2 (Bullough, Hughson et al. 1994) (Chen, Skehel et al. 1999). Although 
formation of the extended super helix in order to deliver the extruded fusion 
peptide to the target membrane is possible, as shown by the extension of the triple-
stranded, α-helical coiled coil in the crystal structure of Bac B59 H1 HA2 (Chapter 
4), this state appears to be unstable. The observed progressive shortening of 
postfusion H1 HA2 may indicate, that this segment extends initially to deliver the 
fusion peptide to the target membrane, but remains flexible in order to facilitate 
membrane fusion. In this sense, the elongated molecule observed in crystal 
structure of Bac B59 H1 HA2 might represent a short-lived intermediate in the 
process of viral membrane fusion. This finding seems interesting, given that coiled 
coil prediction profiles for H2 and highly pathogenic H5 are identical to that of H1 
HA2, and may indicate a correlation in the way that these subtypes perform viral 
membrane fusion. In a hypothetical scenario that HA2 remains positioned 
vertically in relation to the two interacting membranes during viral membrane 
fusion, the stability features of the refolded HA2 of two HA groups may affect the 
distance of apposition between viral and endosomal membranes (H3 TBHA2 ~98 Å 
long/ H1 TBHA2 ~60 Å long). In case of a ‘fold-back’ hypothesis of membrane fusion 
(Skehel and Wiley 2000), the observed flexibility of postfusion H1 HA2 near its N- 
and C-termini may play a role in the overall efficiency of viral membrane fusion. In 
this model, positioning of the HA2 trimer would bring the interacting membranes 
into a proximity of ~4 nm in the region of six-helix-bundle, and less than 1 nm in 
the region of fusion peptide and transmembrane anchor. The shortest postfusion 
molecule present in the crystal of recombinantly-expressed H1 HA2 (Chapter 4) 
containing HA2 residues 75-128 measures ~45 Å (between the N-terminal Arg75 
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and Glu105), and vertical positioning of the molecule during viral membrane 
fusion, would bring the two membranes within a distance of ~4 nm. 
 
7.10 Functional studies using the FI6 antibody 
 
The structural data on postfusion H1 HA2 presented in this thesis are 
supplemented by functional studies involving the cross-reactive FI6 antibody 
(Corti, Voss et al. 2011) that binds near the conserved fusion subdomain of HA2 
(Corti, Voss et al. 2011), and its binding interferes with the low pH-induced 
conformational change of HA after the uptake of the virus into the endosomes. 
Binding of FI6 to purified virus and to a detergent-released HA of the two subtypes 
was studied using the acquired susceptibility of postfusion HA to proteolytic 
cleavage. In this thesis, the FI6 antibody was shown to block the conformational 
change of H1 and H3 influenza A HA using limited digestion of a refolded, virus-
bound HA with trypsin (Section 6.1.1) and electron microscopy (Section 6.1.2). The 
ability of the FI6 antibody to prevent the low pH-induced structural rearrangement 
of a detergent-released molecule (THA) was shown by a decrease in rosette 
formation using electron microscopy (Section 6.2). The antibody does not appear to 
block binding of H1N1 and H3N2 viruses to human and avian receptor analogs 
even at very high concentrations, as shown using surface biolayer interferometry 
(Section 6.3). Cell infection experiments described in Section 6.4 were performed to 
assess the ability of FI6 to neutralize infection of MDCK1 cells with H1N1 and 
H3N2 viruses. Results suggest that FI6 reduces infection with the X31 virus 
(H3N2), and can completely block infection with B59 (H1N1) virus at high 
concentrations. This observation agrees with the fact, that cross-reactive 
antibodies are less efficient than the strain-specific antibodies, and it is possible, 
that FI6 would completely block viral infection with the X31 virus at 
concentrations higher than used in this thesis. The FI6 antibody was shown to be 
more effective in blocking the conformational change of H1 HA using all of the 
above methods. The observed reduced sensitivity of X31 virus to the FI6-mediated 
neutralization, by blocking the conformational change of endosome-internalized 
HA, may be related to the discussed group-specific features within the antibody-
binding regions of prefusion HA. These include a sugar present at HA2 Asn38 in 
four out of five group 2 HA subtypes, and a different conformation of Trp21, which 
could interfere with the accessibility of the antigenic site on helix A of H3 HA. 
These features are described in Section 1.8.2 on antibodies interfering with the 
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conformational change of HA. The overall infectivity of the X31 virus in the 
presence of FI6 was found to be higher than that of the B59 virus using the 
MDCK1 cell infection assay (6.4) 
. 
7.11 Future work 
 
The understanding of HA-mediated viral membrane fusion will be facilitated when 
structures of HA, including the fusion peptide and the transmembrane anchor, 
become available. Stabilization of these hydrophobic domains of HA2 for 
crystallographic studies can be achieved using detergents or lipids, and 
crystallisation trials can be carried out using a lipidic cubic phase technique. 
However, the expected flexibility of those regions of the refolded HA2 molecule 
suggests, that the potential crystal structures of full length HA2 might only 
represent an intermediate in the process of membrane fusion. 
Possible unfolding of the postfusion H1 HA2 super helix should be tested at various 
pH values and incubation times, employing the acquired susceptibility of the 
refolded molecule to protease digestion, and digestion products analysed by N-
terminal sequencing. Additionally, the postfusion viral HA2 from other group 1 HA 
subtypes can be prepared using the enzymatic method and subjected to 
crystallisation trials, and their crystal structures can be compared to the available 
structures of postfusion HA2 from the two groups HA. 
Interpretation of the available structural data will also be facilitated once the 
orientation of HA relative to the interacting membranes, and at various stages of 
viral membrane fusion is determined, and this may possible using a functional 
membrane fusion assay combined with high-resolution electron microscopy. 
Fusogenic properties of various constructs can be measured as a decrease in FRET 
between two liposome membrane-bound fluorescent probes upon fusion (Stegmann, 
Hoekstra et al. 1985) (Wharton, Skehel et al. 1986), and this method could be used 
to test the ability of the FI6-bound HA to perform viral membrane fusion.  
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